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Abstract 
            
The thesis covers three topics: 
i) Synthesis of the uracil D-ring precursor of the cylindrospermopsin 
alkaloids: this study entailed the preparation of compounds I and II which 
were shown to be a RHS D-ring precursor in the synthesis of the 
cylindrospermopsin alkaloids. Compound I was prepared in 3 steps and in 
24% overall yield from dibenzylurea whilst II was prepared from either 
diethyl 1,3-acetonedicarboxylate in 5 steps and 9% overall yield or 
barbituric acid in 5 steps and 16% overall yield. 
ii) Preparation of analogues of cylindrospermopsin: the synthesis of the 
cylindrospermopsin analogue III was achieved in 6 steps and 12% overall 
yield from the literature compound 2,6-dimethoxypyrimidine-4-
carboxaldehyde. 
iii) Preparation and enzymatic studies on 2.4-dinitrobenzamide pro-drugs: the 
known   pro-drugs IV (X = Cl, Br, I), were prepared and found to be good 
substrates for the enzyme NfsA NTR. These can thus be considered as 
alternative pro-drugs to the usually employed CB 1954 in combination 
with NfsA NTR for human chemotherapy. 
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dinitrobenzamide 
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CI   chemical ionization 
d   doublet 
dd   doublet of doublets 
DEPT   directed Enzyme Pro-drug Therapy 
DNA   deoxyribonucleic acid 
eqv.   molar equivalents 
FMN   flavin mononucleotide 
GDEPT  gene-directed enzyme prodrug therapy 
GSH   glutathione 
HRMS   high  resolution mass spectrometry 
h   hour(s) 
HPLC   high performance liquid chromatography 
Km   Michaelis constant (substrate concentration at half of Vmax) 
LHS   left-hand side 
MS   mass spectrometry 
m   multiplet  
NfsA   nodulation factor A 
NfsB   nodulation factor B 
NTR   nitroreductase 
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NMR   Nuclear Magnetic Resonance 
ppm   parts per million 
q   quartet 
RBF   round bottomed flask  
RHS   right-hand side 
Rf   retention factor 
rt   room temperature 
s   singlet 
SN 23862 5-(bis-(2-chloroethyl)amino)-2,4-dinitrobenzamide 
t   triplet 
TAP    tumour-activated pro-drugs 
TLC   thin layer chromatography 
Vmax   maximum rate of reaction 
 
Reagents 
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DIPEA  N,N-diisopropylethylamine 
DMAP   4-dimethylaminopyridine 
NADPH  Nicotinamide adenine dinucleotide phosphate 
TBAF   tetra-n-butylammonium fluoride 
TBSCl   t-Butyldimethylsilyl chloride 
TFA   trifluoroacetic acid 
TMSCl  trimethylsilyl chloride 
p-TsOH  p-toluenesulfonic acid 
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Ac   Acetyl 
Bn   Benzyl 
Boc   t-Butoxycarbonyl 
MOM   Methoxymethyl 
TBS   t-Butyldimethylsilyl 
Solvents 
MeCN   acetonitrile 
DMF   dimethylformamide  
DMSO   dimethyl sulfoxide 
EtOAc   ethyl acetate  
THF   tetrahydrofuran  
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Cylindrospermopsin Alkaloids  
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Introduction 
            
 
The cylindrospermopsin alkaloids  
Since 1979, when the alkaloid cylindospermopsin was associated with an 
outbreak of hepatoenteritis in Palm Island, Queensland, Australia, this family of 
compounds has been studied extensively because of their toxic effects.1 The Palm 
Island hepatoenteritis outbreak affected 138 children, 10 adults and was caused   
by an algal bloom of the strain Cylindrospermopsis raciborskii.1 Since then, other  
cyanobacteria species have also been shown to produce cylindospermopsin, most  
notably strains of Umezakianatans and Aphanizomenon ovalisporum2 the production 
of CYN thus appears strain-specific, not species specific. 
The guanidine functional group is prevalent throughout nature, being present 
in potent toxins produced by various species of the animal kingdom,3 as well as the 
active sites of enzymes4 and in the human body in the form of arginine and its 
metabolites. Several natural and synthetic guanidine derivatives have generated great 
interest, primarily because of their pronounced biological activities.5 However, 
guanidine derivatives have also been shown to have applications in other fields such 
as catalysis,6 peptidomimetics7 and adhesives8 as well as antifouling agents.9 
The guanidine containing marine natural product cylindrospermopsin 1 was 
first isolated from the cyanobacterium C.raciborskii in 1992,10 after suspicion of its 
involvement in an outbreak of hepatoenteritis on Palm Island, Australia.11 Since then, 
it has also been isolated from several other sources12 including fresh water lakes in 
various parts of Europe such as France, Germany, and the Czech Republic. 
Cylindrospermopsin and its diastereoisomer 7-epi-cylindrospermopsin 2 both display 
hepatotoxic,13  cytotoxic,14  neurotoxic,15  and carcinogenic effects.16 The toxicity of the 
deoxygenated metabolite 7-deoxy-cylindrospermopsin 3 remains controversial as it 
has been reported to be much less toxic than its counterparts17 (Figure 1). 
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Figure 1. Main members of the cylindrospermopsin family. 
 
Akinites (dormant cells that act as survival structures) of C. raciborskii can 
survive as spores for long periods in sediments. Akinites generally arise due to 
temperature  fluctuation  and rarely occur in tropical and subtropical zones; in such 
areas, C. raciborskii is perennial.18  In more temperate zones akinites are necessary to 
provide new growth; germination occurs when temperatures rise to 22–24 ºC. The 
cells following germination eventually develop into trichomes19 (Figure 2). 
 
 
Figure 2. C. raciborskiiakinites19  Source: Google images. 
 
 
This work will focus on the synthesis of the uracil side-chain segment of the 
cylindrospermopsin alkaloids as well as developing a strategy for the synthesis of 
analogues of the natural compounds containing the uracil motif. As part of this work, 
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we will review guanidine containing natural products, alkaloids and synthetic methods 
to these metabolites. 
Guanidine and natural occurring guanidine derivatives 
Guanidine 4 is a crystalline, nitrogen containing, strongly basic compound that 
was first synthesised by the oxidation of guanine.20 It is present in nature, for example, 
it is present in urine as a result of protein metabolism. Because of its basic nature, 
guanidine and many of its derivatives are generally found in nature in a protonated 
form. This is known as the guanidinium cation 5, which has an acid dissociation (pKa) 
value of 13.6.20 The stability of the cation lies in the presence of three resonance forms, 
as shown in Figure 3,21 which distribute the positive charge of the cation over the three 
nitrogen atoms. 
 
  
Figure 3. Guanidine and the guanidinium cation. 
 
Substitution of guanidine is possible and obviously up to five substituients are 
possible to give a vast array of derivatives.22 Guanidines have the general structure 
(R1R2N)(R3R4N)C=N-R5 and as the central group has an imine, guanidines are related 
to amindines and to ureas (Figure 4). 
 
Figure 4. General structure of guanidines R = alkyl, aryl etc 
 
Examples of guanidine containing natural products include arginine 6,23 one of 
the twenty common proteinogenic amino acids, saxitoxin 7,24 a shellfish toxin that 
induces paralysis, and triazabicyclodecene 8,25 an organic soluble base much used in 
chemistry to effect organic transformations e.g. aminolysis of esters (Figure 5). 
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Figure 5. Structures of arginine 6, and saxitoxin 7 and triazabicyclodecene 8. 
The guanidine functionality occurs in a wide variety of biologically active 
molecules.3,4 The ubiquitous nature of arginine leads to it being a common structural 
feature in enzyme active sites.4 Synthetic guanidine containing molecules also have 
wider importance as they have applications in catalysis,6,24 adhesives,8 and a range of 
pharmaceuticals.24  
Cyanobacteria 
Cyanobacteria, or blue-green algae, comprise a phylum of bacterial species, all 
of which are capable of photosynthesis26 (Figure 6). 
 
 
Figure 6. Cyanobacteria26 
 
Today, cyanobacteria populate every area of the Earth. Some are 
extremophiles, surviving in extremes of heat or cold. Others prosper at moderate 
temperatures. Some species form colonies; others survive as single cells. Like other 
prokaryotes, all reproduce asexually, and all lack a cell nucleus. Cyanobacteria 
perform vital tasks for Earth’s ecosystem. Aside from photosynthesis, many also fix 
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atmospheric nitrogen into ammonia, nitrates, or nitrites, thereby enabling the nitrogen 
to be available to plants.27 
Nonetheless, today, cyanobacteria receive much negative publicity, largely 
because of their association with algal blooms, 28a which represent the rapid 
reproduction of algal species within an area of water (freshwater or marine).  Typically 
only one particular species is involved in any bloom and the rapid reproduction of this 
microscopic organism leads to visible discolouration of the water, which in the case 
of a cyanobacterium, turns the water a blue-green colour28b (Figure 7). 
 
 
 
Figure 7. Algal bloom in a village river near Chengdu, Sichuan, China.28c 
 
 
Paradoxically, the growth of algal blooms deprives the water of oxygen. This 
is because, although the algae reproduce rapidly, each organism is short-lived and the 
water in the bloom therefore becomes clogged with dead organic matter.  As this dead 
matter decays it consumes free oxygen leading to eutrophication, which leads to the 
death of other life forms from hypoxia.29 
Toxicity 
Algal blooms have long been known to poison wildlife and such blooms are 
termed harmful algal blooms (HABs). This form of water poisoning was first noted in 
1878, when George Francis reported in Nature a bloom in the Murray River estuary 
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on the border between New South Wales and Victoria, Australia.30 This bloom had so 
poisoned the water that wildlife that drank the water subsequently died.30 A more 
recent case in which algal blooms poisoned wildlife involved the death of 100 bottle 
nosed dolphins off the Florida coast in 2004.31 
Algal blooms may affect any of the world’s oceans. The Gulf of Mexico 
appears especially affected.32 Algal blooms are also a problem in the Baltic Sea, where 
the resultant eutrophication is suspected to cause reproductive anomalies in fish.33 
Poisoning associated with cylindrospermopsin is also known to have affected aquatic 
environments as diverse as the Mediterranean and inland waters in Japan, Eastern 
Australia, Brazil, the USA, France and Central and Eastern Europe.2 In addition, 
although wildlife poisoning is associated with HABs, poisoning may also occur in the 
absence of a bloom. This is because the toxins produced by the blooms may persist in 
the aquatic environment long after the bloom has disappeared;1,2 moreover, some algal 
blooms are invisible from the surface.2 About 2% of phytoplankton are known to 
produce toxins,34 although not all involve cylindrospermopsin. 
To an extent, algal blooms appear “natural”, in that they appear to have 
occurred throughout history,35 and in many cases their exact cause is unknown.  
Moreover, although their incidence appears to be becoming more frequent, this 
apparent rise may be a consequence of better environmental monitoring.36,37 
Nonetheless, anthropogenic causes are implicated, most notably leaching of fertilizers 
(especially phosphates) into waterways.2,30,32  In addition, global warming is cited as a 
possible cause.2 The effects of cylindrospermopsin producing bacteria is spreading. 
Initially, it appeared confined to tropical and sub-tropical regions, however it now 
appears to have spread to temperate regions.2 Cylindrospermopsin 1 has been detected 
in countries as diverse as the U.S.A., Brazil, Thailand, Egypt and Japan, though the 
majority of detections have been in Australia.38 On a country by country basis the most 
common source has been C.raciborskii, however several other bacterial species have 
been implicated and some of these seem restricted to only one country. For example, 
Umezakianatans (Japan), Raphidiopsiscurvata (China) and Raphidiopsis 
mediterranea (Australia).38 Cylindrospermopsin has now been found in every 
continent except Antarctica and given the potential for cylindrospermopsin 1 pollution 
to cause harm, this is a matter for concern. 
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C. raciborskii blooms comprise subsurface trichomes in and below the 
euphotic zone (area of water that receives sufficient sunlight for photosynthesis to 
occur).39 These blooms are associated with several environmental conditions; these 
include the water temperature, with the optimal range for growth being 25–30 °C (but 
growth is possible when the temperature range is 15–35 °C).  Other factors include 
high pH, low water level, low water flow, high sulphate concentration, high incident 
sunlight, low levels of macrophytes (aquatic plants), and a low ratio of nitrogen to 
phosphorous.40 
Cyanotoxins 
There are three main classes of cyanotoxin associated with blue-green algae, 
cyclic peptides, alkaloids, and lipopolysaccharides. Table 1 lists the main examples, 
together with the mammalian organs mainly affected and the bacterial genera 
associated with them.41 
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Table 1. Classes of cyanotoxin 
 
 
Class Toxin Organs mainly 
affected in 
mammals 
Bacteria (genera) 
Cyclic peptides  Microcystins  Liver Anabaena, Anabaenopsis, 
Microcystis, Nostoc, Planktothrix, 
Nostoc, Hapalosiphon 
Nodularins Liver Nodularia  
Alkaloids  Anatoxin-a Nerve synapse Anabaena, Planktothrix, 
Aphanizomenon 
Anatoxin-a(S)  Nerve synapse Anabaena 
Aplysiatoxins  Skin Lyngbya, Schizothrix, 
Planktothrix 
Cylindrospermopsins  Liver Cylindrospermopsis, 
Aphanizomenon, Umezakia 
Lyngbyatoxin-a Skin, gastro-
intestinal tract 
Lyngbya  
Saxitoxins  Nerve axons Anabaena, Aphanizomenon, 
Lyngbya, Cylindrospermopsis 
Lipopolysaccharides   Exposed tissue All 
Source: Adapted from Chorus and Bartram.41 
It is apparent that the cyclindrospermopsins comprise only a sub-class of 
alkaloidal cyanotoxins and their main mode of action is upon the liver. However, as 
will be explained, they may be of special concern in that they may affect organs other 
than the liver.41 
It is also clear from the table that cyanotoxins are varied in structure, and may 
induce a wide range of diseases. These include diverse cytotoxins, endotoxins, 
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hepatotoxis and neurotoxins and as such they comprise some of the most deadly 
naturally occurring toxins.42 Aside from their importance to medical and 
environmental issues, cyanotoxins are so potent that they are of interest to the military, 
for purposes of chemical or biological warfare.43 The toxins may affect humans or 
animals by ingestion of contaminated water, injection of contaminated animal protein, 
or simply by skin contact. They may also affect plants.2 
However, as regards the cylindrospermopsin alkaloids, they appear to most 
severely affect organisms with complex metabolic systems, suggesting that the 
metabolites of the alkaloids may be responsible for their toxicity.2 
Alkaloids 
Alkaloids are a diverse group of naturally occurring products and all alkaloids 
contain nitrogen and most taste bitter when ingested by humans. They are synthesized 
by animals, bacteria, fungi and plants but are especially common in plants, although 
their concentration varies according to location within the plant.44 Plants produce 
alkaloids for a variety of reasons but one main reason is for protection, as alkaloids 
are toxic and can protect plants from being eaten or from being attacked by parasitic 
organisms.44 However alkaloids have many other uses, for example, they are also used 
by animals as neurotransmitters and hormones (see below).44 The general 
classification of alkaloids is give in Table 2.44 
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Table 2. Alkaloid classification. 
 
Class 
 
Chemistry Examples 
True alkaloids 
 
Most derive from amino acids. 
All possess nitrogen in the 
heterocycle 
Atropine, nicotine, morphine (originate from  
amino acids), coneiceine (does not originate 
from amino acids) 
Protoalkaloids 
 
Contain nitrogen in a side 
chain, and derive from amino 
acids 
Adrenaline, ephedrine, mescaline, dopamine 
Polyamines 
 
Derive from putrescine, 
spermidine, and spermine 
 
Agrobactine 
 
Peptide and 
cyclopeptides 
 
Derived from amino acids, 
 
Cyiclosporin  
Pseudoalkaloids Not derived from amino 
acids 
Caffeine 
Source: Adapted from Hesse.44 
The table demonstrates that alkaloids are strongly implicated in narcotics (e.g., 
morphine) and other drugs (e.g. nicotine), hormones (e.g. adrenaline), and 
neurotransmitters (e.g., dopamine). They are also strongly implicated in disease.  
Ergoline, for example, is implicated in ergotism, a condition brought on by ingestion 
of fungal infected cereals and associated with delirium, pain, and in extreme form, 
gangrene of the extremities and (later) death. Ergotism also weakens the immune 
system45 so much so that the spread of the Black Death in medieval Europe appears to 
have been facilitated by fungus on grain that weakened the immune systems of those 
who ingested it.46 
This last point, as regards ergoline weakening the immune system, illustrates 
another problem with alkaloids. Although, as discussed above, alkaloid poisoning may 
precipitate specific organ failure (in the case of cylindrospermopsins, often liver 
failure), it may also have general debilitating effects.  Some alkaloids are known 
teratogens (cause malformation of the foetus); for example, the alkaloid cyclopamine 
which is present in the leaves of corn lily, causes facial deformities in lambs born of 
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the ewes that chewed the leaves.47 Alkaloids may also precipitate cancer.44 Alkaloid 
poisoning may thus not only kill or debilitate directly, it may also have long-term 
insidious effects. 
Despite, or perhaps because of, their complexity and their potentially toxic 
effects, alkaloids are of use to medicine and their application is diverse Table 3 gives 
some examples.44 
 
Table 3. Alkaloids and medicine. 
 
 
Alkaloid Condition treated 
Ajmaline  Arrhythmia 
Vinblastine  Tumour  
Vincamine  Hypertension 
Codeine  Cough 
Cocaine  Pain 
Colchicine  Gout 
Morphine Pain 
Reserpine  Hypertension 
Quinidine Arrhythmia 
Quinine Malaria 
Emetine  Protozoan infection 
Ergot alkaloids Hypertension 
Source: Adapted from Hesse.44 
Not all alkaloids have psychoactive effects, however some non-psychoactive 
alkaloids may be used to synthesize psychoactive drugs, for example, 
  
12 
 
methamphetamine can be produced from ephedrine or pseudoephedrine. From this one 
may conclude, along with Hesse,44  that alkaloids are both a blessing and a curse.  They 
are a blessing in that some organisms need a specific alkaloid to survive and in that 
they have great potential use in medicine; they are a curse in that an alkaloid in an 
inappropriate environment may cause great damage, both to individual organisms and 
to ecosystems. 
The cylindrospermopsin family of alkaloids 
There are three members of the cylindrospermopsin family,   
cylindrospermopsin 1,10 7-epi-cylindrospermopsin 2,48 and 7-deoxy-
cylindrospermopsin 3.17,48  Common features in these metabolites are the presence of 
a sulfonated alcohol, a tricyclic guanidine core (the A, B, and C rings), and a uracil 
containing side chain (ring D). The metabolites differ only at the side chain with 
respect to the alcohol functions stereochemistry or absence. The metabolites are 
zwitterions, with a negatively charged sulfate group and a positively charged 
guanidinium ion. This zwitterionic nature leads to high water solubility. 
Cylindrospermopsin 1 is known to be very stable to a wide range of heat, light and pH 
conditions 49 (Figure 8).  
 
 
Figure 8. The cylindrospermopsin alkaloids. 
 
  
Both cylindrospermopsin and 7-epi-cylindrospermopsin are cytotoxic,14 
hepatotoxic,13 and neurotoxic.15 Cylindrospermopsin has also been shown to be a 
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teratogen, at least to mice50  and to be genotoxic.51 There are also strong suggestions 
that cylindrospermopsin and 7-epi-cylindrospermopsin are carcinogens. The toxic 
effects of 7-deoxy-cylindrospermopsin are, as yet, uncertain.2,16 
There is much uncertainty concerning such toxic effects, for example, Falconer 
and Humpage16 used laboratory mice as test subjects to determine whether 
cylindrospermopsin (fed orally) induces cancer. The mice so fed did develop more 
tumours than did control mice; however, the difference was not statistically 
significant. There are also the problems of whether one can generalise from mice to 
other species, including humans, and of whether one can generalise from mice force-
fed suspected carcinogens to mice living in the wild. It has long been known that 
numerous seemingly innocuous substances, including lettuce, orange juice, apple, and 
cinnamon,32,52 produce cancer when they are force fed to mice, which suggests it is the 
force feeding that causes the cancer, not the substance.53 Research also suggests 
considerable variation of cylindrospermopsin toxicity according to the animal model 
employed,54 and indeed variations according to different members of the same 
species.55 The choice of mice as a research animal may also be unfortunate in that it 
might be easier to induce cancer in them than it is in other species. In the case of DDT, 
for example, much research suggested the pesticide induced cancer in mice, especially 
when force fed (or injected) in large quantities, but the DDT seemed to have little to 
no deleterious effects on rats and golden hamsters.52,56,57 Finally in this regard, to date, 
research has mostly concentrated on mammalian species, with a view to determining 
potential threats to humans, while very little has been done as regards the potential 
effects of cylindrospermopsin poisoning in plants or on ecosystems.2 
Nonetheless, although the species-specificity of cylindrospermopsin toxins 
remains uncertain, as is the scale to which it poses a threat to human beings and 
wildlife, there is little doubt that it does constitute a threat, and plausibly a severe one.  
One reason for believing this is the mechanism of cylindrospermopsin action. It tends 
to inhibit protein synthesis,58 thereby potentially damaging any body tissue and, in 
contrast to other cyanotoxins (e.g., microcystins), to affect a wide range of animal and 
plant species.2 It also disrupts DNA synthesis, thereby enhancing its potential 
carcinogenic and teratogenic effects.2 
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A further reason for believing cylindrospermopsin constitutes an especially 
severe threat is that it has been shown to bio-accumulate within ecosystems.40 For 
example it has been shown to bio-accumulate in crayfish,59 mice,60 eel-tailed catfish61 
and snails.62 This raises the possibility, as Kinnear2 suggests, of dangerous levels of 
cylindrospermopsin accumulating within terrestrial animals and plants, with species 
higher up the food chain being most severely affected. 
A third reason to believe cylindrospermopsin is potentially hazardous is simply 
its range. It is found across the globe and this global spread may have been very 
recent.2 Also in this regard, it has now been found within several strains of bacterial 
species within several genera including Raphidiopsis, Aphanizomenon, Anabaena, 
Umezakia and Lyngbya2 in addition to the original Cylindrospermopsis. The only good 
news is that it appears, thus far, that cylindrospermopsin is largely absent from the 
oceans and appears to be mainly a freshwater pollutant.63 
Synthetic approaches to the cylindrospermopsin alkaloids 
Four research groups have attempted the total synthesis of members of the 
cylindrospermopsin alkaloids, namely the Snider group, the Weinreb group, the White 
group and the Williams group. As this current work focuses on the synthesis of the 
uracil D-ring found in the Eastern half of the alkaloids and analogues of this portion 
of the molecule, this section will look at these syntheses and detail the approach to this 
segment of molecules. Two basic strategies can be visualised in order to incorporate 
the uracil ring system into the synthetic scheme, either at an early stage or at a later 
stage, with both these strategies having been adopted with success. We will consider 
the four major approaches in turn from this viewpoint. 
The Snider synthesis 
Snider and co-workers were the first group to report64 the total synthesis of 
cylindrospermopsin 1 albeit in racemic form. Their approach was to prepare an A-ring 
precursor 10 from the pyridine 9 via conjugate addition chemistry then the magnesium 
acetylide of 10 was reacted with the aldehyde 11 to give the key intermediate 12 in 
which the D-ring has been introduced (Scheme 1)65. 
  
15 
 
  
Scheme1. Snider's synthesis of (±) cylindrospermopsin 2.65 (a) EtMgBr, THF, 0 oC, then 11, 83% 
This methodology represents an early stage introduction of this the D-ring 
which remains protected throughout the synthesis in which the C- and B-rings are 
constructed. It is converted into the required uracil side chain only in the final 
deprotection and sulfonation steps. This sequence of reactions gave racemic 
cylindrospermopsin in 3.5% yield over 20 steps. 
The Weinreb Approach 
Weinreb and co-workers were next to report major progress on the synthesis 
of both cylindrospermopsin (1) and 7-epi-cylindrospermopsin (2)66,67 and in doing so 
were able to assign the relative stereochemistry of the 2 metabolites. Their approach 
was similar to Snider's and involved the preparation of the A-ring precursor 16 from 
the pyridine 15 via conjugate addition chemistry, which was modified to the diene 17 
over 8 steps. This was the precursor to the AB-ring intermediate 18 which was formed 
by a N-sulfinyl-hetero-Diels-Alder reaction.68 This intermediate 18 was converted in 
turn to the conjugate ester 19 which was the key precursor to the synthesis of the uracil 
D-ring (Scheme 2). 
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Scheme2. Weinreb’s synthesis of intermediate 19.68 
 
 
The construction of the D-ring was achieved by reaction of ester 19 with N,O-
bis-(trimethylsilyl) hydroxylamine68 to give the conjugate addition product 21. 
Treatment of 20 with phenyl chloroformate and ammonium hydroxide give 22, which 
could be dehydrated on exposure to triflic anhydride in pyridine to give the uracil 23 
(Scheme 3). Modification of 23 over 9 steps gave epi-cylindrospermopsin 2, whilst 
cylindrospermopsin 1 could also be accessed over 9 steps via an epimerisation of the 
alcohol function.67 
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Scheme3. Weinreb’s synthesis of epi-cylindrospermopsin 2 and cylindrospermopsin 1.67 (a) THF, 
EtOH, 82%; (b) (i) PhOCOCl, NEt3, THF, (ii) NH4OH, i-PrOH, 65%; pyridine, CH2Cl2, 73%; (c) (i) 
Tf2O, pyridine, CH2Cl2, (ii) TMSCl, MOMCl, DIPEA, CH2Cl2, 80%. 
The White synthesis 
The next group to report work in this area were White and Hansen,69,70 who 
detailed their synthesis of 7-epi-cylindrospermopsin 2.66 Their synthesis introduced 
the uracil D-ring in the initial steps beginning with barbituric acid 24, which was 
converted into the bromide 25 then metallated and treated with lactone 26 to give the 
hemiketal 27. This was then converted into aldehyde 28 over 7 steps, which on 
reaction with the hydroxylamine 29 give an intermediate nitrone which underwent 1,3-
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dipolar cycloaddition to give 30 as a 2:1 mixture of isomers. Modification of 30 and 
cyclisation gave the cyclic urea 31, which represented an ABD model of the natural 
products. The final C-ring was introduced over 5 steps to give 32, which was treated 
with acid to deprotect the silyl protecting groups and the pyrimidine to give the final 
product 2 after sulfonation. This overall process proceeded in 0.39% overall yield over 
24 steps (Scheme 4). 
 
 
Scheme4. White’s synthesis of epi-cylindrospermopsin 2.69,70 (a) POBr3, NEt3, toluene, Δ, 99%; (b) 
NaOMe, MeOH, 84%; (c) n-BuLi, 26, CeCl3, Et2O/THF, -78 °C to rt, 97%; MeOH, 84%. 
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The Williams synthesis 
Perhaps the most synthetically elegant approach to the cylindrospermopsin 
alkaloids is that of Williams and co-workers, who reported71,72,73 the total synthesis of 
all three of the metabolites. Their strategy is the most adaptable of those considered to 
date as it relies upon a central71,72,73,74 synthetic precursor 38, which is an AC-ring 
system model. Their synthesis begins with the protected amino acid 33, prepared from 
glycine, which is converted over 4 steps to the oxazinone-N-oxide 34 which undergoes 
a 1,3-dipolar cycloaddition to give the tricyclic isoxazolidine 35 in 78% yield. 
Reduction of 35 with DIBAL followed by reductive amination with p-
methoxybenzylamine gave the diol 36. This diol was converted to bicyclic urea 37 in 
67% yield, which was in turn converted to the key intermediate 38 over 5 steps73,74 
(Scheme 5). 
  
 
Scheme 5. Williams synthesis of intermediate 38.73,74 (a) Toluene, 200 °C, sealed tube, 78%;  
(b) (p-NO2C6H4O)2CO, MeCN, 67%. 
 
Williams reported the asymmetric synthesis of 7-epi-cylindrospermopsin 2 
initially by reacting O-ethylisourea 38 under nitro-aldol conditions with aldehyde 11 
and quenched this reaction with acetic acid followed by a reductive cyclisation step to 
give the tetracyclic guanidine 38 (plus isomers). Acidic deprotection and sulfonation 
of this intermediate gave 7-epi-cylindrospermopsin 2 in 59% yield over 2 steps. 
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Following this, Williams adapted the methodology to a synthesis of 
cylindrospermopsin 1. Thus treatment of O-ethylisourea 38 with the dibenzylated 
pyrimidine aldehyde 41 in the presence of TBAF for 30 min, followed by reductive 
guanylation and then acidic deprotection led to the guanidine 42 (plus isomers) in 20% 
yield. Finally, sulfonation under previously reported conditions afforded 
cylindrospermopsin (1) in a 60% yield, representing the first asymmetric synthesis of 
this metabolite. Having completed the synthesis of the two oxygenated 
cylindrospermopsin alkaloids, work was directed toward the previously unprepared 
metabolite 7-deoxy-cylindrospermopsin 3.71,72,73 Thus treatment of racemic 38 with the 
aldehyde 41 in the presence of acetic anhydride and excess cesium fluoride coupled 
the two units together under aldol condensation conditions to give the nitroalkene 39 
in 67% yield. Reduction of 39 with sodium borohydride followed by hydrogenation 
over Pearlman’s catalyst and deprotection, gave 40 which was sulfonated to give 
racemic 7-deoxy-cylindrospermopsin 3 (Scheme 6). 
 
 
Scheme 6. Willams synthesis of all three cylindrospermopsin alkaloids 1-3.71,72,73 (a) 2.0 eq. TBAF, 
THF, -15 °C, 15 min; (b) Pd(OH)2, H2, MeOH, 5% HOAc; (c) conc. HCl, Δ, 12 h, 32%; (d) SO3.Py, 
3Å, molecular sieves, DMF, 59%; (e) 1.0 eq. TBAF, -15 °C, 0.5 h; (f) Pd(OH)2, H2, MeOH, 5% 
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AcOH; (g) conc.HCl, Δ, 0.5 h, 20%; (h) SO3.py, 3Å molecular sieves, DMF, 60%; (i) CsF, Ac2O, 
MeCN, 67%; (j) NaBH4, EtOH; (k) Pd(OH)2, H2, MeOH, 5% AcOH; (l) conc. HCl, Δ, 0.5 h; (m) 
SO3.Py, 3Å molecular sieves, DMF, 33%. 
Within this work Williams and co-workers reported the first 19-step 
enantioselective synthesis of cylindrospermopsin 1 in 0.34–0.57% overall yield, a 19-
step synthesis of 7-epi-cylindrospermopsin 2 in 0.47–0.82% overall yield, and the 
first, 20-step, racemic synthesis of 7-deoxy-cylindrospermopsin 3 in 0.62–1.05% 
overall yield. 
Conclusions on the reported total syntheses of the 
cylindrospermopsin alkaloids  
From the synthetic work to date it is interesting to note that White’s approach 
to the alkaloids introduces the D-ring into the synthesis at a very early stage and 
constructs the metabolites in the sequence D→AD→ABD→ABCD. Snider similarly 
incorporates the D-ring in a fairly early part of the synthesis and constructs the target 
in the sequence A→AD→ACD→ABCD. In contrast, Weinreb introduces the D-ring 
in a stepwise manner and constructs the metabolite in the sequence 
A→AB→ABD→ABCD and Williams incorporates the uracil D-ring in the very late 
stages of his synthesis, which takes the order A→AC→ACD→ABCD. In all the 
methodologies reported to date, the uracil D-ring is protected throughout the synthesis 
and is deprotected in the final steps. The use of an O-alkylated protecting group has 
been predominant with both -OMe and OBn being used by three groups whilst 
Weinreb utilized the N-MOM protecting group in his synthesis (Figure 9). 
 
 
 
Figure 9. D-Ring protecting groups employed in the synthesis of the cylindrospermopsin alkaloids. 
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The synthetic approach adopted by the Murphy group 
A recent report75 on the biosynthesis of cylindrospermopsin suggests that it is 
produced in a step-wise manner from guanidino acetate 43, with sequential polyketide 
extensions and Michael type ring closures to generate, in turn, the C ring (44→45), 
the A ring (46→47), and the B ring (48 →49). A final series of polyketide extensions 
and an oxidation then provides the three main members of the cylindrospermopsin 
family 1-3 (Scheme 7). 
 
 
Scheme 7. Biosynthesis of the cylindrospermopsin alkaloids75 
This biosynthesis led Evans and Murphy38 to suggest a potential biomimetic 
synthesis of the three alkaloids which might be achieved by using the chirality of the 
initial C ring 45 to generate the stereochemistry of the later A 47 and B 49 rings. A 
model study was performed by Evans and Murphy,38 who prepared the aldehyde 58 
from 1,5-pentanediol 50 over 9 steps and coupled this with allyl acetoacetate 58 under 
Biginelli conditions to generate the tricyclic guanidine 59 in 43% yield from 57. The 
relative stereochemistry across the piperidine ring was found to be identical to that 
found in natural cylindrospermopsin 1. Decarboxylation and reduction of the 
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intermediate enamine led to the saturated tricyclic model 60, which possesses the 
correct stereochemistry across all three rings and represented a rapid method for the 
construction of this moiety (Scheme 8)38. It is interesting to note that this follows the 
biosynthetic hypotheses in that the sequence of the construction of the rings is 
C→AC→ACB→ABCD. 
 
Scheme 8. Murphy’s approach to the cylindrospermopsin alkaloids.38 
 
(a)TBSCl, NaH, THF, 2h, 61%; (b) oxalyl chloride, DMSO, NEt3, CH2Cl2, -78 °C, 3h, 89%; (c) 
MeNO2, DIPEA, CH2Cl2, 36h, 81%; (d) NiCl2·6H2O, NaBH4, MeOH, NEt3, 0 °C, 3h: (e) 53, 48h, 
78% (2 steps from 52); (f) PPh3, I2, imidazole, CH2Cl2, -20 °C, 1h, 96%: (g) TBAF, THF, 0 °C–rt, 
24h, 99%; (h) Dess-Martin periodinane, pyridine, CH2Cl2, 24h, 96%; (i) acetic acid, 24h; (j) 
morpholine acetate, 58, Na2SO4, CF3CH2OH, 70 °C, 12d, 43%; (k) Pd(PPh3)4, pyrrolidine, 
THF/MeOH, 1h 30 min; (l) NaBH3CN, AcOH/MeOH, 16h, 57% (2 steps from 60). 
 
Analogues of the cylindrospermopsin alkaloids 
There have been attempts to link the toxicity of cylindrospermopsin 1 to 
specific features of its molecular structure. An initial study by Sukenik48,77 suggested 
that the uracil moiety of 1 is at least partly responsible for its potency. He reasoned 
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that either competitive or inhibitory binding to a catalytic site is responsible73 for the 
activity. Very little has been reported on the preparation of synthetic analogues of the 
natural products possibly because of their structural complexity; however, one report17 
on the synthesis of simple analogues sought to investigate the structural requirements 
for the activity. Within this paper17 the unsulfonated analogues 42 and 61 were studied 
as was the tricyclic analogue 62. In addition, the very simplified uracil analogue 63 
was also studied as was the bicyclic sulfonate 64, which lacks the uracil side chain. 
These compounds were prepared in the synthetic work of Snider (Figure 10).65 
 
 
Figure 10. Cylindrospermopsin analogues. 
Within this paper, the toxicity of racemic synthetic cylindrospermopsin ±1 was 
compared with that of native 7-epi-cylindrospermopsin 2. Results suggested that the 
orientation of the hydroxyl group at C-7 was irrelevant as regards the biological 
activity or transport of toxin. In addition, comparison of the activity of ±1 and 2 with 
the corresponding unsulfonated diols ±42 and 61 indicated that ±1 and ±42 both 
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inhibited protein synthesis with near identical IC50 values of 0.20 and 0.21μM. 
Furthermore, 7-epi-cylindrospermopsin 2 and the corresponding diol ±42 each 
depleted cell GSH by similar amounts. This seems to suggest that the sulfate group 
plays no important role in the biological activity or uptake of the toxin. It was also 
reported that the AB model compound 62 had an inhibitory effect on protein synthesis, 
but only at concentrations 500-1000 fold higher than cylindrospermopsin 1. In 
contrast, compounds ±63 and ±64 lacked any significant biological activity, at least in 
concentrations of up to 800 and 2000 μM. These results suggest that the presence of 
both the guanidine and the uracil moieties is essential for the biological activity 
observed in these compounds.78 It was concluded that removal of either of the C-ring 
or the A-ring functionality reduces the toxicity of cylindrospermopsin more than 100-
fold, and that the uracil ring is implicated in the biological activity and may be 
involved in transporting the metabolites into the cell. 
The role of the hydroxy-group adjacent to the uracil was investigated by 
Shaw,78 who studied the effects of 7-deoxy-cylindrospermopsin 3 in four different 
mammalian cell lines. They observed clear dose response curves for all cell lines, 
suggesting that 3 is at least as toxic as cylindrospermopsin 1. Results also suggested 
that 1 and 3 inhibit protein synthesis in a similar manner having IC50 values of 340 
and 220 nM respectively.78 This result was corroborated by Williams et al., who 
determined that the two toxins inhibit protein synthesis within one order of magnitude 
and each also has a similar inhibitory effect on cell GSH.71 
It is thus uncertain whether the uracil moiety of cylindrospermopsin 1 is 
implicated only in transport, or is a key feature for in vitro activity as well. The finding 
that the orientation or absence of the hydroxyl group at C-7 results in no appreciable 
loss of biological activity is also somewhat surprising, as is the fact that the sulfate 
group appears to play no role in the biological activity and is not implicated in 
transport across cell membranes. 
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Aims and previous work 
With the report of the biosynthesis of cylindrospermopsin 1, it was proposed 
by Evans and Murphy38 that it might be possible to prepare these alkaloids in a 
biomimetic manner. A retrosynthetic analysis leads to the conclusion that the molecule 
might be split into LHS 65 and RHS 66 synthons with the stereochemistry in the LHS 
C-ring being defined and used to control the stereochemistry of the tricyclic ring 
system during the synthesis (Figure 11).64,66,67,70,72 
Figure 11. Retrosynthetic analysis of the cylindrospermopsin alkaloids 
 
 
The aims of this work are to prepare suitable compounds which will act as the 
RHS synthon and to prepare models of the cylindrospermopsin alkaloids which 
contain the uracil and guanidine functionality.  
An initial hypothesis (Scheme 9) is that the right hand sub-units might be 
prepared from the known pyrimidine 67.79 It was envisaged that reaction of 67 with 
phosphorus oxychloride, followed by sodium methoxide should give the protected 
pyrimidine 68.80 Subsequent activation of 71 with DCC followed by treatment with 
Meldrum’s acid, then reaction with allyl alcohol will lead to the α-ketoester precursor 
69, which is required for the synthesis of 7-deoxy-cylindrospermopsin 3.81 
Introduction of the oxygen function at the 7-position in cylindrospermopsin 1 and 7-
epi-cylindrospermopsin 2 may be possible by oxidation of an intermediate in the 7-
deoxy-cylindrospermopsin synthesis. However a more elegant solution could be to 
prepare the enolate of acid 68 and oxidise this under Davis’s conditions leading to the 
β-hydroxy acid 7082 Protection and coupling with Meldrum’s acid and allyl alcohol 
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should give 72. A similar sequence using the Davis reagent B will furnish 73 (Scheme 
9). 
 
Scheme 9. Synthetic approachs to the RHS synthons of the cylindrospemopsin alkaloids:  a) POCl3; 
(b) NaOMe, MeOH; (c) Davis oxidation A; (d) Davis oxidation B; (e) TBSCl, imid, DMF; (f) 
Meldrum’s acid, DCC, DMAP; (g) allyl alcohol. 
With suitable intermediates in hand the next stage in the synthesis is to prepare 
a model of the natural product; for example, incorporation of the intermediate 69 into 
the known model synthesis could result in the synthesis of 77 a model of 7-deoxy-
cylindrospermopsin. (Scheme 10). 
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Scheme 10. Proposed synthesis of a model of 7-deoxy-cylindrospermopsin: (a) acetic acid; (b) 
morpholine acetate, 69, Na2SO4, CF3CH2OH, ; (c) Pd(PPh3)4, pyrrolidine, THF/MeOH; (d) 
NaBH3CN,  AcOH/MeOH, 16h; (e) HCl, . 
Our interest in preparing analogues of the cylindrospermopsin alkaloids stems 
from a desire to investigate the minimum requirement for activity. It is apparent that 
the uracil and the guanidine portions of the metabolite appear to be the key factors 
contributing to the biological activity.77 We propose that the removal of the ABC ring 
structures to give “stripped down” analogues 78 will leave the activity largely intact 
and the synthesis of these will be investigated (Figure 12). 
 
 
 
Figure 12. Synthetic analogues of the cylindrospermopsin alkaloids. 
  
  
29 
 
Results and Discussion 
            
Synthesis of the uracil D-ring precursor of the cylindrospermopsin 
alkaloids 
As discussed in the introduction, the first major goal of this work was the 
preparation of a uracil containing D-ring precursor for the total synthesis of the 
cylindrospermopsin alkaloids. From our retrosynthesis the synthon 6983 was identified 
as a potential candidate and a synthesis from the compound 67 was proposed (Scheme 
11). 
 
 
Scheme 11. Proposed synthesis of 69. 
 
(a) POCl3; (b) NaOMe, MeOH; (c) Meldrum’s acid, DCC, DMAP; (g) allyl alcohol, . 
 
On investigation of the literature, compound 80 was reported84 to be easily 
prepared from diethyl 1,3-acetonedicarboxylate 79 and we envisaged that the 
chlorinated pyrimidine could be formed by85 treatment with POCl3 in the presence of 
base.85 We then envisaged that treatment of 81 with sodium methoxide would give the 
trans-esterified pyrimidine 82 and that hydrolysis of this under basic conditions would 
yield the acid 68 (Scheme 12). 
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Scheme 12. Proposed synthesis of of 68: (a) urea, H2SO4, C6H6, EtOH; (b) POCl3, i-PrNEt2, Tol. 
reflux, 3 h; (c) NaOMe, MeOH, 1 day; (d) i) NaOH, MeOH, ii) 2M HCl. 
On attempting the first reaction it was found that reaction of diethyl 1,3-
acetonedicarboxylate with urea in anhydrous benzene-ethanol (2:1), in the presence of 
a catalytic amount of sulfuric acid under reflux for 10 days, gave 80 as a white powder 
in 80% yield. The 1H NMR of 80 displayed 6 resonances at  1.20 (3H, t, J = 7.1 Hz, 
Me), 3.48 (2H, s, CH2), 4.11 (2H, q, J = 7.1, CH2), 5.46 (1H, s, CH), and 10.41-11.27 
(2H, br s, 2 x NH) ppm, together with 8 separate carbon environments in the 13C NMR 
at C 168.1 (C), 164.1 (C), 151.4 (C), 149.0 (C), 100.8 (CH), 60.9 (CH2), 37.2 (CH2), 
and 14.0 (CH3) ppm. This data suggested a successful reaction and on determination 
of the melting point of 80, we obtained a value of 188 °C, which is in good agreement 
with the literature5 value of 186–189 °C (Scheme 13). 
 
 
Scheme 13. Synthesis of 80: urea, H2SO4, C6H6, EtOH,10 days, 80%. 
With 80 in hand, it was treated with POCl3 in the presence of N-
ethyldiisopropylamine at reflux for 3 h.6 After a hydrolytic work up, the dichloride 81 
was obtained as red oil in 76% yield. The 1H NMR of 81 displayed 4 resonances at 
1.26 (3H, t, J = 7.2 Hz, CH3), 3.79 (2H, s, CH2), 4.19 (2H, q, J = 7.2 Hz, CH2), and 
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7.38 (1H, s, CH) ppm, whilst the carbon spectrum contained 8 resonances at 168.0 
(C), 167.0 (C), 162.7 (C), 160.4 (C), 120.1 (CH), 61.8 (CH2), 42.5 (CH2), and 14.0 
(CH3) ppm, thus indicating a successful reaction. Analysis of the MS data gave the 
distinctive pattern for a di-chlorinated molecule with masses at 235.0 (100%, 
[M+H+]), 237.0 (64%, [M+2+H+]) and 239.0 (10%, [M+4+H+]) Daltons, for the three 
possible isotopic combinations. In addition, high resolution MS gave a mass of 
235.0038 Daltons which is in good agreement with the required mass 235.0036 for 
C8H9
35Cl2N2O2 ([M+H
+]) (Scheme 14). 
 
 
 
Scheme 14. Synthesis of 81: POCl3, i-PrNEt2, Toluene. , 3 h, 76%. 
 
 
Reaction of 81 with sodium methoxide in methanol for 24 h gave after column 
chromatography86,87 compound 82 as a red oil in 40-57% yield over 2 attempts. The 
1H NMR of 82 displayed 5 resonances at H3.57 (2H, s, CH2), 3.64 (3H, s, Me), 3.88 
(3H, s, Me), 3.89 (3H, s, Me), and 6.28 (1H, s, CH) ppm, indicating that the ethyl ester 
had undergone trans-esterification during the course of the reaction. The 13C NMR 
displayed 9 resonances at C171.9 (C), 169.7 (C), 165.1 (C), 164.2 (C), 100.9 (CH), 
54.5 (CH3), 53.6 (CH3), 52.0 (CH3), and 42.5 (CH2) ppm which corresponds to the 
required environments (Scheme 15). 
 
 
Scheme 15. Synthesis of 82: NaOMe, MeOH, 3 h, 40-57%. 
 
.   
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Hydrolysis of the methyl ester of 82 was easily achieved by reaction with sodium 
hydroxide in methanol over 16 h followed by acidification with hydrochloric acid to 
give 6888 in 96% yield. Compound 68 gave a simple proton spectrum with five 
resonances at H 3.61 (1H, s, CH2), 3.88 (3H, s, CH3), 3.89 (3H, s, CH3), 6.54 (1H, s, 
CH) and 5.90-8.20 (1H, br s, OH) ppm, together with eight resonances in the carbon 
spectrum at C 171.5 (C), 170.6 (C), 165.5 (C), 164.6 (C), 101.1 (CH), 54.4 (CH3), 
53.8 (CH3) and 42.4 (CH2) ppm. High resolution mass spectrometry gave a mass of 
199.0713 Daltons corresponding exactly to the required mass for the [M+H]+ ion 
(Scheme 16). 
 
 
Scheme 16. Synthesis of carboxylic acid 68: i) NaOH, MeOH, 16 h. ii) 1M HCl, 96%. 
In parallel with the above study, an alternate route to 68 was investigated as 
some of the previous steps were low yielding. On investigation of the literature, we 
found that a patent89 reported that the chlorinated pyrimidine 83 on treatment with an 
excess of dimethyl malonate in the presence of NaH gave the substitution product 85 
in 55% yield (Scheme 17). 
 
 
Scheme 17. Synthesis of malonate 85: sodium hydride, DMF, 18h at 100 °C, 55%. 
This led us to propose the Scheme 18 shown below in which barbituric acid 24 
is converted90 into the trichloropyrimide 86 and then substituted firstly by methoxide 
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to give 8791 and then by malonate to give 88, Finally, hydrolysis and decarboxylation 
should lead to the previously prepared acid 68. 
 
 
Scheme 18. Alternate synthesis of acid 68: (a) POCl3, N,N-dimethylaniline, 0 °C, reflux 45 min; (b) 
NaOMe, MeOH, 3 h, 0 °C; (c) diethyl malonate, NaH, DMF, 100 °C; (d) NaOH, then HCl. 
We thus prepared the trichlorinated pyrimidine 87 by reaction of barbituric 
acid 24 with phosphorous oxychloride to give 8691 in 83% yield. Identification of 86 
was determined by the single signal at  7.4 (1H, s, CH) ppm in the 1H NMR spectrum 
along with 3 resonances for the 13C NMR at 163.3 (C), 160.2 (C), and 120.2 (CH) 
ppm. Reaction of 86 with 2 equivalents of sodium methoxide in methanol at 0 ºC 
followed by stirring overnight gave the dimethoxypyrimidine 87 in 67% yield. The 
proton NMR gave 3 resonances at H 3.96 (3H, s, Me), 3.99 (3H, s, Me) and 6.38 (1H, 
s, CH) ppm and six resonances in the carbon NMR at C 172.2 (C), 164.9 (C), 161.2 
(C), 100.9 (CH), 55.3 (CH3) and 54.4 (CH3) ppm. The recorded melting point for 87 
was 68-69 °C which compared well with the literature value of 71-73 °C91. 
With 87 in hand the key reaction with diethyl malonate was attempted. Thus 
diethyl malonate was added drop wise to a stirred mixture of the pyrimidine 87 and 
sodium hydride in DMF at 0 °C which was followed by heating the mixture at 100 °C 
for 16 h. After work up and chromatography the malonate 88 was obtained as an oil 
in 67% yield. The proton NMR of 88 gave major resonances at δH 1.25 (6H, t, J = 7.1 
Hz, 2 × Me) and 3.93 (6H, s, 2 × Me) ppm for the 6 methyl resonances and at 4.10-
4.26 (4H, m, 2 × CH2) ppm for the methylene protons of the ethyl esters. The two 
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methyl resonances at δH 4.67 (1H, s, CH) and 6.45 (1H, s, CH) ppm confirmed the 
formation of 88. The required 10 resonances were present in the carbon spectrum and 
high resolution mass spectrometry gave a mass of 299.1237 Daltons which was in 
close agreement with the calculated mass of 299.1238 required for C13H19N2O6 
([M+H]+). In addition to the major resonances in the spectrum, it was apparent that 
several smaller resonances were present corresponding to enolic forms of 88 (Scheme 
19). 
 
Scheme 19. Synthesis of malonate 88: Diethyl malonate, NaH, DMF, 100 °C, 16h, 54-66%. 
 
Hydrolysis of the two ethyl ester of 88 was easily achieved by reaction with 
sodium hydroxide in methanol over 16 h followed by acidification with hydrochloric 
acid to effect decarboxylation. Initial observation of the proton NMR spectrum of the 
crude product indicated that two products were present as there were four methoxy- 
environments observed. We theorized that the dicarboxylic 89 acid which is initially 
formed in the reaction was not undergoing complete decarboxylation It was found 
however, that when this mixture was treated with 3M hydrochloric acid for 6 hours 
conversion to the previously prepared acid prepared 68 was observed in quantitative 
yield which gave identical spectroscopic data to that reported above (Scheme 20). 
 
 
 
Scheme 20. Synthesis of carboxylic acid 68: i) NaOH, MeOH, 16h. ii) 1 M HCl, 100%. 
With the acid 68 in hand we moved onto the key reaction with Meldrum’s acid 
which has been reported83 to give acylated derivatives similar to 90 which on heating 
with alcohols can be converted to the desired -ketoester 69 (Scheme 21). 
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Scheme 21. Proposed synthesis of -ketoester 69: (a) DCC, DMAP, Meldrum's acid; (b) Allyl 
alcohol, PhH, . 
The reaction of 68 was attempted using DCC as an activating agent and an 
excess of DMAP as a basic catalyst, which leads to the acylated intermediate 90. 
Following completion of the reaction, the literature method83 used an acidic work up 
to remove the DMAP and to protonate the enolate salt 91 which is an intermediate in 
the reaction. On applying this work up to our reaction we were unable to obtain any 
product which was identifiable as 90. We repeated the reaction and on completion, we 
evaporated the solvent and inspected the crude product proton NMR which gave no 
clear evidence of the presence of 90 and it was apparent that the mixture contained 
large amounts of DCCU and DMAP as contaminants. Mild acidic work up of this 
mixture then gave a product which on proton NMR analysis, did not suggest the 
formation of 90. This led us to theorize that the compound 90 might be zwitterionic in 
nature and might be highly soluble in water. With this in mind, we attempted to recover 
the putative compound 90 from the aqueous layer by careful neutralisation, however 
no significant material was isolated. We also attempted to convert the mixture from 
this reaction directly to the ester 69 by treating it with allyl alcohol in benzene at reflux. 
This again led to a complex mixture of products and acidic work up led to the loss of 
the majority of the material. Attempted chromatography of the crude reaction mixture 
was unsuccessful as it was difficult to remove the DMAP and DEAD by-products from 
the reaction mixture (Scheme 22). 
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Scheme 22. Attempted preparation of -ketoester 69: (a) i) DCC, DMAP 
 ii) Meldrum’s acid, CH2Cl2, 5 h at rt; (b) allyl alcohol, reflux benzene. 
 
On inspection of the literature an alternative method92 was found which utilized 
carbodiimidazole (CDI) as the coupling reagent. This method has the advantage over 
the previous method of only producing imidazole as the by-product, which should be 
easier to remove. Thus heating the acid 68 with CDI in THF overnight was attempted 
which unfortunately led to considerable decomposition, which was associated with the 
low solubility of the acid in THF and associated charring because of this. We repeated 
the reaction using DMF and were pleased to observe the formation of the intermediate 
adduct 90 as evidenced by proton NMR resonances at H 1.64 (6H, s, 2 × CH3) ppm 
for the methyl groups of the cyclic diester acid and at H 3.99 (1H, s, CH) ppm for the 
methyne proton. It was also apparent that an enol was present as a signal at H 11.65 
ppm was observed. This product was dissolved in allyl alcohol (7 mL) and heated at 
90 °C for 16 h to effect conversion to the -ketoester 69. However, after evaporation 
and column chromatography a complex mixture of products was obtained, none of 
which was indicative of the presence of the required product. The reasons for the 
failure of this reaction were unclear and it was proposed that impurities in the crude 
product were the cause. It was also observed that DMF was a major contaminant and 
we attempted to remove this impurity by washing with saturated LiBr solution, which 
is known to remove DMF impurities. On attempting this process, it was observed that 
the product 69 passed into the aqueous phase, which supported our theory of high 
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water solubility in the initial reactions. We were able to get the majority of the product 
back by acidification and re-extraction, however the purity by proton NMR looked to 
have diminished and there seemed to be more contamination. We also tied to purify 
this material by column chromatography and again found a loss of most of the 
material, which suggested the decomposition of the intermediate on silica gel. It was 
also attempted to purify the compound on triethylamine washed silica gel, however 
the only product obtained was the triethylamine enolate salt 91 (R = Et) in a very low 
3% yield. 
Part of the problem with this reaction was assumed to be the presence of an 
excess of the solvent DMF in the initial step and the use of neat allyl alcohol in the 
final step. With this in mind, the reaction was repeated with a small volume of DMF 
in the initial stage of the reaction and after the isolation of the intermediate 90, the 
allylation step was performed in benzene solution with five equivalents of allyl 
alcohol. Column chromatography of the crude compound obtained gave the desired -
ketoester 69 in 28% yield (Scheme 23). 
 
 
Scheme 23. Synthesis of carboxylic acid 69:  
(a) Meldrum’s acid, CDI, DMF 50 °C, 5 h; (b) allyl alcohol, , PhH, 28%. 
 
Analysis of the proton NMR of 69 gave a complex spectrum which was 
thought to be due to the presence of enol tautomers of 69. The major resonances were 
present at H (DMSO) 3.78 (2H, s, CH2), 3.86 (3H, s, CH3), 3.88 (3H, s, CH3) and 3.91 
(2H, s, CH2) ppm for the two methoxy and methylene resonances whilst the allyl ester 
resonances were present at H 4.55-4.58 (2H, m, CH2), 5.20-5.24 (1H, m, CH), 5.28-
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5.35 (1H, m, CH) and 5.83-5.97 (1H, m, CH) ppm. The uracil CH proton was found 
at H 6.47 (1H, s, CH) ppm and several enolic resonances were observed at H 5.53 
(CH), 6.25 (CH) and 13.71 (OH) ppm. The carbon spectrum gave 13 major resonances 
corresponding to the required number for 69, whilst high resolution MS gave a mass 
of 281.1134 Daltons which corresponds closely to the desired mass of 281.1132 
Daltons for C13H17N2O5 ([M+H]
+).  
Whilst the synthesis of 69 was a satisfactory achievement the various problems 
with the synthesis, which stem from the coupling stage and the basicity of the 
pyrimidine ring, led to low yields and problems with purification. Therefore, it was 
proposed that an alternative approach be adopted in which we protect the pyrimidine 
in its benzyl amide form and the following synthesis was proposed (Scheme 24). In 
this synthesis the protecting groups are introduced in the first step of the synthesis 
which is the condensation of diethyl 1,3-acetonedicarboxylate and dibenzylurea. 
Hydrolysis of this ester followed by coupling and allyl ester foamation should yield 
the RHS analogue 96. 
 
 
Scheme 24. Proposed synthesis of the RHS analogue 96: 
(a) diethyl 1,3-acetonedicarboxylate, PhH, p-TsOH, , 4 days; (b) NaOH, EtOH, 
 0oC-rt; (c) Meldrum's acid, CDI, THF, at 50 °C, 16 h (d) allyl alcohol, 110 °C, 16 h. 
 
 
Dibenzylurea 92 was prepared using the method described by Wolman and 
Gallop,93 in which a vigorously stirred suspension of finely powdered carbohydrazide 
and benzylamine was treated with I2 to give 92
93 as a white solid in 48-64% yield over 
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four attempts. The preparation of the urea was also realised by the reaction of 
benzylamine with carbodiimidazole (CDI) in refluxing THF which gave 92 in 68% 
yield. The proton NMR spectrum for 92 gave three diagnostic resonances at H 4.23 
(4H, d, J = 6.0 Hz, 2 × CH2), 6.43 (2H, t, J = 6.0 Hz, 2 × NH) and 7.20-7.33 (10H, m, 
2 × Ph) ppm with 6 resonances in the carbon spectrum at C 43.0 (2 × CH2), 126.5 
(CH), 127.0 (CH), 128.2 (CH), 140.9 (C), and 158.1 (C=O) ppm. Analysis by high 
resolution MS gave a value of 241.1333 Daltons which corresponded well with the 
expected mass of 241.1335 Daltons and a recorded melting point of 165-168 °C 
corresponded well with the literature93 value of 168-169 °C (Scheme 25). 
 
Scheme 25. Two syntheses of dibenzylurea 92.93 
        (a) I2, DMF, benzylamine, 1h, 64%.; (b) benzylamine, THF, , 16 h, 68%. 
 
 
With the urea 92 in hand the preparation of the pyrimidine 93 was investigated. 
Reaction of 92 with 2 equivalents of diethyl 1,3-acetonedicarboxylate  92 in refluxing 
benzene with the removal of water under soxhlet extraction with molecular sieves (4 
Å) gave 93 as a pale yellow solid in 67% yield. Diagnostic NMR resonances were at 
δH 1.26 (3H, t, J = 7.2 Hz, CH3) and 4.13 (2H, q, J = 7.2 Hz, CH2) ppm for the ethyl 
ester group and at δH 3.42 (s, 2H) ppm for the methylene group. The vinylic proton 
was also present at δH 5.76 (1H, s, CH) ppm with signal for the 2 benzyl groups being 
observed at δH 5.13 (2H, s, CH2), 5.17 (2H, s, CH2), and 7.11-7.50 (10H, m, 2 × Ph) 
ppm. Diagnostic quaternary were also observed at δC 152.3 (C=O), 161.6 (C=O) and 
167.2 (C=O) for the urea carbon and carbonyl groups. High resolution mass 
spectroscopy gave a mass of 379.1650 ([M+H]+) Daltons which is in excellent 
agreement with the calculated value of 379.1652 (Scheme 26).  
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Scheme 26. Synthesis of pyrimidine 93: 
(a) diethyl 1,3-acetonedicarboxylate, PhH, p-TsOH, , 4 days, 90%. 
 
The ester 93 was then hydrolyzed in an uneventful manner with ethanolic 
sodium hydroxide over 5 days and after purification the acid 94 was obtained as an off 
white solid in 74% yield. The signal for the alkene proton was observed at δH 5.89 
(1H, s, CH) ppm whilst the carboxylic acid proton was observed at δH 13.09 (1H, br s, 
OH) ppm. Diagnostic carbon resonances were observed for the alkene proton at δC 
103.0 ppm and the acid carbonyl at 169.4 ppm. High resolution MS gave a mass of 
351.1340 [M+H]+ Daltons which is in good agreement with the expected value of 
351.1339 Daltons (Scheme 27). 
 
 
 
Scheme 27. Synthesis of acid 94: (a) NaOH, EtOH, 0 °C rt 2 days, 93-96%. 
 
Initial attempts the formation of -ketoester 96 were based on the treatment of 
94 with an excess of CDI at 50 °C for 5 hours followed by the addition of Meldrum's 
acid 98 and continued heating overnight. On work up the crude intermediate 95 was 
heated with excess allyl alcohol resulting in decarboxylation and ester formation to 
give 96. After chromatography the desired product 96 was obtained, however large 
amounts of compound 98 were obtained which we thought might be occurring via 
decarboxylation of the acid 94 on heating. It was found that combining directly the 
pyrimidine 94, Meldrum's acid and an excess of CDI followed by heating at 50 °C for 
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16 h minimized the formation of 98 and on work up gave 96 in 46-49% yield over 
three attempts (Scheme 28).  
 
 
Scheme 28. Preparation of the pyrimidine 96: (a) Meldrum's acid, CDI, anhydrous THF, 50 °C, 16 h; 
(b) Allyl alcohol, 110 °C, 16 h, 46-48%. 
The spectrum of 96 was more complex than expected because of the presence 
of tautomers of the -ketoester however, diagnostic resonances were observed at δH 
(DMSO) 3.77 (2H, s, CH2), 3.97 (2H, s, CH2) for the two chain methylene groups 
whilst the allyl ester methylene was observed at δH 4.57 (2H, dt, J = 5.5, 1.3 Hz, CH2) 
ppm. The alkene protons were observed at δH 5.21 (1H, dq, J = 10.5, 1.3 Hz, CH), 
5.31 (1H, dq, J = 17.3, 1.3 Hz, CH), and 5.87 (1H, ddt, J = 17.3, 10.5, 5.5 Hz, CH) 
ppm whilst the uracil methyne proton was observed at 5.79 (1H, s, CH) ppm. Final 
confirmation of structure was obtained by high resolution MS which gave a mass of 
433.1756 Daltons which is in close agreement with the calculated mass for [M+H]+ of 
433.1758 Daltons. 
The conclusions from this stage of the work are that the two RHS synthons for 
deoxy-cylindrospermopsin were successfully prepared. The methoxy protected 69 
proved difficult to prepare and the benzyl protected 96 differs significantly from 
previously utilized methoxy- and benzyloxy- ether protected uracil groups found in 
other total syntheses. This protecting group will require a different deprotection 
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strategy and this will need to be addressed in the total synthesis. The failure of the 
Meldrum’s acid/allylation strategy in the methoxy-ether series is not easy to explain 
and possibly given more time this might be worth reinvestigating.  
Synthesis of analogues of the cylindrospermopsin alkaloids  
The second goal of the project was to prepare simplified analogues of 
cylindrospermopsin to investigate structure activity relationships. From a previous 
report17 it is apparent that the uracil group, the hydroxyl function and the guanidine 
are essential for activity whereas the sulfate group plays a small role in the biological 
properties.  
Simplifying cylindrospermopsin 1 leads to a “stripped down” analogue 78, 
which can be retrosynthesised to give the known aldehyde 11 and the protected 
Grignard reagents 100 (Figure 13). 
 
 
 
Figure 13. Proposed retrosynthesis of cylindrospermopsin 1 model compounds 78 
Aldehyde 11 was considered to be a good starting point for this synthesis as it 
has been employed in several syntheses of cylindrospermopsin and can be converted 
into the uracil by treatment with acid. Aldehyde 11 can be prepared in three steps from 
orotic acid as shown in (Scheme 29).94 
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Scheme 29. Preparation of aldehyde 11: (a) orotic acid monohydrate, POCl3, PCl5 reflux16 h, then 
MeOH, 24 h; (b) THF, LiBH4, EtOH, rt, 2 h; (c) Dess-Martin periodinane, CH2Cl2, rt 2 h. 
Snider reported the synthesis of the methyl ester 102 from orotic acid by 
heating at 120 °C overnight with POCl3 and PCl5 to giving crude 2,6-
dichloropyrimidine-4-carbonyl chloride which on reaction with dry methanol gave the 
methyl ester 102 in 57% yield. We repeated his reported method and obtained 102 
with spectroscopic data identical to that reported, however in considerably lower 
yields of 9-17% over three attempts. Snider also reported the isolation of the 
corresponding acid 105 from his reaction in 18%, however we were unable to isolate 
any of this by-product from the process. We were concerned that the reaction details 
reported in the literature were in error and that possibly sodium methoxide was 
required as a nucleophilic reagent to react with the intermediate acid chloride 104. We 
thus repeated the reaction using this reagent but unfortunately similar yields of 9-18% 
were obtained (Scheme 30).  
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Scheme 30. Preparation of ester 102: (a) i) orotic acid monohydrate, POCl3, PCl5 reflux,16 h; ii) 
MeOH, 24 h, 9-18%. 
Despite the low yields obtained in the previous step, we proceeded to the 
reduction of the ester 102 to the aldehyde 103. Thus a solution of ester 102 was 
reduced with LiBH4 dissolved in EtOH/THF to give the alcohol 103 in 84%. The data 
for 103 was in good agreement with the literature and had diagnostic NMR resonances 
at δH 3.25 (1H, s) ppm for the alcohol group and at δH 4.58 (2H, s) and δC 63.6 ppm 
for the methylene protons (Scheme 31).  
 
Scheme 31. Preparation of alcohol 103: (a) LiBH4, EtOH/THF, rt, 2 h, 84%. 
Oxidation of 103 to the aldehyde 11 was reported to be possible using Dess-
Martin periodinane in CH2Cl2.
94 We thus applied this method to alcohol 103 and after 
work up and silica gel chromatography we obtained the aldehyde 103 as a pale yellow 
solid in 81-96% yield over 2 attempts. Again the compound was in good agreement 
with the literature and had diagnostic NMR resonances for the aldehyde functional 
group at δH 9.89 (1H, s, CH) ppm and δC 192.1 (CH) ppm (Scheme 32). 
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Scheme 32. Oxidation of alcohol 103 to aldehyde 11: (a) Dess-Martin periodinane, CH2Cl2, rt, 2 h, 
81-96%. 
With the aldehyde prepared we turned to the preparation of the required 
Grignard precursor 109 which was easily prepared by silylation 3-bromopropan-1-ol 
106 with TBSCl in the presence of imidazole and DMAP (Scheme 33), 
after work up and purification the silane 107 was obtained as colourless oil in 87% 
yield. The data for this compound was in agreement with the literature,94 with five 
resonances in the proton NMR at H 0.06 (6H, s, 2 × CH3), 0.89 (9H, s, 3 × CH3), 2.02 
(2H, tt, J = 5.7, 6.5 Hz, CH2), 3.50 (2H, t, J = 6.5 Hz, CH2) and 3.72 (2H, t, J = 5.7 
Hz, CH2) ppm. This together with 6 resonances in the carbon spectrum at c 60.3 
(CH2), 35.5 (CH2), 30.5 (CH2), 25.9 (3 × CH3), 18.2 (C) and -5.4 (2 × CH3) ppm 
confirmed the structure of 11.  
 
 
Scheme 33. Preparation of silyl ether (a) 107: TBSCl, imidazole, DMAP, CH2Cl2, rt, 5 d, 90%. 
Our initial attempts at forming a Grignard reagent with 108 were unsuccessful 
as it was slow to react with magnesium and eventually we found that we were able to 
form the Grignard by vigorous heating in THF for 30 min. Once formed reaction with 
the aldehyde 11 did not give the desired addition product but instead led to the 
formation of the alcohol 103 in 46% yield (Scheme 34). 
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Scheme 34. Attempted preparation of alcohol 109: (a) Mg, THF, , 30 min; (b) 11, 16 h, 48%. 
 
 
The rationale for the formation of 11 is that Grignard reagent are known under 
certain circumstances to prefer reduction as to addition and the mechanism of this is 
related to the-elimination of a hydride from the Grignard leading to the formation of 
a reduced product and an alkene as shown in (Scheme 35). 
 
 
Scheme 35. Proposed mechanism for the reduction of aldehyde 103 by the Grignard reagent 108 
Our initial conclusions from this work were not promising as there were two 
major problems with the methodology. Firstly, we were unable to prepare the aldehyde 
11 as reported by Snider in very high overall yields and secondly the addition of the 
Grignard reagent to the aldehyde 11 was unsuccessful. We thus required a change of 
strategy and on inspection of the literature95 we found a report on the preparation of 
the protected aldehyde 113 in two steps for the previously prepared benzyl urea 92 in 
high yield (Scheme 36). 
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Scheme 36. Preparation of aldehyde 113: (a) Ac2O, DMAP, pyridine, 115 °C, 5 h; (b) SeO2, THF, 
CH3CO2H, , 24 h 
Snider had also reported the addition of the alkyne species 114 to the aldehyde 
11 in his synthetic studies towards cylindrospermopsin 1. This reaction uses a 
Grignard exchange protocol and the acetylenic Grignard intermediate formed adds to 
the aldehyde in 83% yield 64 (scheme 37). 
 
 
Scheme 37. Key step from Snider’s synthesis94 of 115: (a) EtMgBr, THF, 0 °C 
By combining these two reaction sequences we hoped to apply the modified 
synthetic approach shown in (Scheme 38) in which the uracil ring is protected by two 
N-benzyl groups and the alkane side chain is introduced as an alkyne and is later 
reduced (Scheme 38). 
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Scheme 38. Modified retrosynthesis of the cylindrospermopsin model compounds 78 
 
 
The previously prepared 1,3-dibenzylurea was next treated with an excess of 
acetic anhydride in the presence of DMAP in pyridine at reflux for 5h. After work up 
and purification by chromatography the pyrimidine 77 was obtained in a 76-78% yield 
over three attempts as an oil. Data was in good agreement with the literature95 with 
diagnostic resonances being observed at δH  2.14 (3H, s, CH3) and 5.65 (1H, s, CH) 
ppm together with δC 19.8 (CH3) and 102.0 (CH) ppm for the methyl and alkene 
resonances respectively (Scheme 39). 
 
 
Scheme 39. Synthesis of pyrimidine 98: (a) Ac2O, DMAP, pyridine,  115 °C 5 h, 76-78%.  
The pyrimidine 9895 was then treated with an excess of selenium dioxide in 
acetic acid at reflux for 16 h and after work up the aldehyde 11396 was obtained as an 
oil in 74-77% yield over four attempts. Diagnostic resonances for the aldehyde group 
were observed at δH 9.41 (1H, s, CH) and δC 185.6 (CH) ppm which were in agreement 
with that reported in the literature96 (Scheme 40). 
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Scheme 40. Preparation of aldehyde 113 by selenium dioxide oxidation: (a) SeO2, THF, AcOH,  
115 °C, 24 h, 74%. 
The required silylated propargyl alcohol 119 was prepared97 in 91% yield by 
the addition of TBSCl to a mixture of propargyl alcohol and imidazole in dry 
dichloromethane. The corresponding homopropargyl silane 121 was similarly 
produced in 90.5% yield using the same method98 (Scheme 41). 
 
 
 
Scheme 41. Preparation of silanes 119, 91% and 121, 81%. (a) TBSCl, CH2Cl2, imidazole, DMAP, rt, 
24 h. 119; 91%, 121; 81%. 
With the precursors 119 and 121 in hand, the coupling of these two was 
attempted. Thus a THF solution of EtMgBr was added to a cooled (-40˚C) solution of 
the propargylsilane 119 dissolved in dry THF and the mixture stirred to rt over 1 h. 
This solution was then transferred by syringe to a cooled (-78 ˚C) solution of the 
pyrimidine aldehyde 113 in dry THF. After 5 h, aqueous work up and chromatography 
gave the desired product 122 in 75-77% yield over five attempts. Confirmation of the 
structure of 122 was obtained on analysis of the proton NMR which gave diagnostic 
resonances at δH 3.43 (1H, d, J = 6.8 Hz, OH) ppm for the hydroxyl proton and at 5.11-
5.18 (3H, m, CH, CH2) for the methyne and methylene protons adjacent to the alcohol 
and silyl ether functional groups, whilst the uracil proton was found at δH 6.25 (1H, s, 
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CH) ppm. Resonances in the carbon at δC at 60.3 (CH) and 51.5 (CH2) ppm confirmed 
the presence of these groups, whilst high resolution mass spectrometry gave a mass of 
490.2350 Daltons which is in good agreement with the expected value for 
C28H35N2O4Si ([M+H]
+) which requires 490.2361 Daltons (Scheme 42). 
 
 
Scheme 42. Preparation of alcohol 122: (a) i) EtMgBr in THF (1M), –40 °C; ii) 113, –78 °C – rt, 3 h, 
78%. 
In a similar manner, the homopropargyl ether 121 was reacted with the 
aldehyde 113 to give 123 in 51-66% yield over three attempts. Confirmation of the 
structure of 123 was obtained on analysis of the proton NMR which gave diagnostic 
resonances at δH 2.36 (2H, dt, J = 1.8, 6.9 Hz, CH2) and 3.64 (2H, t, J = 6.9 Hz, CH2) 
ppm for the two coupled methylene protons and at δH 3.43 (1H, d, J = 6.8 Hz, OH) 
ppm for the alcohol proton. The methyne proton adjacent to the alcohol was observed 
at δH 5.07 (1H, m, CH) ppm whilst the uracil proton was found at δH 6.22 (1H, s, CH) 
ppm. Resonances in the carbon spectrum at δC 60.3 (CH) and 61.1 (CH2) ppm also 
confirmed the presence of these functional groups. High resolution MS gave a mass 
of 505.2507 Daltons, which is in good agreement with the expected value for 
C29H37N2O4Si ([M+H]
+) which requires 505.2517 Daltons (Scheme 43). 
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Scheme 43. Preparation of alcohol 123: i) 121, EtMgBr in THF (1M), –40 °C; ii) 113, –78 °C – rt, 6h, 
51-66%. 
 
The alkyne 122 was then hydrogenated by reaction with hydrogen gas in the 
presence of palladium on activated carbon which gave the alcohol 124 in 73% yield 
after chromatography. Analysis by proton NMR confirms the disappearance of the 
alkyne resonances and the presence of saturated methylene resonances at H 1.48-1.88 
(4H, m, 2 × CH2) and 3.55-3.67 (2H, m, CH2) ppm. The benzylic methylene protons 
were still present at H 5.01 (1H, d, J = 16.4 Hz, CH), 5.10 (1H, d, J = 13.8 Hz, CH), 
5.15 (1H, d, J = 13.8 Hz, CH), and 5.33 (1H, d, J = 16.4 Hz, CH) whilst the uracil 
proton was observed at H 6.04 (1H, s, CH) ppm. The carbon spectrum contained the 
required 21 resonances and the high resolution MS gave a mass of 494.2666 Daltons 
which is in good agreement with the expected value for C28H39N2O4Si ([M+H]
+) 
which requires 494.2674 Daltons (Scheme 44). 
 
 
Scheme 44. Hydrogenation of alkyne 122: (a) Pd/C (10%), EtOAc, H2, 2 h, 73%. 
Similarly the alkyne 123 was hydrogenated by reaction with hydrogen gas in 
the presence of palladium on activated carbon to give the alcohol 125 in 64% yield 
after chromatography. Again analysis by proton NMR confirms the disappearance of 
the alkyne resonances and the presence of saturated methylene resonances at H 1.34-
1.53 (4H, m, 2 × CH2), 1.54-1.66 (2H, m, CH2) and 3.55-3.67 (2H, m, CH2) ppm. The 
benzylic methylene protons were still present at H 4.98 (1H, d, J = 16.3 Hz, CH), 5.10 
(1H, d, J = 13.7 Hz, CH), 5.15 (1H, d, J = 13.7 Hz, CH) and 5.31 (1H, d, J = 16.3 Hz, 
CH), whilst the uracil proton was observed at H 5.99 (1H, s, CH) ppm. The carbon 
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spectrum contained the required 22 resonances and the high resolution MS gave a 
mass of 509.2819 Daltons, which is in good agreement with the expected value for 
C29H45N2O4Si ([M+H]
+) which requires 509.2830 Daltons (Scheme 45). 
 
 
Scheme 45. Hydrogenation of alkyne 123: (a) Pd/C (10%), EtOAc, H2, 2 h, 64-72%. 
With the two alcohols 124 and 125 in hand, the desilylation of 125 was 
attempted and thus treatment with TBAF in THF led to the removal of the silyl 
protecting group and the formation of the diol 126 in 77% yield. Proton NMR 
confirmed the loss of the silyl protecting group resonances and the appearance of a 
broad signal at H 3.00 (2H, br s, 2 × OH) ppm corresponding to the two hydroxyl 
protons. The desired 19 resonances were observed in the carbon spectrum and a broad 
band in the IR spectrum at 3386 cm-1 confirmed the presence of the 2 alcohol groups. 
High resolution MS also gave a mass of 396.1565 Daltons which is in exact agreement 
with the expected value for C23H27N2O4 ([M+H]
+) (Scheme 46). 
 
 
Scheme 46. TBAF Deprotection of 125: (a) TBAF (1M), THF, rt 2 h, 77%. 
Guanylation of 126 was then attempted under Mitsunubo conditions and on 
treatment with N,N'-di-Boc-guanidine, triphenylphosphine and DIAD, a product was 
isolated which appeared to incorporate the guanidine group. However on analysis by 
NMR spectrometry a complex spectrum was obtained which suggested that a 
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compound thought to be 127 had been formed in 81% yield. This might have arisen 
from the incorporation of one guanidine residue and one equivalent of the by-product 
from the DIAD reaction and this eventuality was confirmed by the high resolution MS 
data which gave a mass at 822.4390 Daltons which corresponds well to the calculated 
mass 822.4396 Daltons for C42H59N7O10  ([M+H]
+) (Scheme 47). 
 
 
Scheme 47. Preparation of 127: (a) DIAD, PPh3, N,N'-di-Boc-guanidine, THF, rt 16 h, 81%.  
With the problems encountered in selective guanylation, it was envisaged that 
a different sequence of protection/deprotection reactions was required and we thus 
acetylated the secondary alcohol function in 124 using acetic anhydride and pyridine 
in dichloromethane to give the acetate 128 in 75-98% yield over four reactions. 
Analysis of the proton NMR spectrum of the diagnostic resonances at H 2.02 (3H, s, 
CH3) ppm for the acetate methyl and at H 5.49 (1H, dd, J = 9.5, 2.3 Hz, CH) ppm for 
the downfield shifted methyne proton adjacent to the acetate. The required 23 
resonances were observed in the carbon spectrum and high resolution MS gave a mass 
of 537.2769 Daltons which corresponds well to the required mass of 537.2779 for 
C30H41N2O5Si ([M+H]
+) (Scheme 48). 
 
 
Scheme 48. Acetyl protection of alcohol 124: (a) Ac2O, pyridine, DMAP, CH2Cl2, rt, 1 h, 75-98%. 
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Subsequent desilylation of 128 was easily achieved using a solution of TBAF 
in THF to give 129 as colorless oil in 73-89% yield over 3 reactions. Analysis of the 
proton NMR spectrum confirmed the disappearance of the resonances for the silyl 
protecting group and the appearance of a signal at H 3.10 (1H, br s, OH) ppm 
corresponding to the alcohol group. The carbon spectrum had the desired 20 
resonances and the high resolution MS gave a mass of 423.1917 Daltons which 
corresponds well to the required mass of 423.1914 Daltons for C24H27N2O5 ([M+H]
+) 
(Scheme 49). 
 
 
 
Scheme 49. TBAF Deprotection of 128: (a) TBAF (1M), THF, rt, 2 h, 73-80%. 
 
 
With alcohol 129 in hand, its guanylation was investigated. Thus alcohol 129 
was coupled under Mitsunobu conditions with 2 equivalents of the N,N'-di-Boc-
guanidine. After purification by column chromatography the guanidine 130 was 
obtained in a disappointing 19-26% yield over three attempts. Analysis of the proton 
NMR spectrum indicated the presence of resonances for the 2 tBu groups of the Boc 
protecting groups at H 1.37 (9H, m, 3 × Me) and 1.51 (9H, m, 3 × Me) ppm and two 
resonances at H 8.56 (1H, br s, NH) and 8.90 (1H, br s, NH) ppm for the NH groups. 
The required 27 resonances were observed in the carbon spectrum and high resolution 
MS gave a mass of 663.3143 Daltons, which is in close agreement with the calculated 
mass of 663.3160 Daltons for C35H45N5O8Na ([M+Na]
+) (Scheme 50). 
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Scheme 50. Guanylation of 129 using N,N'-di-Boc-guanidine: (a) DIAD, PPh3, N,N'-di-Boc-
guanidine, THF, rt 16 h, 19-26%. 
The low yield in this reaction prompted us to attempt a coupling with the 
N,N’,N'’-tri-Boc-guanidine as an alternate guanylating agent. Thus reaction of 129 
with 2 equivalents of the N,N’,N'’-tri-Boc-guanidine, triphenylphosphine and DIAD 
on THF gave 131 in 34-39 % yield over three attempts. Again, analysis of the proton 
NMR spectrum indicated the presence of resonances for the 3 tBu groups of the Boc 
protecting groups at H 1.37 (9H, m, 3 × Me), 1.44 (9H, m, 3 × Me) and 1.51 (9H, m, 
3 × Me) ppm and a signal at H 10.40 (1H, s, NH) ppm for the NH proton. The required 
29 resonances were observed in the carbon spectrum and high resolution MS gave a 
mass of 764.3864 Daltons, which is in close agreement with the calculated mass of 
764.3865 Daltons for C40H54N5O10 ([M+H]
+) (Scheme 51). 
 
 
Scheme 51. Guanylation of 129 using N,N’,N'’-tri-Boc-guanidine: (a) DIAD, PPh3, N,N’,N'’-tri-Boc-
guanidine, THF, rt 16 h, 34-39%. 
 
The formation of 130 and 131 represented a major achievement in the synthesis 
in that all the features of the required model compound are in place and all that is 
required is to deprotect the three required functional groups. The removal of the 
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acetate functional group was easily achieved by treatment of 131 with potassium 
carbonate in methanol rt for 1 h and after purification the alcohol 132 was obtained as 
a white solid in 76% yield. Analysis of the proton NMR spectrum indicated the loss 
of the acetate methyl and the appearance a signal at H 1.94 (1H, br s, OH) ppm for 
the alcohol proton as well as the CH proton at H 5.34 (1H, t, J = 7.4 Hz, CH) ppm. 
High resolution MS gave a mass of 722.3757 Daltons which is in close agreement with 
the required mass of 722.3760 Daltons for C38H52N5O9 ([M+H]
+) (Scheme 52). 
 
 
Scheme 52. Deprotection of acetate 131: (a) K2CO3, MeOH, rt, 1 h, 76%. 
With 132 available, we attempted to deprotect the benzyl groups and initially 
attempted a transfer hydrogenation reduction over Pd/C in the presence of ammonium 
formate as the hydrogen source. This method was reported as being effective at 
deprotecting similar uracils.99 Applying this method to compound 132 and after 
refluxing for 16 hours, work up gave a product which on NMR appeared to be a 
complex mixture of compounds. The NMR spectrum lacked the required uracil CH 
proton signal as well as the proton adjacent to the hydroxyl group, the resonances for 
the Boc protecting groups had also disappeared. This suggested that under these 
conditions the uracil ring was possibly being destroyed and that the hydroxyl group 
might be undergoing hydrogenolysis. In a related hydrogenation Weinreb et al. 
reported67 a similar problem in a hydrogenation of an N,N’-dibenzyl protected uracil. 
(Scheme 53). 
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Scheme 53. Attempted deprotection of acetate 132: (a) Pd/C, MeOH, HCO2NH4, , 16 h. 
An attempt was also made to remove all three protecting groups in one step 
under acidic conditions similar to those reported in several syntheses of 
cylindrospermopsin 1. Whilst benzyl groups are generally resistant to acidic condition 
it was hoped that the strong acidic conditions might lead to a nucleophilic substitution 
of the benzylic groups and that the uracil group might be a good leaving group in this 
process. Reaction of 133 with concentrated hydrochloric acid for 16 h gave a product 
which on analysis by MS gave two species at 422.2 (70%, [M+H+]) and 440.2 (100%, 
[M+H+]) Daltons which did not correspond to the desired product 133. Analysis by high 
resolutuon MS suggested the formation of the partially deprotected product 134 as a mass 
422.2162 corresponds closely to the desired mass of 422.2187 Daltons for C23H28N5O3  [M+ 
H+] Daltons. Similarly the mass at 440.1819 Daltons corresponds closely to the product 135 
in which the acetate group of 131 has been replaced by a chlorine. This compound requires a 
mass of 440.1848 Daltons for C23H2835ClN5O3 ([M+ H+]). It is thus apparent that the benzyl 
groups are resistant to the action of strong acids and that the benzylic acetyl group 
might be prone to substitution (Scheme 54). 
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Scheme 54. Attempted deprotection of 131 under acidic conditions: (a) HCl, , 16 h. 
 
The conclusion from this work was that whilst this methodology was 
unsuccesful at preparing the desired analogue, it was successful in generating the 
methodology for joining the three required functional groups together, albeit 
protected. We thus wished to revert to a global deprotection strategy and proposed the 
synthetic route show in Scheme 55. 
 
 
Scheme 55. Global deprotection approach to the cylindrospermopsin analogue 133 
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We initially investigated the coupling of the previously prepared aldehyde 11 
with the silane 119. A THF solution of EtMgBr was added to a cooled (-40˚C) solution 
of 119 in dry THF and the mixture stirred to rt over 1 h. This solution was then 
transferred by syringe to a cooled (-78 ˚C) solution of the aldehyde 11 in THF and 
stirred overnight. After work up and chromatography the desired product 137 was 
obtained in 71-75% yield over 2 attempts. Analysis of the IR spectrum of 137 gave a 
broad band at 3392 cm-1for the OH group, whilst in the proton NMR resonances at H 
0.09 (6H, s, 2 × CH3) and 0.87 (9H, s, 3 × CH3) ppm confirmed the presence of the 
silyl protecting group. The OH signal was present at H 1.95 (1H, br s, OH) whilst the 
two uracil methoxy groups were present at H 3.97 (3H, s, CH3) and 3.99 (3H, s, CH3) 
ppm. The methylene and methyne protons were observed at H 4.35 (2H, d, J = 1.1 
Hz, CH2) and 5.31 (1H, t, J = 1.1 Hz, CH) ppm respectively and shared a 1.1 Hz 
propargylic coupling constant, whilst the uracil proton was observed at H 6.54 (1H, 
s, CH). The required 13 resonances were observed in the carbon spectrum whilst high 
resolution MS gave a mass of 338.1735 which corresponds exactly to the mass 
required for C16H27N2O4Si ([M+H]
+) (Scheme 56). 
 
Scheme 56. Preparation of alcohol 137: (a) i) 121, EtMgBr in THF (1M), -78 °C, 2 h. ii) 11, rt 16 h, 
71-75 %. 
The alkyne 137 was then hydrogenated by reaction with hydrogen gas in the 
presence of palladium on activated carbon which gave the alcohol 141 in 79 % yield 
after chromatography.  Analysis of the proton spectrum indicated the appearance of 2 
coupled methylene groups at H 1.60-1.78 (3H, m, CH, CH2) and 1.93-2.03 (1H, m, 
CH) and the presence of methylene proton adjacent to oxygen at H 3.65 (2H, t, J = 
6.5 Hz, CH2) ppm and the alcohol at H 4.13 (1H, br s, OH) ppm. The carbon spectrum 
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contained the required 13 resonances and high resolution MS gave a mass of 343.2049 
which is in very close agreement with the calculated mass of 343.2048 for 
C16H31N2O4Si ([M+H]
+) (Scheme 57). 
 
 
Scheme 57. Hydrogenation of alkyne 137: Pd/C (10%), EtOAc, H2, 2 h, 79%. 
We next acetylated the secondary alcohol function in 141 using acetic 
anhydride and pyridine in dichloromethane to give the acetate 142 in 75% yield. 
Analysis of the IR spectrum indicated the absence of the OH stretch and the 
appearance of a carbonyl stretch at 1744 cm-1, whilst the proton NMR indicated an 
acetate signal at H 2.13 (3H, s, CH3) ppm and the methyne proton downfield shifted 
to H 5.61 (1H, dd, J = 4.8, 7.8 Hz, CH) ppm. The carbon NMR spectrum gave the 
required 11 resonances, whilst high resolution MS gave a mass at 385.2146 Daltons 
which is in close agreement with the calculated mass of 385.2153 for C18H33N2O5Si 
([M+H]+) (Scheme 58). 
 
 
Scheme 58. Acetyl protection of 141: Ac2O, pyridine, DMAP, CH2Cl2, rt, 1 h, 68 %. 
Desilylation of 142 was achieved using a solution of TBAF in THF to give 138 
as colourless oil in 80% yield. Analysis of the IR spectrum of 138 indicated the 
presence of a hydroxyl group as evidenced by the band at 3440 cm-1, whilst the 
carbonyl stretch of the acetate was at 1738 cm-1. Analysis of the NMR spectrum 
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indicated the loss of the resonances associated with the silyl protecting group and the 
presence of the OH group at H 3.59 (1H, br s, OH) ppm. The carbon NMR spectrum 
gave the required 12 resonances whilst high resolution MS gave a mass of 271.1287 
Daltons which corresponds closely to the calculated value of 271.1288 required for 
C12H19N2O5 ([M+H]
+) (Scheme 59). 
 
 
Scheme 59. TBAF Deprotection of 142: TBAF (1M), THF, rt, 2 h, 80%. 
The coupling of alcohol 138 with N,N’,N'’-tri-Boc-guanidine was attempted 
using triphenylphosphine and DIAD in THF. After work up and chromatography the 
guanidine 140 was obtained in 49% yield. Analysis of the product by proton NMR 
indicated the presence of the three tBu groups for the three Boc protecting groups at 
H 1.32 (9H, s, 3 × CH3), 1.49 (9H, s, 3 × CH3) and 1.50 (9H, s, 3 × CH3) ppm whilst 
the NH proton of the guanidine was observed at H 10.71 (1H, s, NH) ppm. Analysis 
of the high resolution MS gave a mass at 612.3225 Daltons which is in close agreement 
with the desired mass of 612.3239 Daltons for C28H46N5O10 ([M+H]
+) (Scheme 60). 
 
 
Scheme 60. Guanylation of 138: (a) DIAD, PPh3, N,N’,N'’-tri-Boc-guanidine, THF, rt 16 h, 49%. 
 
With the protected analogue prepared the global deprotection was attempted 
by two different methods. The first method involved heating a sample of 140 in 
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concentrated HCl at 100 °C for 6 h whilst the second method involved heating a sample 
under the same conditions but only at 80 °C but for 96 h (Scheme 61). 
 
 
Scheme 61. Acetate deprotection of 140: (a) cHCl, 100 °C 6 h or 80 °C, 96 h. 
Visually, the longer time scale reaction seemed to give a darker product on 
work up but the NMR spectra of the two appeared similar; however the proton spectra 
were generally broad and not easy to interpret. Despite this it was possible to identify 
key resonances in the crude product at H 1.52-2.20 (4H, m, 2 × CH2) and 3.55-3.69 
(2H, m, CH2) for the three methylene resonances, together with broad resonances at 
H 4.27-4.43 (1H, m, CH) and 5.56 (1H, s, CH) ppm for the methyne protons. However 
analysis of the carbon spectrum suggested that the product was a mixture of 2 
compounds as six methylene resonances were present as pairs at C 29.4/30.0, 
31.8/32.5 and 44.8/61.8 ppm. Similarly two pairs of resonances were present at C 
53.8/53.9 and 97.9/98.1 ppm for the at two methyne protons. Analysis of the reaction 
product by high resolution MS indicated that the compound 133 was present and a 
mass of 242.1248 was measured which is an exact match to the required formula of 
C9H16N5O3 ([M+H]
+). However, closer inspection of the MS data suggested the 
presence of another compound which has the mass of 260.0911 Daltons which 
corresponds closely to the formula C9H15
35ClN5O2 ([M+H]
+) which has a mass of 
260.0909 Daltons. This was confirmed by a peak at 262.0880 Daltons corresponding 
exactly to the isotopic ion C9H15
37ClN5O2 and was found in a relative ratio of 3:1 as is 
expected for chlorine. This would suggest the formation of the byproduct 143 in this 
reaction (Figure 14). 
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Figure 14. By-product 143 
An attempt was made to analyse the product of each reaction by LCMS and 
although some separation appeared to be possible, we were unable to access suitable 
preparative LC equipment to attempt this method of purification. Time was not 
available to repeat this work on a larger scale and this will remain the goal of future 
studies.   
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Conclusions and further work  
The work directed towards the synthesis of the RHS fragment of deoxy-
cylindrospermopsin was successfully in that a benzyl96 and methoxy-protected 69 
synthon were prepared. The benzyl protected RHS fragment 96 differs significantly 
from the previously utilized methoxy- and benzyloxy- ether protected uracil groups 
used in other total syntheses and will require a different deprotection strategy which 
will need to be addressed in the total synthesis. The low yields in the Meldrum’s acid 
coupling reaction in the methoxy-ether series is not easy to explain and possibly given 
more time this might be worth reinvestigating.  
The β-Keto ester 96 was utilised by a co-worker in the tethered Biginelli 
reaction with aminal 57 and succesfully gave the desired tricyclic intermediate 144; 
however the yield for this step was only a modest 19%. Despite this the 
deallylation/decarboxylation sept was undertaken using Pd(PPh3)4 followed by 
exposure of the resulting material to NaBH3CN in a 1:1 mixture of AcOH/MeOH 
which gave the guanidine 145 in 75% yield over 2 steps. As with our studies, attempts 
to remove the benzyl protecting groups of 145 by catalytic transfer hydrogenation was 
unsuccessful returning only unreacted starting material. Fortunately debenzylation 
could be accomplished by treatment with BBr3 in refluxing xylenes for 16 h followed 
by quenching with methanol. This led to the successful preparation of a model of the 
biosynthetic intermediate 7-deoxy cylindrospermopsin 77 in 94% yield100 (Scheme 
62). 
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Scheme 62. Synthesis of the deoxy-cylindrospermopsin analogue 77: (a) AcOH, 24h; (b) 
morpholinium acetate, 96, Na2SO4, CF3CH2OH, 100 °C, 12 days, 19%; (c) Pd(PPh3)4, pyrrolidine, 
THF/MeOH, 16 h; (d) NaBH3CN, AcOH/MeOH, 0 °C-rt, 16 h, 75%; (e) BBr3, xylenes, 135 °C, 24h; 
(f) MeOH, rt, 24 h, 94%. 
The attempts at preparing analogues of cylindrospermopsin proved highly 
informative with regard to the reactivity of this type of compound. Using one route, 
the desired compound (133) was almost cerinly prepared, albeit as a mixture with the 
corresponding chloride 143. These key reactivity issues focussed on the deprotection 
chemistries and are summarised below The advanced fully protected intermediates 
131 and 140 were successfully prepared via an acetylenic Grignard methodology, 
however attempts to deprotect them were not straightforward (Scheme 63). Partial 
deprotection of 131 was successful yielding 132. However, attempted hydrogenation 
of the benzyl protecting groups was not effective and led to complete decomposition 
of the substrate. Similarly attempted acidic deprotection of 131 led to the loss of the 
Boc- and acetate protecting groups; however the benzyl groups were not removed and 
a byproduct 135 was also isolated in which the acetate group has been replaced by a 
chlorine. The fully protected analogue 140 was able to undergo deprotection under 
acidic condition to give 134 however, this also contained the chlorinated analogue 143 
which may have arisen from the same process (Scheme 63). 
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Scheme 63. Attempted deprotection reactions of 131 and 140: (a) K2CO3, MeOH, rt, 1 h; (b) Pd/C, 
MeOH, HCO2NH4, , 16 h; (c) HCl, , 16 h; (d) cHCl, 100 °C 6 h or 80 °C, 96 h. 
The future of this work has two possibilities, firstly the reinvestigation of the 
deprotection of 131 or 132 and the work done on the synthesis of the analogue 77100 
might offer some hope. The BBr3 mediated deprotection of compound 145 may be 
applicable to compound 132, despite the presence of the sensitive alcohol function, 
and this reaction will be attempted in the future. In addition, more work needs to be 
performed on the deprotection of compound 140, in that the substitution of chloride 
for the acetate group could be suppressed by partial deprotection of  140. Removal of 
the acetate group to give an alcohol followed by an acidic deprotection might now be 
more successful. The use of a non-nucleophilic acid such as wet trifluoroacetic could 
be used in the deprotection of 140 as this might suppress the substitution of the alcohol.
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Section B: 
Dinitrobenzamides as Pro-drugs 
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Dinitrobenzamides as Pro-drugs 
 
Introduction 
 
Cancer chemotherapy 
In recent years, many different strategies have been exploited concerning the 
development of new chemotherapeutic drugs. The main problem with many of these 
strategies is a lack of tumour specificity101 resulting in systemic toxicity and a low 
therapeutic index.102 These drugs can interfere with cells by attacking some aspects of 
their deoxyribonucleic acid (DNA) synthesis, replication or processing.103 Since they 
preferentially kill rapidly dividing cells, some normal cells are also exposed to toxic 
levels, resulting in severe undesirable side effects such as damage to hair follicles, the 
kidney, liver, bone marrow104 and gut epithelia.103 Despite this, chemotherapy still 
remains the primary systemic treatment for cancer. Consequently, there is a need to 
develop new and improved drugs which are more selective in their function, but still 
maintain their cytotoxic activity.  
Pro-drugsOne approach first introduced by Albert105 and Harper106 in the late 
1950’s is the design of relatively non-toxic pro-drugs. These can be converted either 
through metabolism by endogenous enzymes or spontaneously into the 
pharmacologically active species and activated within the tumour mass.107 They have 
been employed to improve the efficacy of anti-cancer agents by the modification, of 
their physiochemical108 and/or pharmacokinetic109 properties. More specifically this 
includes their (i) solubility and lipophilicity (ii) bioavailability108 (iii) stability110 (iv) 
toxicity (v) transport properties109 (vi) site and duration of action110,111 and (vii) first-
pass metabolic effects.112 
Classes of pro-drug 
There are many different types of pro-drug which were developed to exploit various 
aspects of the tumour physiology, such as selective enzyme expression, hypoxia and 
low extracellular pH. Others are targeted towards to tumour-specific delivery 
techniques such as antibody- and gene-directed enzyme prodrug therapy (ADEPT and 
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GDEPT). The hypoxia-selective tumour-activated pro-drugs (known as hypoxia-TAP) 
rely on the deficiency of oxygen (hypoxia)113 that can be classified into two broad 
types, the first (i) chronic or diffusion hypoxia keeps cells that are ample distance 
(approx 150 µm) away from the nearest functional blood capillary hypoxic in the long 
term. The second (ii) transient or perfusion hypoxia is due to a temporary shutdown 
of  blood vessels keeping sections of tissue hypoxic in the short term.107,114 Hypoxia 
has been shown to exist in a number of different diseases including some cancers, i.e. 
brain, head and neck, breast and cervix,115 rheumatoid arthritis and diabetes.116 It is 
often characterised by low oxygen tension, nutrient levels117,118 and pH.117,119 Hypoxic 
cells are commonly found in most solid tumours as the result of a poor blood supply,114 
high interstitial pressures,114,120 enhanced metabolic rate104 and an inefficient 
vasculature system.114 They have been found to be resistant to both radiotherapy and  
chemotherapy.121 Since severe hypoxia only exists in tumours, an opportunity arose to 
exploit this phenomenon for its potential therapeutic advantage121 and to develop non-
toxic hypoxia-activated prodrugs. By concentrating the cytotoxic anti-cancer agents 
inside the tumour mass, this could dramatically minimise the risk of destroying normal 
cells. 
The major classes of hypoxia-TAP include nitroaromatics, heterocyclics, 
quinones, aromatic and aliphatic N-oxides and transition metal complexes. Each class 
can be activated under hypoxic conditions and in the presence of reductive enzymes 
(Scheme 64). 
 
 
 
Scheme 64. General mechanism of prodrug activation under hypoxia103,107. 
 
One specific example of this is found in nitro-group containing compounds 
which can undergo a series of up to six one-electron reductions starting with the nitro 
group 146 to give the nitro anion radical 147 (Scheme 65). This intermediate can be 
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back-oxidised by molecular oxygen present in normoxic tissues to regenerate the 
parent compound 146. Further reduction produces the nitroso 148, radical 149, 
hydroxylamine 150 and amine 151 as the subsequent products. Only in hypoxic tissue 
will the reduction proceed to these highly cytotoxic species.109 
 
 
Scheme 65. Pathway of reductive activation for a nitroaromatic drug 
 
Many nitro-aromatics prodrugs have been studied including 2-nitroimidazoles 
such as misonidazole 152123 etanidazole 153107 and dinitrobenzamide 5-(1-aziridinyl)-
2,4-dinitrobenzamide 154123,124 (CB-1954) (Figure 15). 
 
Figure 15. Structure of misonidazole 152 tanidazole 153 and 5-(1-aziridinyl)-2,4-dinitrobenzamide 
154 
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Nitrogen containing mustards 
Nitrogen mustards 155 were developed during the second world war and are 
analogues of the sulfur mustard gas 156 which was implemented as a weapon in World 
War I (Figure 16).125 
 
 
Figure 16. Structures of nitrogen and sulfur mustards 
 
These mustards are DNA alkylating agents often used in chemotherapy 
(Scheme 66).126,127 Since chlorine is a good leaving group this facilitates nucleophilic 
attack of the nitrogen in the mustard 155128  which cyclises to form an aziridinium ion 
158.126 This strained three-membered ring system readily alkylates preferentially at 
the N7 position of guanine 157 to form the monoalkylation adduct 159.128 Minor 
alkylations can also occur at other sites such as the N3 position of adenine.126,129 This 
process is then repeated with the cyclisation of the adduct 159 to form the aziridinium 
ion 160 which alkylates guanine 157 to give the crosslinked DNA 161. These 
bifunctional adducts can generate an interstrand crosslink which is as much as 100 
fold more cytotoxic than its monofunctional adduct.130 
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Scheme 66. Mechanism of DNA alkylation and interstrand crosslinking by nitrogen mustards 
 
 
Crosslinking can occur between two complementary strands of DNA 
(interstrand) or on the same strand of DNA (intrastrand) (Figure 17).128 
 
 
Figure 17. Types of DNA crosslinking128 
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Interstrand crosslinks are essential for maximal cell mortality130 since they 
prevent two opposing strands in DNA from separating during replication or 
transcription. The overall result of this process is inhibition of DNA synthesis and it 
was found that there was a direct correlation between interstrand crosslinking and 
cytotoxicity.131 
Examples of nitrogen mustards 
 
The simplest member of the nitrogen mustard family is mechlorethamine 162 
(Figure 18)131,132 which was the first clinically useful anti-tumour substance.131 
 
 
Figure 18. Structure of mechlorethamine 
The problem is that mechlorethamine 162 reacts rapidly with biological 
material and water making it highly vesicant and chemically labile. To overcome these 
problems, the methyl group in 162 was replaced with an aromatic moiety (Figure 18). 
This lowers its reactivity, to give more time for absorption and distribution before 
DNA alkylation, allowing oral administration. However, the simplest aromatic 
mustard 163 is insoluble in water. Although its carboxylic acid analogue 164 is 
soluble, it was found to be inactive.128 To overcome this solubility issue a considerable 
amount of research has been carried out developing more water-soluble N-
mustards.133,134  It was found that addition of CH2 groups as spacers gave water-soluble 
active compounds such as chlorambucil 145 and melphalan 166 (Figure 19).127 
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Figure 19. Structures of some aromatic nitrogen mustards 
 
For over 50 years chlorambucil 165 has been used in the treatment of chronic 
lympocytic leukaemia.135,136  Similarly, melphalan 166 is used in certain types of bone 
marrow tumours, including multiple myeloma137 and cancers such as ovarian, breast138 
and colorectal.139,140 
Another widely studied cytotoxic aromatic mustard is N1,N1-bis(2-chloroethyl) 
benzene-1,4-diamine 167 (Figure 20), which can be used directly or in a pro-drug 
activated system.141 
 
 
Figure 20. Structure of aniline mustard 
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Aims of the study 
Current anticancer therapies indiscriminately kill malignant cells as well as 
healthy cells resulting in severe side effects and the development of therapy-induced 
tumours. In the last decades, the search for tumour selectivity led to the development 
of Directed Enzyme Pro-drug Therapy (DEPT), which consists of the targeted delivery 
of enzymes directly to the malignant growth, where the enzymes convert an inactive 
pro-drug into a cytotoxic drug, normally exploiting antibodies or adenoviral vectors 
as vehicles for the enzymes’ delivery. Two requirements are needed in order to realise 
this new anticancer approach: first, the pro-drug-activating enzymes must not be 
naturally present in human cells; second, the pro-drug must undergo a great increase 
in its cytotoxicity after the enzymatic activation. According to these fundamental 
requirements, the combination NTR/CB 1954 is currently the most investigated in 
human enzyme/prodrug therapy. The compound CB 1954 (5-[aziridin-1-yl]-2,4-
dinitrobenzamide) 154, is a monofunctional alkylating pro-drug, which is converted 
to a potent interstrand DNA-crosslinking agent upon nitro-reduction of either its 2- or 
4-nitro group by E. coli NfsB nitroreductase (NTR).142 However problems associated 
with the slow turn-over rate143 of  NfsB, for 154 and the inefficient activation of 154 
in vivo144 led to the evaluation of alternative enzyme/prodrug combinations for DEPT. 
NfsA, the major E. coli oxygen-insensitive nitroreductase, has been shown to 
catalyse the nitroreduction of CB 1954 ~ 18-fold more efficiently than NfsB with its 
preferred cofactor NADPH,144 making NfsA a suitable candidate for NTR/CB 1954 
154 combination. The crystal structure104 shows that NfsA is a homodimeric protein, 
with one FMN molecule tightly bound to each subunit.145,146 NfsA is able to reduce 
the 2-nitro group of CB 1954 in the presence of NADPH,144,147,148 involving two 
successive two-electron transfers. These E. coli NTRs offer the versatility of 
metabolising a wide range of nitroaromatic compounds149,150 which may be useful in 
the investigation of alternative pro-drugs with possibly greater therapeutic efficacy 
than the current NTR/CB 1954 154 combinations.  
The present study intends to investigate the activity of the alternative known 
pro-drugs 2,4-dinitrobenzamides 168, which have been shown to be toxic to hypoxic 
rat Walker tumour cells.154 However, to date their metabolism by NQO1 enzymes has 
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not been studied and the present work will investigate the activity of NQO1 on 2,4-
dinitrobenzamide 168 (Figure 21). 
  
 
Figure 21. Generic structure of 2,4-dinitrobenzamide; R = halogen. 
The most studied alternative prodrug to CB 1954 154 for use in combination 
with NTRs is SN 23862 174, the nitrogen mustard analogue of CB 1954 154. Like CB 
1954 154, SN 23862 174 is a non-toxic, pro-drug which is converted to the alkylating 
cytotoxic derivatives by enzymatic nitroreduction.151 E.coli nitroreductases can only 
reduce the 2-nitro group of the mustard to the corresponding 2-hydroxylamine. This 
is then readily reduced to the 2-amine, the principal cytotoxic metabolite, responsible 
for the alkylating reactivity of SN 23862 174.152,153 To date, no studies have been done 
to evaluate the NfsA NTR capacity of SN 23862 activation. In this work, we evaluate 
the ability of NfsA NTR of activating the prodrug SN 23862 and its halogen analogues 
analogues the brominated 175 and iodinated 176. The present study involves two 
stages, firstly the synthesis of a series of 2,4-dinitrobenzamide pro-drugs 174-176 and 
secondly the evaluation of these candidate molecules by electrode-binding each with 
E.coli NTR. The initial aims of this research is repeat and improve upon the synthesis 
of  the 2,4-dinitrobenzamide 174-176 which have been reported in the literature.155,156  
The chemistry to be used is shown in Scheme 67. 
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Scheme 67. Synthesis of 2,4-dinitrobenzamides: (a) H2SO4/KNO3, ; (b) i) SOCl2; ii) NH3.; (c) 
HN(CH2CH2OH)2, ; (d) MsCl, pyridine.(e) DMF, MX . (M = Li, Na, X = Cl, Br, I.).  
Results and Discussion 
The first stage in the synthesis is the nitration of chlorobenzoic acid 169 using 
potassium nitrate in sulphuric acid which was reported155 to give 5-chloro-2,4-dinitro-
benzoic acid 170 in 36% yield. We repeated this literature process and obtained the 
desired compound 170 as a crystalline solid in an improved yield of 68% (Scheme 68). 
The proton NMR of 170 displayed 2 resonances  at H 8.75 (1H, s, CH) and 8.25 (1H, 
s, CH) ppm whilst the presence of 7 separate carbon environments in the carbon NMR 
spectrum indicated a successful reaction. The melting point of 170 was found to be 
179 °C, which is in good agreement with the literature value of 180-183 °C.155 
 
 
 
Scheme 68.  Nitration of 169: (a) H2SO4/KNO3, 100 °C, 68%. 
 
The formation of 5-chloro-2,4-dinitrobenzamide 171155 was reported in 84% 
yield by the amidation of 5-chloro-2,4-dinitro-benzoic acid 170 using thionyl chloride 
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and DMF followed by the addition of ammonium hydroxide. We repeated this process 
and obtained the desired 171 as a pale yellow solid in 87% yield (Scheme 69). The 
proton NMR of 170 displayed four resonances at H 8.74 (1H, s, CH), 8.07 (1H, s, 
CH), 7.8 (1H, br s, NH) and 7.4 (1H, br s, NH) ppm, whilst the carbon spectrum 
displayed 7 resonances at C 123.0 (CH), 132.0 (C), 133.2 (CH), 137.7 (C), 146.4 (C), 
148.5 (C) and 165.3 (C) ppm. This data is indicative of the formation of 171 and the 
melting point of our sample was 200 °C, which is in good agreement with the literature 
value of 201-203 °C.155 
 
 
Scheme 69. Preparation of amide 171: (a) i) SOCl2/DMF, , 4h, ii) NH4OH, 87%. 
 
 
The formation of 5-[bis-(2-hydroxyethyl)-amino]-2,4-dinitrobenzamide 172 
was reported to proceed in 45% yield by the reaction of chloride 171 with 
diethanolamine at 100 °C for 4 h in the absence of solvent.156 We repeated this reaction 
and isolated the desired compound as an orange yellow solid in an improved yield of 
80% (Scheme 70). Diagnostic proton NMR resonances were observed at δH 3.79 (4H, 
t, J = 5.4 Hz, 2 × CH2) and 3.61 (4H, t, J = 5.4 Hz, 2 × CH2) ppm and high resolution 
mass spectrometry gave a mass of 315.0939 Daltons which corresponds closely to the 
required mass of 315.0935 for C11H15O7 N4 ([M
 +H] +).  
 
 
Scheme 70. HN(CH2CH2OH)2, 100oC, 4 h, 80%. 
The key intermediate in the synthesis of the halogenated mustards is the 
mesylate 173 as this compound is able to undergo displacement by the alkali metal 
halides to give the desired compounds. All the preparations followed a literature 
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procedure,156 and reaction of 172 with excess methanesulfonyl chloride (MsCl) in dry 
pyridine gave the desired bis-mesylate 172 in 67% yield after column 
chromatography. This compares well with the reported literature yield of 74%.156  
(Scheme 71) Significant nmr resonances were observed at δH 4.49 (4H, t, J = 5.3 Hz, 
2 × CH2) and 3.89 (4H, t, J = 5.35, Hz, 2 × CH2) ppm for the methylene proton and at 
δH 3.09 (6H, s, 2 × CH3) ppm for the mesylate groups. High resolution MS gave a 
mass of 471.0482 Daltons which corresponds closely to the required mass of 471.0486 
Daltons for C13H19O11N4S2 ([M
 +H] +) 
 
 
Scheme 71. MsCl, pyridine, 0 °C, 67%. 
 
The final step in the synthesis of 174-176 was realized in a straightforward 
manner. This involved heating a solution of the mesylate 173 in dry DMF with an 
excess of either LiCl, NaBr, or NaI at 125 °C for 15 min, to effect nucleophilic 
displacement of the mesylate group.156  Purification by column chromatography gave 
the chloride 174 in 75% yield, the bromide 175 in 98% yield and the iodide 176 in 
81% yield respectively. NMR and mass spectrometry confirmed the displacement of 
the mesylate groups in each case (Scheme 72). 
 
Scheme 72. DMF, 125 °C, MX (M = Li, Na, X = Cl; 75%. Br; 98%. I; 81%.) 
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Enzyme activity of the mustard pro-drugs 174-176 
Concentration versus reaction rate 
 
The rate of reduction of 174 as estimated by the rate of NADPH oxidation, was 
shown to increase proportionally with the enzyme concentration present in the assay, 
for both the NfsA wild-type and the NfsA-Cys enzymes (data not shown). For wild-
type NTR, the rate of NADPH oxidation was shown to increase proportionally by 
adding 2.5 to 30 µg/ mL  enzyme, whereas for NfsA-Cys, the rate of NADPH 
oxidation was found to increase proportionally by using 2.5 to 15 µg/ mL enzyme; the 
addition of higher enzymeconcentrations led to a decrease in the NADPH oxidation 
rate for both enzymes. The NADPH and CB 1954 154 concentrations were constant 
during the experiment. 
Substrate concentration versus reaction rate 
As part of a previous study157 the kinetic parameters Km and Vmax were 
determined in 0.05 M phosphate buffer (pH 7.2) for purified NfsA-Cys by varying the 
substrate154 concentration, in the presence of a constant concentration of 400 µM 
NADPH and of a constant enzyme concentration (10 µg/ mL). The rates of formation 
of the 2- and 4-hydroxylamine products of CB 1954 154 were monitored 
spectrophotometrically at 420 nm, based on an equal absorption of both 2- and 4-
NHOH reduction products of CB 1954 154 at this wavelength (ε =1200 mol L-1 cm-1). 
Apparent differences in Km and Vmax between the tagged and non-tagged NfsA 
indicate that the incorporated cysteine residues affect the catalytic reaction: for NfsA-
Cys, a decrease in the Km value indicates that the enzyme-substrate binding is 
enhanced, but the enzyme-substrate complex reacts more slowly, since Vmax is lower, 
compared to NfsA wild-type. Considering the Kcat/Km of the two enzymes, NfsA wild-
type was shown to be ~ 5-fold more active with CB 1954 154 than NfsA-Cys. 
NfsA-Cys kinetics with SN 23862 and its analogues 
The reaction rates of NfsA-Cys NTR with the pro-drug SN 23862 174 and the 
bromo- 175 and iodo- 176 analogues as substrates were determined 
spectrophotometrically. This was achieved by observing the decrease in the NADPH 
UV absorbance at 340 nm, as the enzyme consumes this co-factor during the substrate 
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reduction and the appearance of the hydroxylamine reduction product at 420 nm. The 
reaction rates, i.e. the rates of NADPH oxidation, were measured by adding 2.5 to 30 
µg mL-1 enzyme and were shown to increase proportionally with the enzyme 
concentration. Each concentration was tested three times, and the mean absorbance of 
taken as indicative of typical activity. Standard deviations of each were also 
calculated.  
It was observed that for each of the compounds 174-176, the relationship 
between concentration and activity was positive, with increasing concentration of 174-
176 leading to an increased activity. In addition, this relationship was strongly linear 
and the standard deviations of activity at each different concentration were small. 
Figures 22-24 show the activity for each compound and the trend-line in each 
illustrated the relationship between concentration and activity.  The error bars in each 
show the standard deviation for each concentration measurement. The figures also 
provide the regression equation and the amount of explained variance (R2). 
 
 
Figure 22. NfsAcys activity profile with 174 
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Figure 23. NfsAcys activity profile with 175 
 
 
 
Figure 24. NfsAcys activity profile with 176 
Finally, Figure 25 compares the rates of enzymatic activation of the three 
prodrugs as 30 µg mL-1 of NfsA-Cys enzyme were added, showing the Br-substituted 
mustard 175 appears to be the best substrate for NfsA-Cys NTR. 
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Figure 25. NfsA-Cys activity with substrates SN 23862 174, 175 and 176 
 
Conclusions 
It proved relatively easy to synthesize the required 5-bis-(2-haloethyl)-amino-
2,4-dinitrobenzamide 174-176. SN 23862 174 and its bromo- 175 and iodo- 176 
analogues. These compounds proved to be good substrates for NfsA NTR, and thus 
can be considered as alternative pro-drugs to CB 1954 154 in combination with NfsA 
for human chemotherapy. However, further studies are required to evaluate the precise 
rate of 174-176 bioactivation by NfsA NTR. 
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Experimental 
            
General Procedures 
Unless otherwise noted all reactions were stirred and monitored by TLC. plates 
were visualized using iodine, phosphomolybdic acid, 2,4-dinitrophenylhydrazine or 
under UV light. All anhydrous reactions were conducted under a static argon 
atmosphere using oven-dried glassware that had previously been cooled under a 
constant stream of nitrogen.  
Materials 
Reagents and starting materials were purchased from commercial suppliers 
and used without further purification unless otherwise noted. All anhydrous solvents 
were distilled over either sodium wire and benzophenone (THF/Et2O) or calcium 
hydride (DCM); these were used immediately or stored over molecular sieves prior to 
use. Flash column chromatography was performed on Davisil® silica gel (35-70 
microns) with the eluent specified in each case, TLC was conducted on precoated 
E.Merck silica gel 60 F254 glass plates. 
Instrumentation 
Melting points were determined using a Gallenkamp MF370 instrument and 
are uncorrected. 1H and 13C NMR spectra were recorded on a Bruker Avance 400 or 
500 spectrometer with an internal deuterium lock at ambient temperature, with 400 or 
500 MHz for proton and 100 or 125 MHz for carbon. Internal references of δH 7.26 
and δC 77.0 ppm for CDCl3, δH 3.31 and δC 49.0 ppm for CD3OD and δH 2.54 ppm 
and δH 39.52 ppm for DMSO were used. All mass spectra were performed at the 
EPSRC National Mass Spectrometry Service Centre based in Swansea. Low 
resolution Chemical Ionisation (CI) and Electrospray Ionisation (ESI) mass spectra 
were recorded on a Micromass Quattro II spectrometer and high resolution mass 
spectra were recorded on either a Finnigan MAT 900 XLT or a Finnigan MAT 95 XP. 
Infrared samples were prepared by dissolving solids in dry chloroform and evaporated 
onto a NaCl plate, whilst oils/gums were pressed between two NaCl plates; spectra 
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were acquired on a Bruker Tensor 37 FT-IR machine and are reported as reciprocal 
wavenumbers (cm-1).  
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Preparation of ethyl 2-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetate 
(80).84 
 
 
In a 1 L RBF, a mixture of anhydrous benzene/ethanol (68:32 v/v, 400 mL), 
diethyl 1,3-acetonedicarboxylate 79 (50.0 g, 0.247 mol), urea (14.8 g,  0.247 mol) and 
concentrated sulfuric acid (3 mL) were combined. At this point a soxhlet apparatus 
containing a drying thimble of 3Ǻ powdered molecular sieves (ca. 20 g) was added 
and the mixture heated at reflux with stirring for 10 days with the sieves being replaced 
every 24 h. After 10 days the reaction was cooled and the solid precipitate removed 
by filtration to give 80 (39.0 g 196.8 mmol) as a white powder in 80% yield. 
 
Mp   186-190 °C (lit. 189-191 °C84) 
Rf   0.37 (20% MeOH in CHCl3) 
H ((CD3)2SO)  1.20 (3H, t, J = 7.1 Hz, Me), 3.48 (2H, s, CH2), 4.11 (2H, q, J 
= 7.1, CH2), 5.46 (1H, s, CH), 10.41-11.27 (2H, br s, 2 x NH) 
C ((CD3)2SO) 168.1 (C), 164.1 (C), 151.4 (C), 149.0 (C), 100.8 (CH), 60.9 
(CH2), 37.2 (CH2), 14.0 (CH3) 
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Preparation of ethyl 2-(2,6-dichloropyrimidin-4-yl)acetate (81). 
 
 
 
A mixture of N-ethyldiisopropylamine (12.2 g, 12.77 mL, 100.9 mmol, 2 eqv.) 
and compound 80 (10 g, 50.5 mmol) dissolved in toluene (150 mL) was heated to 105 
°C and a solution of POCl3 (23.3 g, 14.2 mL, 151.5 mmol, 3eqv.) in toluene (20 mL) 
was added drop wise to this mixture over 10 min. After 3 h. the reaction was cooled 
to rt and poured onto crushed ice and water (ca. 500 mL) with rapid stirring. After 
warming to rt overnight the aqueous phase was basified to pH = 9 by the addition of 
solid sodium carbonate then extracted with ethyl acetate (3 × 150 mL). The combined 
organic phases were washed with water (100 mL), dried (MgSO4), filtered and 
evaporated in vacuo to give a dark red oil. Purification by flash chromatography on 
silica gel (120 g) eluting with EtOAc in petrol (gradient 0 to 35%) gave 81 (9.10 g, 
38.7 mmol) in 77% yield as a red oil. 
This reaction was repeated using N-ethyldiisopropylamine (26.09g, 35.16 mL, 
201.16 mmol, 2 eqv.), 80 (20.0 g, 100.9 mmol) in toluene with POCl3 (23.3 g, 14.2 
mL, 151.5 mmol, 3eqv.) in toluene (150 mL) to give 81 (18.0 g, 76.6 mmol, 76%). 
 
Rf   0.37 (20% EtOAc in petrol) 
vmax 3130, 3076, 2983, 1737, 1560, 1527, 1465, 1396, 1369, 1334, 
1306, 1244, 1192, 1128, 1028, 867, 829, 737 
H (CDCl3) 1.26 (3H, t, J = 7.2 Hz, CH3), 3.79 (2H, s, CH2), 4.19 (2H, q, J 
= 7.2 Hz, CH2), 7.38 (1H, s, CH) 
C (CDCl3) 168.0 (C), 167.0 (C), 162.7 (C), 160.4 (C), 120.1 (CH), 61.8 
(CH2), 42.5 (CH2), 14.0 (CH3) 
m/z (CI) 235.0 (100%, [M+H+], 2 × 35Cl), 237.0 (64%, 
[M+H+],35Cl/37Cl), 239.0 (10%, [M+H+], 2 × 37Cl) 
HRMS (CI)  C8H9
35Cl2N2O2 [M+H
+] requires 235.0036, found 235.0038 
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Preparation of methyl 2-(2,6-dimethoxypyrimidin-4-yl)acetate (82). 
 
 
 
Sodium methoxide (prepared from sodium metal, 0.86 g, 37.4 mmol), in dry 
MeOH (50 mL) was added drop wise over 1 h to a cooled (0 °C) and stirred solution 
of 81 (4.0 g, 17.0 mmol) dissolved in dry MeOH (75 mL). After 3 h the reaction was 
allowed to warm to rt and stirred for a further 1 h. The reaction mixture was then 
concentrated in vacuo and diluted with water (100 mL) and then extracted with ethyl 
acetate (3 x 150 mL). The combined organic extracts were dried (MgSO4), filtered and 
evaporated in vacuo to give crude 7 which was purified by column chromatography 
(gradient elution; 5-15% EtOAc in petrol) to give 82 (1.53 g, 6.76 mmol) in 40% yield 
as a yellow oil.  
This reaction was repeated using sodium methoxide (prepared from sodium 
metal, 0.62g, 27.1 mmol), in dry MeOH (30 mL) with 81 (2.90 g, 12.34 mmol) in dry 
MeOH (20 mL) to give 82 (1.50 g, 7.1 mmol, 57%) 
 
Rf   0.28 (20% EtOAc in petrol) 
vmax 2995, 2955, 1743, 1597, 1571, 1483, 1460, 1330, 1255, 1157, 
1101, 1058, 1044, 984, 835, 787, 756 
H (CDCl3) 3.57 (2H, s, CH2), 3.64 (3H, s, Me), 3.88 (3H, s, Me), 3.89 
(3H, s, Me), 6.28 (1H, s, CH) 
C (CDCl3) 171.9 (C), 169.7 (C), 165.1 (C), 164.2 (C), 100.9 (CH), 54.5 
(CH3), 53.6 (CH3), 52.0 (CH3), 42.5 (CH2)  
m/z (CI) 213.1 (100%, [M+H]+) 
HRMS (CI) C9H13N2O4 ([M+H]
+) requires 213.0870, found 213.0866 
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Preparation of 2-(2,6-dimethoxypyrimidin-4-yl)acetic acid (68) from (82) 
 
 
 
A solution of sodium hydroxide (175.0 mg, 4.37 mmol) in 3 mL of dry MeOH 
was added drop wise to a cooled (0 °C) solution of 82 (232.0 mg, 1.09 mmol) in dry 
MeOH (3 mL) and the mixture stirred overnight to rt (TLC indicated the complete 
consumption of 82). The reaction mixture was then cooled (0 °C) and acidified to pH 
3 by the careful addition of HCl (1 M). After evaporated to dryness under vacuum, the 
solid mass obtained was triturated with diethyl ethyl acetate (3 x 20 mL) and the 
triturates discarded. The remaining solid was then triturated with a 3:2 mixture of 
CHCl3 and MeOH (2 x 10 mL) and the triturates filtered and evaporated to give 68 
(207.0 mg,1.05 mmol) in 96% yield as an off white/cream coloured solid. 
 
Mp    82-85 °C 
Rf   0.45 (20% MeOH/CHCl3) 
H (DMSO) 3.61 (2H, s, CH2), 3.88 (3H, s, CH3), 3.89 (3H, s, CH3), 6.54, 
(1H, s, CH), 5.90-8.20 (1H, br s, OH) 
C (DMSO) 171.5 (C), 170.6 (C), 165.5 (C), 164.6 (C), 101.1 (CH), 54.4 
(CH3), 53.8 (CH3), 42.4 (CH2) 
vmax 3500-2500 (broad), 1727, 1648, 1614, 1574, 1496, 1455, 
1396, 1359 
1273, 1215, 1180, 1089, 1060, 923, 898, 838, 758 
m/z (CI)  199.1 (100%, [M+H]+) 
HRMS (CI)  C8H11N2O4 ([M+H]
+) requires 199.0713, found 199.0713. 
  
  
89 
 
Preparation of 2,4,6-trichloropyrimidine (86).91 
 
 
 
Barbituric acid 24 (49.85 g, 389.2 mmol, 1 eqv.) and phosphorus oxychloride 
(257 g, 1.67 mol, 4.3 eqv.) were combined in a 1 L RBF and the mixture stirred at 0 
°C for 20 mins. N,N-Dimethylaniline (46.4 g, 311.4 mmol, 0.8 eqv.) was then added 
drop-wise and the mixture heated at reflux for 45 mins. After cooling (0 °C) crushed 
ice (400 g) was then added in small portions to the red reaction mixture which was 
then stirred to rt overnight. Diethyl ether (200 mL) was added and after agitation the 
ether layer was separated and the aqueous layer further extracted with diethyl ether (3 
x 100 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure to yield 86 as a yellow oil (70.1 g 382 mmol, 
98%).  
 
Rf   0.58 (20% ether petrol) 
δH (CDCl3)   7.4 (1H, s, CH) 
δC (CDCl3)   163.0 (C), 160.2 (C), 120.2 (CH) 
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Preparation of 4-chloro-2,6-dimethoxypyrimidine (87).91 
 
 
 
A solution of sodium methoxide was prepared by adding sodium metal (10.08 
g, 438.3 mmol, 2 eqv.) in small portions to cooled (0 °C) anhydrous methanol (200 
mL) with stirring until all the sodium was consumed. A solution of pyrimidine 86 
(40.34 g, 219.95 mmol, 1 eqv.) in anhydrous methanol (200 mL) was then added drop 
wise over a period of 1 h. The solution was stirred to rt overnight and then concentrated 
in vacuo and diluted with water (200 mL). The resultant mixture was extracted with 
ethyl acetate (3 x 100 mL) and the combined organic extracts dried (MgSO4), filtered 
and the solvent removed in vacuo to give a creamy white, crystalline solid. This solid 
was dissolved in hot ether (ca. 100 mL) and diluted with hexane (ca. 100 mL) to the 
cloud point. On standing, a white solid deposited which were removed by filtration to 
give 87 (22.63 g 129.6 mmol) in 59% yield. 
This reaction was repeated using sodium metal (5.8 g, 251.9 mmol, 2.2 eqv.), 
methanol (150mL) and 86 (21.0 g, 114.5 mmol, 1 eqv.) in anhydrous methanol (200 
mL) to give 87 (18.0 g, 103.1 mmol) in 90% yield. 
 
Rf   0.39 (20% ether: petrol)  
Mp    68-69 °C (Lit. 71-73 °C91) 
δH (CDCl3)   3.96 (s, 3H), 3.99 (s, 3H), 6.38 (s, 1H) 
δC (CDCl3)  172.2 (C), 164.9 (C), 161.2 (C), 100.9 (CH), 55.3 (CH3), 54.4 
(CH3) 
vmax 3092, 2987, 1587, 1563, 1450, 1397, 1343, 1190, 1167, 976, 
937, 832, 760 
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Preparation of diethyl 2-(2,6-dimethoxypyrimidin-4-yl)malonate (88) 
 
 
 
Diethylmalonate (11.0 g, 68.7 mmol, 6.0 eq) was added to a stirred suspension 
of sodium hydride (2.75 g of 60 percent dispersion in mineral oil, 68.7 mmol) in cooled 
(0 °C) dimethylformamide (50 mL).  The reaction was stirred at this temperature for 1 
h, whereupon pyrimidine 87 (2.0 g, 11.46 mmol) was added in small portions over 5 
min and the reaction stirred at rt for 1 h, then heated to 100 °C for 18 hours. The 
reaction was then cooled to rt and the solvent was removed in vacuo. The residue was 
then dissolved in ethyl acetate (100 mL) and water (100 mL), separated and the 
aqueous phase extracted with further ethyl acetate (3 x 50 mL) then the combined 
extracts were washed with water (3 x 50 mL). After drying (MgSO4) and concentration 
in vacuo, purification by flash chromatography on silica gel (5-15% EtOAc in petrol) 
gave 88 (2.27 g, 7.61 mmol) as a pale yellow oil in 66% yield. 
 This reaction was repeated twice: i) Diethylmalonate (55.0g, 343.7  mmol, 6.0 
eq), sodium hydride (8.25g, 343.7 mmol), DMF (200 mL) and 87 (2.0 g, 11.46 mmol) 
to give 88 (9.5 g, 341.8 mmol, 55%); ii) Diethylmalonate (66.1 g, 412.4  mmol, 6.0 
eq), sodium hydride (9.9g, 412.4 mmol), DMF (200mL) and 87 (2.0 g, 11.46 mmol) 
to give 88 (11.0g, 36.9mmol, 54%). 
 
Rf   0.18 (20% EtOAc in petrol)  
δH (CDCl3)  1.25 (6H, t, J = 7.1 Hz, 2 × Me), 3.93 (6H, s, 2 × Me), 4.10-
4.26 (4H, m, 2 × CH2), 4.67 (1H, s, CH), 6.45 (1H, s, CH)   
δC (CDCl3) 172.2 (C), 166.5 (C), 165.2 (C), 162.8 (C), 101.4 (CH), 62.2 
(CH2), 59.7 (CH), 54.90 (CH3), 54.1 (CH3), 14.1 (CH3) 
vmax 3456, 2986, 1737, 1627, 1598, 1571, 1483, 1462, 1386, 1358, 
1307 
1248, 1206, 1176, 1153, 1101, 1029, 984, 863, 788, 749 
  
92 
 
m/z (CI)  299.1 (100%, [M+H]+), 227.1 (35%) 
HRMS (CI)  C13H19N2O6 ([M+H]
+)  requires 299.1238, found 299.1237  
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Preparation of 2-(2,6-dimethoxypyrimidin-4-yl)acetic acid (68) from (88) 
 
 
 
Sodium hydroxide (1.05 g, 26.3 mmol) dissolved in dry MeOH (5 mL) was 
added drop wise over 5 min to a cooled (0 °C) solution of 88 (0.87 g, 2.92 mmol) in 
dry MeOH (10 mL). After stirring to rt overnight (tlc at this point indicated the 
complete consumption of 88 the solution was adjusted to pH = 1 using aqueous HCl 
(2 M) and then evaporated in vacuo to give a solid. This was triturated firstly with 
diethyl ethyl (2 x 30 mL) to remove any unreacted 88 and the remaining solid was 
triturated with a mixture of CHCl3/MeOH (3:2, 2 x 10 mL), filtered and the filtrate 
evaporated to give 68 (0.58 g, 2.92 mmol) as a pale yellow solid in 100% yield. Data 
was as reported previously on page 88.  
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Attempted preparation of allyl 4-(2,6-dimethoxypyrimidin-4-yl)-3-oxobutanoate 
(69) using DCCI and Meldrum’s acid  
 
 
 
A mixture of pyrimidine 68 (0.50 g, 2.53 mmol, 1 eqv), DMAP (457.0 mg, 
3.75 mmol 1.45 eqv.) and Meldrum's acid (364.0 mg, 2.53 mmol, 1.1 eqv) were 
combined in dissolved in CH2Cl2 (15 mL) to give a clear solution. At this point DCCI 
(0.60 g, 2.91 mmol, 1.15 eqv) was added and the mixture stirred at rt for 5 h. After 
filtration (to remove precipitated DCCU (0.67 g)) and the solid washed with a small 
volume of cold CH2Cl2 (ca 10 mL) and then evaporated to give a solid (1.50 g). This 
was dissolved in DCM and washed with saturated sodium sulfate solution (20 mL), 
water (20 mL) and brine (20 mL). After drying (MgSO4) and evaporated under 
vacuum, a brown solid (0.40 g) 90 was obtained. On acidification of the aqueous layer 
and re-extraction no further material was obtained. This residue was dissolved in dry 
benzene (10 mL) together with allyl alcohol (1.47 g, 25.3 mmol, 1.7 mL) and heated 
at reflux for 3 h. Removal of solvent under reduced pressure gave a brown solid (0.42 
g) which was a complex mixture of compounds as evidenced by tlc and NMR 
Attempts to isolate 69 from this mixture by column chromatography were 
unsuccessful. 
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Attempted preparation of allyl 4-(2,6-dimethoxypyrimidin-4-yl)-3-oxobutanoate 
(69) using CDI and Meldrum’s acid in allyl alcohol 
 
 
 
Meldrum's acid (148.0 mg, 1.03 mmol, 1.1 eqv) and CDI (227.0 g, 1.40 mmol, 
1.5 eqv) were added to a stirred solution of pyrimidine 68 (185.0 mg, 0.93 mmol, 1.0 
eqv.) in anhydrous DMF (2 mL) and the mixture heated at 50 °C for 16 h. On cooling 
to rt the reaction was diluted with ethyl acetate (50 mL) and water (50 mL) and 
acidified to pH 1 by the slow addition of HCl (aqueous 1 M). The organic layer 
separated and the aqueous phase extracted with further ethyl acetate (3 x 50 mL). The 
combined extracts were washed with brine (20 mL), dried (MgSO4) and evaporated to 
give crude 90 as a red solid (0.30 g). 
Partial data 
Rf   0.33 (streaks in 10% MeOH in CHCl3) 
H (CDCl3) 1.64 (6H, s, 2 × CH3), 3.83 (3H, s, CH3), 3.85 (3H, s, CH3), 
3.99 (1H, s, CH), 4.31 (2H, s, CH2), 6.26 (1H, s, CH), 11.65 
(enol) 
C (CDCl3) 191.7 (C), 171.9 (C), 165.1 (C), 164.5 (C), 162.7 (C), 101.1 
(CH), 54.6 (CH3), 53.8 (CH3), 42.7 (CH2), 26.7 (CH3) 
 
This solid was dissolved in allyl alcohol (7 mL) and heated at 90 °C for 16 h. 
After evaporation, column chromatography gave a complex mixture of products. 
This reaction was repeated using Meldrum's acid (400.0 mg, 2.78 mmol, 1.1 
eqv), CDI (613.7 mg, 3.78 mmol, 1.5 eqv) and pyrimidine 68 (500.0 mg, 2.52 mmol, 
1.0 eqv.) in DMF (10 mL). After work up (which included a LiBr wash and re-
extraction), the crude product was purified by column chromatography to give the 
triethylamine salt of 90 (26.0 mg, 0.072 mmol, 3% yield) as the only identifiable 
product 
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Rf   0.33 (streaks in 10% MeOH in CHCl3); 
H (CDCl3) 1.14 (9H, t, J = 7.3 Hz, 3 × CH3), 1.61 (6H, s, 2 × CH3), 3.04 
(6H, q, J = 7.3 Hz, 3 × CH2), 3.88 (3H, s, CH3), 3.89 (3H, s, 
CH3), 4.25 (2H, s, CH2), 6.26 (1H, s, CH), 10.33 (1H, br s, 
enol H) 
C (CDCl3) 192.9 (C), 171.7 (C), 169.4 (C), 166.1 (C), 164.9 (C), 161.4 
(C), 101.4 (CH), 89.4 (C), 54.5(CH3), 53.7 (CH3), 50.4 (CH2), 
45.9 (CH2), 26.4 (CH3), 8.4 (CH3) 
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Preparation of allyl 4-(2,6-dimethoxypyrimidin-4-yl)-3-oxobutanoate (69) using 
CDI and Meldrum’s acid in benzene 
 
 
 
Meldrum's acid (160.0 mg, 1.11 mmol, 1.1 eqv) and CDI (246.0mg, 1.51 
mmol, 1.5 eqv) were added to a stirred solution of pyrimidine 68 (200.0 mg, 1.01 
mmol, 1.0 eqv.) in anhydrous DMF (1 mL) and the mixture heated at 50 °C for 16 h. 
The solvent was removed by evaporation under high vaccum (70 °C) and the residue 
diluted with ethyl acetate (10 mL) and water (10 mL) and acidified to pH 1 by the 
slow addition of HCl (aqueous 1 M). The organic layer separated and the aqueous 
phase extracted with further ethyl acetate (3 x 50 mL). The combined extracts were 
washed with brine (2 x 10 mL), dried (MgSO4) and evaporated to give a red solid (0.65 
g).This solid was dissolved in benzene (5 mL) and allyl alcohol (0.57 g, 0.67 mmol, 
0.70 mL) was added and the mixture heated at reflux for 16 h. The reaction was 
evaporated onto silica and purified by column chromatography (5-20% EtOAc in 
petrol) gave 69 (79.7 g, 0.28 mmol) as a pale yellow oil in 28% yield. 
 
Rf   0.31 (streaks 30% EtOAc in petrol) 
H (DMSO) 3.78 (2H, s, CH2), 3.86 (3H, s, CH3), 3.88 (3H, s, CH3), 3.91 
(2H, s, CH2) 4.55-4.58 (2H, m, CH2), 5.20-5.24 (1H, m, CH), 
5.28-5.35 (1H, m, CH), 5.83-5.97 (1H, m, CH), 6.47, (1H, s, 
CH); enolic resonances at 5.53 (CH), 6.25 (CH) and 13.71 
(OH)  
C (DMSO) 199.4 (C), 171.5 (C), 166.6 (C), 165.0 (C), 164.8 (C), 132.3 
(CH), 118.0 (CH2), 101.5 (CH), 65.0 (CH2), 54.4 (CH3), 53.8 
(CH3), 50.4 (CH2), 48.8 (CH2) 
 vmax 3089, 3017, 2992, 2952, 1743, 1654, 1596, 1570, 1549, 1483, 
1459, 1410, 1392, 1359, 1326, 1256, 1209, 1149, 1059, 1003, 
991, 933, 838, 756 
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m/z (CI)  281.1 (100%, [M+H]+), 303.1 (30%, [M+Na]+) 
HRMS (CI) C13H17N2O5 ([M+H]
+), requires 281.1132, found 281.1128 
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Preparation of 1,3-dibenzylurea (92)93 
 
 
From carbohydrazide: A vigorously stirred suspension of finely powdered 
carbohydrazide 97 (4.50 g, 50.0 mmol, 1 eqv) in DMF (100 mL) and benzylamine 
(54.5 mL, 500 mmol, 10 eqv) was cooled to 0 °C. Iodine (50.76 g, 200 mmol, 4 eqv) 
was then added portion-wise over 1 h until a brown colour persisted. Excess iodine 
was then quenched by the addition of Na2S2O3 (Sat.) until a straw yellow solution 
resulted and the desired compound was precipitated from the by the addition of water 
(400 mL). After filtration and washing with water, the solid was dried under vacuum 
to give 92 as a white solid (7.65 g, 32.0 mmol, 64%)  
From CDI: CDI (8.25g, 50.88 mmol) and benzyl amine (16.36 g, 152.7 mmol, 16.86 
mL, and 3 eqv) were dissolved in THF (250 mL) and the mixture heated at reflux for 
16 h. After cooling, the reaction was evaporated and the residue dissolved in 
dichloromethane, washed with water (200 mL), HCl (aqueous, 1M, 100 mL) and brine 
(50 mL) after separation and drying (MgSO4), evaporation gave a crude product which 
was recrystallized from hot ethyl acetate to give 92 as white crystal (8.35 g, 34.87 
mmol) 68%. 
This reaction was repeated on 10 occasions and gave yields of 49-68%.  
 
Rf   0.20 (50% ethyl acetate in petrol); 
Mp   165-168 °C (lit.2 168-169 °C) 
vmax   3337, 3086, 3062, 3030, 2919, 2874, 1627, 1613, 1589, 1574, 
1493, 1472, 1453 and 1421 
δH (CD3)2SO)  4.23 (4H, d, J = 6.0 Hz, 2 × CH2), 6.43 (2H, t, J = 6.0 Hz, 2 × 
   NH), 7.20-7.33 (10H, m, 2 × Ph) 
δC (CD3)2SO)  43.0 (2 × CH2), 126.5 (CH), 127.0 (CH), 128.2 (CH), 140.9 
(C) and 158.1 (C=O)  
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m/z (CI) 503.0 (25%, [2M+Na]+), 481.0 (100%, [2M+H]+), 263.0 (8%, 
[M+Na]+) and 241.1 (95%, [M+H]+) 
HRMS (CI)  C15H17N2O ([M+H]
+) requires 241.1335, found 241.1333  
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Preparation of ethyl 2-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-
yl)acetate (93) 
  
 
To a stirred solution of urea 92 (5 g, 20.82 mmol, 1 eqv.) and diethyl 1,3-
acetonedicarboxylate (7.56 mL, 41.64 mmol, 2 eqv) in benzene (150 mL) was added 
p-TsOH (717.0 mg, 4.16 mmol, 0.2 eqv) and the mixture heated to reflux at 115 °C in 
a soxhlet extractor containing 4 Å molecular sieves in the thimble. The molecular 
sieves were replaced every other day and after 3 days, 1H NMR analysis indicated 
complete consumption of the starting material. The reaction mixture was then cooled 
to rt, diluted with dichloromethane (400 mL) and washed with NaHCO3 (saturated 3 
x 150 mL) and brine (100 mL). After drying and evaporation the resulting viscous oil 
was stirred/triturated with petroleum ether (300 mL). After 1 h the petroleum ether 
was decanted and the remaining solid precipitate triturated with Et2O (4 x 100 mL) to 
give ester 93 as a pale yellow solid (7.0 g, 18.5 mmol, 89%). 
This reaction was repeated twice: i) Urea 92 (12.0 g, 50.0 mmol, 1 eqv.) and 
diethyl 1,3-acetonedicarboxylate (11.7 mL, 70.0 mmol, 1.4 eqv) in benzene (300 mL) 
with p-TsOH (860 mg, 4.99 mmol, 0.1eqv) to 93 (16.40 g, 43.3 mmol, 87%); ii) Urea 
92 (24.0 g,100.0 mmol, 1 eqv.) and diethyl 1,3-acetonedicarboxylate (33.5 mL, 200 
mmol, 2 eqv) in benzene (300 mL) with p-TsOH (3.44 g, 20 mmol, 0.2 eqv) to give 
93 (34.0 g, 89.8 mmol, 90%). 
 
Rf    0.41 (50% ethyl acetate in petrol);  
Mp    120-123 °C  
vmax 3090, 3061, 3023, 3008, 2979, 2935, 1738, 1702, 
1693, 1654, 1662, 1617, 1584, 1495, 1451, 1423, 
1396, 1367, 1333 
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δH (CDCl3)  1.26 (3H, t, J = 7.1 Hz, CH3), 3.42 (2H, s, CH2), 4.13 
(2H, q, J = 7.2 Hz, CH2), 5.15 (2H, s, CH2), 5.19 (2H, 
s, CH2), 5.76 (1H, s, CH), 7.12-7.16 (2H, m, 2 × CH), 
7.25-7.37 (6H, m, 6 × CH), and 7.47-7.52 (2H, m, 2 × 
CH)  
δC (CDCl3)  13.9 (CH3), 38.3 (CH2), 44.5 (CH2), 47.8 (CH2), 60.1 
(CH2), 104.0 (CH), 125.8 (2 ×CH), 127.3 (CH), 127.6 
(CH), 128.1 (2 × CH), 128.6 (2 × CH), 128.8 (2 × 
CH), 135.6 (C), 136.5 (C), 147.6 (C), 152.3 (C=O), 
161.6 (C=O) and 167.2 (C=O) 
m/z (CI) 779 (6%, [2M+Na]+), 757 (100%, [2M+H]+), 401 (5%, 
[M+Na]+) and 379 (95%, [M+H]+)  
HRMS (CI)   C22H23N2O4, requires 379.1652, found 379.1650  
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Preparation of 2-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic 
acid (94) 
  
 
Sodium hydroxide (5.28 g, 132.13 mmol, 10 eqv,) was added to a cooled (0 
°C) and stirred suspension of ester 93 (5.0 g, 13.213 mmol, 1 eqv) in ethanol (100 mL). 
After stirring to rt overnight. The mixture was diluted with water (600 mL) and the pH 
adjusted to pH 1-2 by the slow addition of HCl (aqueous, 1M) then extracted with 
dichloromethane (3 x 100 mL) and the combined organic extracts dried (MgSO4). 
After evaporation the resulting light brown solid was triturated with Et2O (3 x 40 mL) 
to give the acid 94 as an off white solid (4.46 g, 12.73 mmol, 96%). 
This reaction was repeated three times: i) Sodium hydroxide (306.5 mg, 7.66 
mmol, 2.9 eqv) and ester 93 (1.00 g, 2.64 mmol, 1 eqv) in ethanol (10 mL) gave 94 
(0.90 g, 2.6 mmol, 97%); ii) Sodium hydroxide (1.90g, 47.6 mmol, 9 eqv,) and ester 
93 (2.00 g, 5.29 mmol, 1 eqv) in ethanol (60 mL) gave 94 as an off white solid (1.8 g, 
5.14 mmol, 97%); iii) sodium hydroxide (10.0 g, 250.0 mmol, 9 eqv,) and ester 93 
(10.5g, 27.8 mmol, 1 eqv) in ethanol (150 mL) gave 94 (9.0 g, 25.7 mmol, 93%). 
 
Rf    0.27 (20% methanol in CH2Cl2) 
Mp    139-140 °C  
vmax 3442, 3096, 3063, 3034, 2921, 2793, 2695, 2576, 
1722, 1705, 1693, 1642, 1598, 1496, 1472, 1454, 
1423, 1399, 1367, 1351 1315 
δH (CD3)2SO) 3.58 (2H, s, CH2, obscured), 5.03 (2H, s, CH2), 5.05 
(2H, s, CH2), 5.89 (1H, s, CH), 7.13-7.19 (2H, m, 2 × 
CH), 7.22-7.38 (8H, m, 8 × CH) and 13.09 (1H, br s, 
OH)  
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δC (CD3)2SO) 38.0 (CH2), 43.8 (CH2), 47.5 (CH2), 103.0 (CH), 125.9 
(2 × CH), 127.2 (CH), 127.4 (CH), 127.6 (2 × CH), 
128.4 (2 × CH), 128.7 (2 × CH), 136.4 (C), 137.0 (C), 
149.6 (C), 152.0 (C=O), 161.3 (C=O) and 169.4 
(COOH) 
m/z (CI) 701 (100%, [2M+H]+), 373 (15%, [M+Na]+) and 351 
(100%, [M+H]+) 
HRMS (CI) C20H19N2O4 ([M+H]
+) requires 351.1399, found 
351.1340 
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Preparation of allyl 4-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-
3-oxobutanoate (96) 
 
 
 
Meldrum's acid (1.23 g, 8.56 mmol, 1.1 eqv) and CDI (1.38 g, 8.56 mmol, 1.1 
eqv) were added to a stirred solution of pyrimidine 94 (2.7 g, 7.71 mmol, 1.0 eqv.) in 
anhydrous THF (60 mL) and the mixture heated at 50 °C for 16 h. On cooling to rt the 
solvent was removed under reduced pressure and the residue taken in CH2Cl2/H2O 
(80/60 mL). The pH was then adjusted to pH 2 by the slow addition of HCl (aqueous 
1 M), the organic layer separated, and the organic extract washed with H2O (100 mL) 
and dried (MgSO4) and evaporated to give a yellow solid (3.30 g). This solid was 
dissolved in allyl alcohol (50 mL) and heated at 110 °C for 16 h. Excess alcohol was 
removed under reduced pressure and the resulting material purified by flash column 
chromatography on silica gel using ethyl acetate/petroleum ether (15:85 to 30:70). 
Fractions eluting in 25:75 ethyl acetate/petroleum ether gave 96 as viscous yellow oil 
(1.60 g, 3.70 mmol, 48%) 
This reaction was repeated twice: i) Meldrum's acid (452.5 mg, 3.14 mmol, 1.1 
eqv) CDI (509.1 mg, 3.14 mmol, 1.1 eqv) and 94 (1.00 g, 2.85 mmol, 1 eqv.) in THF 
(20 mL) to give 96 (0.578 g, 2.31 mmol, 47%); ii) Meldrum's acid (3.69 g, 25.62 
mmol, 1.1 eqv), CDI (4.15 g, 25.29 mmol, 1.1 eqv) and 94 (8.16 g, 23.29 mmol, 1 
eqv.) in THF (180mL) to give 96 (4.67 g, 10.8 mmol, 46%). 
 
Rf    0.08 (30% ethyl acetate in petrol) 
vmax  3094, 3067, 3023, 3002, 2968, 2939, 1746, 1727, 
1705, 1702, 1663, 1628, 1586, 1497, 1453,1396, 1347, 
1328 
δH (CD3)2SO) 3.77 (2H, s, CH2), 3.98 (2H, s, CH2), 4.57 (2H, dt, J = 
5.5, 1.3 Hz, CH2), 4.95 (2H, s, CH2), 5.01 (2H, s, 
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CH2), 5.21 (1H, dq, J = 10.5, 1.3 Hz, CH), 5.31 (1H, 
dq, J = 17.3, 1.3 Hz, CH), 5.80 (1H, s, CH), 5.88 (1H, 
ddt,  J = 17.3, 10.5, 5.5 Hz, CH), 7.14-7.16 (2H, m, 2 × 
CH); 7.23-7.36 (8H, m, 8 × CH) 
δC (CD3)2SO) 43.8 (CH2), 46.0 (CH2), 47.6 (CH2), 48.1 (CH2), 65.1 
(CH2), 103.2 (CH), 118.2 (CH2), 126.0 (CH), 127.2 
(CH), 127.3 (CH), 127.5 (CH), 128.3 (CH), 128.7 
(CH), 132.1 (CH), 136.6 (C), 137.0 (C),149.2 (C), 
151.8 (C), 161.2 (C), 166.6 (C), 198.3 (C) 
MS (CI) 865 (50%, [2M+H]+), 455 (6%, [M+Na]+) 433 (100%, 
[M+H]+) 
HRMS (CI) C25H25N2O5 ([M+H]
+) requires 433.1758, found 
433.1756  
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Preparation of 1,3-dibenzyl-6-methylpyrimidine-2,4 (98)95 
 
Acetic anhydride (15.4 g, 150.9 mmol, 3.36 eqv, 14.3 mL) was added slowly 
to a cooled (0 °C) solution of 92 (10.8 g, 44.9 mmol) in pyridine (200 mL) following 
which DMAP (5.49 g, 44.9 mmol, 1.0 eqv) was added in small portions and the 
mixture was heated (115 °C) for 5 hours. The reaction mixture was then cooled and 
the pyridine removed under reduced pressure to give a solid residue was dissolved in 
CHCl3 (150 mL) and washed with HC1 (aqueous, 2N, 2 x 200 mL) and saturated 
sodium bicarbonate solution (2 x 60 mL). After drying (MgSO4) and evaporation the 
residue was purified using column chromatography (10-50% ethyl acetate in petrol) 
to give 98 (10.7 g, 34.9 mmol) as a yellow oil in 78% yield. 
 This reaction was repeated twice: i) acetic anhydride (25.6 g, 280.0 mmol, 3.36 
eqv. 26.38 mL), 92 (20.0 g, 83.23 mmol), pyridine (500 mL) and DMAP (10.17 g, 
83.23 mmol, 1.0 eqv) to give 98 (19.87 g, 65 mmol, 78%): ii) acetic anhydride (7.14 
g, 69.91 mmol, 3.36 eqv. 6.60 mL), 92 (5.0g, 20.81 mmol), pyridine (70 mL) and (2.54 
g, 20.81 mmol, 1.0 eqv) to give 98 (4.85 g, 65.0 mmol, 76% yield). 
 
Rf    0.25 (40% ethyl acetate in petrol); 
δH (CDCl3)  2.14 (3H, s, CH3), 5.09 (2H, s, CH2), 5.17 (2H, s, 
CH2), 5.65 (1H, s, CH), 7.12-7.17 (2H, m, 2 × CH), 
7.22-7.36 (6H, m, 6 × CH), 7.46-7.50 (2H, m, 2 × 
CH).. 
δC (CDCl3) 162.0 (C), 152.6 (C), 151.7 (C), 136.9 (C), 136.0 (C), 
128.9 (2 × CH), 128.8 (2 × CH), 128.3 (2 × CH), 127.7 
(2 × CH), 127.4 (CH), 126.0 (CH), 102.0 (CH), 47.9 
(CH2), 44.5 (CH2), 19.8 (CH3). 
MS (CI) 307.1 (100%, [M+H]+), 613.3 (20%, [2M+H]+), 635.3 
(10%, [2M+Na]+)  
HRMS (CI) C19H19N2O2 ([M+H]
+) requires 307.1441, found 
307.1441 
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Preparation of 1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-
carbaldehyde (113)96 
 
A mixture of 98  (10.7 g, 34.93 mmol) and SeO2 (11.63 g, 104.8 mmol) was 
suspended in a mixture of THF (200 mL) and glacial acetic acid (200 mL) and heated 
at reflux for 24 h. After cooling the solution was filtered through a pad of Celite©, 
evaporated to dryness and the residue purified by silica gel chromatography (10-50% 
EtOAc in petrol) to give 113 (8.28 g, 35.0 mmol) as yellow oil in 74% yield. 
 This reaction was repeated three times: i) pyrimidine 98 (4.59 g, 15 mmol), 
SeO2 (5.0 g, 45.0 mmol, 3.0 eqv), in THF (45 mL) and glacial acetic acid (45 mL) to 
give 116 (3.60 g, 11.2 mmol, 75%); ii) pyrimidine 113 (9.45 g, 30.85 mol), SeO2 (10.3 
g, 92.5 mmol, 3.0 eqv) in THF (90 mL) and glacial acetic acid (90 mL) to give 116 
(7.60 g, 23.7 mmol, 77%); iii) pyrimidine 98 (3.0 g, 9.79 mmol), SeO2 (3.26 g, 29.4 
mmol, 3 eqv) in THF (50 mL) and glacial acetic acid (50 mL) to give 113 (2.33 g, 7.3 
mmol, 74% yield) 
 
Rf 0.23 (35% EtOAc/petrol)  
δH (CDCl3)  5.19 (2H, s, CH), 5.51 (2H, s, CH2), 6.28 (1H, s, CH), 
7.17-7.22 (2H, m, 2 × CH), 7.23-7.34 (6H, m, 6 × CH). 
7.46-7.51 (2H, m, 2 × CH), 9.41 (1H, s, CH) 
δC (CDCl3) 185.6 (C), 161.6 (C), 152.0 (C), 144.6 (C), 136.4 (C), 
136.4 (C), 129.1 (2 × CH), 128.8 (2 × CH), 128.6 (2 × 
CH), 128.0 (2 × CH), 127.9 (CH), 127.3 (CH), 114.1 
(CH), 46.7 (CH2), 45.1 (CH2). 
 vmax 3749, 3649, 3609, 3467, 2926, 2857, 2726, 1743, 
1607, 1554, 1535, 1493, 1460, 1377, 1326, 1258, 
1209, 1154, 1049, 824,  
HRMS (CI) C19H17N2O3 [M+H
+] requires 321.1234, found 
321.1237  
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Preparation of (3-bromopropoxy)(tert-butyl)dimethylsilane (107)94 
 
 
 
Alcohol, 105 (5.0 g, 36.0 mmol) was dissolved in cooled (0 °C) dry CH2Cl2 (70 mL) 
and imidazole (2.94 g, 43.2 mmol, 1.2 eqv) and DMAP (ca. 25 mg) were added and 
the mixture stirred. tert-Butyldimethylsilyl chloride (5.42 g, 36.0 mmol, 1 eqv) was 
then added and the mixture stirred at rt for 3 days. The mixture was then diluted with 
water, separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic layers 
were washed with water (3 × 30 mL), then dried (MgSO4) and concentrated under 
reduced pressure to give an oil. This was dissolved in hexane and passed through a 
short plug of silica gel (ca. 2 cm) to give 107 (8.22 g, 32.46 mmol) as an oil in 90% 
yield. 
 
δH (CDCl3)  0.06 (6H, s, 2 × CH3), 0.89 (9H, s, 3 × CH3), 2.02 (2H, 
tt, J = 5.7, 6.5 Hz, CH2), 3.50 (2H, t, J = 6.5 Hz, CH2), 
3.72 (2H, t, J = 5.7 Hz, CH2) 
δC (CDCl3) 60.3 (CH2), 35.5 (CH2), 30.5 (CH2), 25.9 (3 × CH3), 
18.2 (C), -5.4 (2 × CH3) 
 vmax 3749, 3749, 3648, 3470, 3098, 2985, 2960, 2906, 
2875, 2670, 2583.  
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Attempted preparation of 4-((tert-butyldimethylsilyl)oxy)-1-(2,6-
dimethoxypyrimidin-4-yl)butan-1-ol (109) 
 
 
 
Bromide 108 (1.0 g, 3.95 mmol, 2.77 eqv.) was added to a suspension of 
magnesium turnings (0.148 g, 6.09 mmol) in dry THF (5 mL) and the mixture heated 
at reflux until the metal had largely reacted (ca 30 min). At this point the reaction was 
cooled (0 °C) and the aldehyde 11 (0.24 g, 1.43 mmol) was added as a solution in dry 
THF (2 mL). After stirring to rt over 12 h, the reaction was diluted with ether (30 mL) 
and quenched with saturated NH4Cl (100 mL). After separation, the organic layer was 
washed with brine (2 × 50 mL), dried (MgSO4) and concentrated under reduced 
pressure. Purification of the residue on silica gel chromatography (gradient elution; 
10-100% EtOAc in petrol) gave no evidence for the formation of 109, but gave instead 
the previously prepared alcohol 103 (0.116 g, 0.68 mmol) as a solid in 48% yield. Data 
was identical to that previously prepared (See page 46) 
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Preparation of tert-butyldimethyl(prop-2-yn-1-yloxy)silane (119).97 
 
 
Alcohol 118 (8.0 g, 142.7 mmol, 1.0 eqv.) was dissolved in dry CH2Cl2 (50 mL) and 
cooled (0 °C) whereupon imidazole (19.43 g, 285.4 mmol, 2 eqv.) and tert-
butyldimethylsilyl chloride (21.5 g, 142.7 mmol) were added and the reaction mixture 
stirred to rt overnight. The reaction was diluted with cold water 50 mL and filtered 
through a pad of celite, which was washed with further portions of CH2Cl2. After 
separation of the organic phase the aqueous phase was extracted with CH2Cl2 (3 × 50 
mL) and the combined extracts washed with water (50 mL) and brine (50 mL) then 
dried (MgSO4) and evaporated under reduced pressure to give and oil.This was 
dissolved in hexane and passed through a short plug of silica gel (ca. 2 cm) to give 
119 (22.0 g, 129.2 mmol) in 91% yield as a colourless oil. 
             This reaction was repeated using 118 (5.0 g, 89.2 mmol, 1.0 eqv.), CH2Cl2 (35 
mL), imidazole (12.14 g, 178.4 mmol, 2 eqv.) and tert-butyldimethylsilyl chloride to 
give 119 (13.77 g, 81.0 mmol, 91%). 
 
δH (CDCl3)  0.09 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH3), 2.34 (1H, 
t, J = 2.4 Hz, CH), 4.26 (2H, d, J = 2.4 Hz, CH2) 
δC (CDCl3) 82.3 (C), 72.8 (CH), 51.4 (CH2), 22.7 (3 × CH3), 18.2 
(C), -5.3 (2 × CH3). 
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Preparation of (but-3-yn-1-yloxy)(tert-butyl)dimethylsilane (121)98 
 
 
Following a general literature procedure:98 Alcohol 120 (8.0 g, 114.1 mmol, 
1.0 eqv.) was dissolved in dry CH2Cl2 (50 mL) and cooled (0 
°C) whereupon imidazole 
(18.92 g, 171.2 mmol, 2 eqv.) and tert-butyldimethylsilyl chloride (18.92 g, 125.6 
mmol 1.1 eqv.) were added and the reaction mixture stirred to rt overnight. The 
reaction was diluted with cold water 50 mL and filtered through a pad of celite, which 
was washed with further portions of CH2Cl2. After separation of the organic phase the 
aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the combined extracts 
washed with water (50 mL) and brine (50 mL) then dried (MgSO4) and evaporated 
under reduced pressure to givean oil.This was dissolved in hexane and passed through 
a short plug of silica gel (ca. 2 cm) to give 121 (17.0 g, 92.21 mmol) in 81% yield as 
a colourless oil. 
 
δH (CDCl3)  0.07 (6H, s, 2 × CH3), 0.89 (9H, s, 3 × CH3), 1.95 (1H, 
t,  J = 2.6 Hz, CH), 2.39 (2H, dt, J = 2.6, 7.1 Hz, CH2), 
3.73 (2H, t, J = 7.1 Hz, CH2) 
δC (CDCl3) 81.5 (C), 69.3 (CH), 61.7 (CH2), 25.9 (3 × CH3), 22.8 
(CH2), 18.3 (C), -5.3 (2 × CH3) 
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Preparation of 1,3-dibenzyl-6-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybut-2-
yn-1-yl)pyrimidine-2,4(1H,3H)-dione (122) 
 
 
 
Alkyne 119 (1.35 g, 7.93 mmol, 2.0 eqv) dissolved in dry THF (1 mL) was added drop 
wise over 10 min to a cooled (-40 °C) solution of EtMgBr in THF (1M, 6.0 mL 6.0 
mmol, 1.5 eqv) and the resulting mixture stirred for 1 h. The reaction was then cooled 
(– 78 °C) and a solution of aldehyde 113 (1.27 g, 3.96 mmol) in dry THF (1 mL) was 
then added and the mixture was stirred at this temperature for 3 h. After warming to rt 
overnight, NH4Cl solution (saturated. aq. 20 mL) was added and the reaction extracted 
with EtOAc (3 × 50 mL), following which the combined organic extracts were washed 
with brine (50 mL) and water (50 mL) then dried (MgSO4) and evaporated under 
reduced pressure. The crude product was purified by flash chromatography on silica 
gel (EtOAc/petrol 30-50%) to give 122 (1.52 g, 3.10 mmol) as a colourless oil in 78% 
yield. 
This reaction was repeated 4 times: i) alkyne 119 (1.22 g, 7.2 mmol, 2.0 eqv), 
EtMgBr in THF (1M, 5.4 mL 5.4 mmol) and aldehyde 113 (1.15 g, 15.61 mmol) gave 
122 (1.38 g, 2.81 mmol, 78%); ii) alkyne 119 (2.96 g, 17.36 mmol, 2.0 eqv), EtMgBr 
in THF (1M, 16.5 mL 16.5 mmol, 19 eqv) and aldehyde 113 (2.78 g, 8.68 mmol) gave 
122 (3.30 g, 6.7 mmol, 78%); iii) alkyne 119 (5.30 g, 31.2 mmol, 2.0 eqv), EtMgBr in 
THF (1M, 29.7 mL 29.7 mmol, 1.9 eqv) and aldehyde 113 (5.00 g, 15.6 mmol) stirring 
for 5 h (- 78 °C) gave 122 (5.78 g, 11.8 mmol, 75%); iv) alkyne 119 (4.25 g, 25.0 
mmol, 2.0 eqv), EtMgBr in THF (1M, 23.7 mL 23.7 mmol, 1.9 eqv) and aldehyde 113 
(4.00 g, 12.50 mmol) gave 122 (4.80 g, 9.80 mmol, 78%). 
 
Rf 0.27 (30% EtOAc/petrol) 
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δH (CDCl3)  0.07 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH3), 3.43 (1H, 
d, J = 6.8 Hz, OH), 4.28 (2H, d, J = 0.6 Hz, CH2), 
5.11-5.18 (3H, m, CH, CH2), 5.28 (1H, d, J = 16.6 Hz, 
CH), 5.35 (1H, d, J = 16.6 Hz, CH), 6.25 (1H, s, CH) 
7.11-7.13 (2H, m, 2 × CH), 7.22-7.36 (6H, m, 6 × CH) 
and 7.45-7.47 (2H, m, 2 × CH) 
δC (CDCl3) 162.6 (C), 152.4 (C), 152.2 (C), 136.6 (C), 136.1 (C), 
129.1 (2 x CH), 129.0 (2 x CH), 128.4 (2 × CH), 127.8 
(CH), 127.7 (CH), 125.9 (2 × CH), 100.7 (CH), 87.8 
(C), 79.8 (C), 60.3 (CH), 51.5 (CH2), 47.3 (CH2), 44.7 
(CH2), 25.7 (3 × CH3), 18.2 (C) and -5.3 (2 × CH3) 
vmax 3419, 3032, 2954, 2928, 2885, 2856, 1691, 1646, 
1604, 1585, 1496, 1454, 1400, 1361, 1339, 1100, 
1073, 1053, 833, 697 
MS(CI) 491.2 (100%, [M+H]+), 513. 2 (25%, [M+Na]+) 918.5 
(25%, [2M+H]+) 
HRMS (CI) C28H35N2O4Si ([M+H]
+) requires 490.2361, found 
490.2350 
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Preparation of 1,3-dibenzyl-6-(5-((tert-butyldimethylsilyl)oxy)-1-hydroxypent-2-
yn-1-yl)pyrimidine-2,4(1H,3H)-dione (123) 
 
 
 
A solution of EtMgBr in THF (0.9 M, 7.71 mL 6.94 mmol, 1.9 eqv) was added 
over 10 min to a stirred and cooled (–40 °C) solution of 121 (1.35 g, 7.30 mmol, 2.0 
eqv.) in dry THF (5 mL) and the resulting mixture was stirred for 6 hour at rt. At this 
point the reaction was cooled (–78° C) and a solution of aldehyde 113 (1.17 g, 3.65 
mmol, 1.0 eqv) dissolved in dry THF (3 mL) was added by syringe and the mixture 
was stirred for 1 h. After warming to rt overnight, a solution of NH4Cl (aq. sat. 50 mL) 
was added and the mixture extracted with EtOAc (3 × 50 mL). The combined organic 
extracts were washed with brine (50 mL) and water (50 mL) then dried (MgSO4) and 
evaporated under reduced pressure. The crude residue was purified by flash 
chromatography on silica gel (EtOAc/petrol 20-40%) to give 123 (0.935 g, 1.85 mmol) 
in 51% as a yellow semi-solid. 
This reaction was repeated twice: i) EtMgBr in THF (0.9 M, 16.7 mL 16.7 
mmol, 1.9 eqv), 121 (2.91 g 15.80 mmol, 2.0 eqv.), THF (5 mL) and aldehyde 113 
(2.53 g, 7.90 mmol, 1.0 eqv) gave 123 (2.51 g, 5.00 mmol, 63%); ii) EtMgBr in THF 
(0.9 M, 7.71 mL 6.94 mmol, 1.9 eqv), 121 (1.35 g 7.30 mmol, 2.0 eqv.), THF (5 mL) 
and 113 (1.17 g, 3.65 mmol, 1.0 eqv) gave 123 (1.22g, 2.40 mmol, 66%). 
 
Rf   0.32 (35% EtOAc in petrol) 
H (CDCl3) 0.02 (6H, s, 6 × CH3), 0.85 (9H, s, 9 × CH3), 2.36 (2H, dt, J = 
1.8, 6.9 Hz, CH2), 3.42 (1H, d, J = 6.0 Hz, OH), 3.64 (2H, t, J 
= 6.9 Hz, CH2), 5.07 (1H, m, CH), 5.12 (2H, s, CH2), 5.31 
(2H, s, CH2), 6.22 (1H, s, CH), 7.10-7.12 (2H, m, 2 × CH), 
7.20-7.35 (6H, m, 6 × CH) and 7.43-7.46 (2H, m, 2 × CH) 
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C (CDCl3) 162.7 (C), 153.0 (C), 152.4 (C), 136.6 (C), 136.2 (C), 129.0 (2 
× CH), 128.9 (2 × CH), 128.4 (2 × CH), 127.7 (CH), 127.6 
(CH), 125.9 (2 × CH), 100.3 (CH), 87.3 (C), 76.6 (C), 61.1 
(CH2), 60.3 (CH), 47.3 (CH2), 44.7 (CH2), 25.8 (3 × CH3), 
23.0 (CH2), 18.2 (C), -5.4 (2 × CH3) 
vmax 3414, 3089, 3065, 3033, 2954, 2923, 2851, 1711, 1655, 1649, 
1585, 1496, 1464, 1389, 1349, 1205, 1130, 1005, 836, 779, 
729, 696, 601  
m/z (CI)  505.3 (100%, [M+H]+), 1009.5 (25%, [2M+H]+) 
HRMS (CI)  C29H37N2O4Si ([M+H]
+) requires 505.2517, found 505.2507 
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Preparation of 1,3-dibenzyl-6-(5-((tert-butyldimethylsilyl)oxy)-1-hydroxypentyl) 
pyrimidine-2,4(1H,3H)-dione (125) 
 
 
 
Palladium supported on activated carbon (10%, 0.66 g) was added to a solution 
of alkyne 123 (0.66 g, 1.22 mmol) in EtOAc (4 mL) under an argon blanket in a 25 
mL RBF. The flask was purged with hydrogen gas (balloon) mixture and the mixture 
vigorously stirred under the hydrogen atmosphere for 2 h. The mixture was then 
filtered through a Celite© pad which was washed with further portions of EtOAc and 
the filtrate concentrated by evaporated under reduced pressure. The crude product was 
purified by column chromatography on silica gel (10-20% EtOAc/petrol) to give 125 
(0.428 g, 0.84 mmol) as a colorless oil in 64% yield. 
This reaction was repeated twice: i) Pd/C (10%, 2.0g), and alkyne 123 (2.0 g, 
4.08 mmol) in EtOAc (10 mL) gave 125 (1.42 g, 2.90 mmol, 70%); ii) Pd/C (10%, 2.0 
g) alkyne 123 (2.77 g, 5.64 mmol) in EtOAc (10 mL) gave 125 (2.00 g, 4.04 mmol, 
72%). 
 
Rf   0.23 (20 % EtOAc/petrol) 
H (CDCl3) 0.03 (6H, s, 2 × CH3), 0.88 (9H, s, 9 × CH3), 1.34-1.53 (4H, 
m, 2 × CH2), 1.54-1.66 (2H, m, CH2), 3.13 (1H, d, J = 5.2 Hz, 
OH), 3.56 (2H, t, J = 5.0 Hz, CH2), 4.38-4.46 (1H, m, CH), 
4.98 (1H, d, J = 16.3 Hz, CH), 5.10 (1H, d, J = 13.7 Hz, CH), 
5.15 (1H, d, J = 13.7 Hz, CH), 5.31 (1H, d, J = 16.3 Hz, CH), 
5.99 (1H, s, CH), 7.08-7.10 (2H, m, 2 × CH), 7.19-7.37 (6H, 
m, 6 × CH) and 7.43-7.46 (2H, m, 2 × CH) 
C (CDCl3) 162.8 (C), 157.7 (C), 152.5 (C), 136.7 (C), 136.2 (C), 129.0 (2 
× CH), 128.9 (2 × CH), 128.4 (2 × CH), 127.7 (CH), 127.6 
(CH), 125.8 (2 x CH), 99.1 (CH), 68.6 (CH), 62.7 (CH2), 47.2 
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(CH2), 44.6 (CH2), 35.8 (CH2), 31.9 (CH2), 25.9 (3 × CH3), 
22.3 (CH2), 18.3 (C), -5.3 (2 × CH3) 
vmax 3387, 3065, 3033, 2953, 2930, 2857, 1702, 1654, 1496, 1453, 
1393, 1348, 1255, 1215, 1192, 1099, 1030, 1005, 937, 835, 
776, 733, 697, 668 
m/z (CI) 509.3 (100%, [M+H]+), 1017.6 (20%, [2M+H]+) 
HRMS (CI)  C29H41N2O4Si ([M+H]
+) requires 509.2830, found 509.2819 
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Preparation of 1,3-dibenzyl-6-(1,5-dihydroxypentyl)pyrimidine-2,4(1H,3H)-
dione (126) 
 
 
A solution of TBAF (1 M, 0.943 mL, 0.943 mmol, 1.5 eqv) in THF was added 
to a cooled (0 °C) solution of silane 125 (0.32 g, 0.629 mmol, 1.0 eqv.) in dry THF (2 
mL) and the mixture stirred for 2h. After warming to rt overnight, the solvent was 
removed under reduced pressure the residue purified by flash chromatography on 
silica gel (gradient elution; 50-100% EtOAc in petrol) to give 126 (0.19 g, 0.482 
mmol) as a colourless oil in 77% yield. 
 
Rf   0.28 (EtOAc) 
H (CDCl3) 1.33-1.62 (6H, m, 3 × CH2), 3.00 (2 H, br s, 2 × OH), 3.46-57 
(2H, m, CH2), 4.42-4.46 (1H, m, CH), 5.01 (1H, d, J = 16.4 
Hz, CH), 5.10 (1H, d, J = 13.9 Hz, CH), 5.15 (1H, d, J = 13.9 
Hz, CH), 5.29 (1H, d, J = 16.4 Hz, CH), 5.99 (1H, s, CH), 
7.03-7.17 (2H, m, 2 × CH), 7.18-7.36 (6H, m, 6 × CH) and 
7.41-7.50 (2H, m, 2 × CH) 
C (CDCl3) 163.1 (C), 158.1 (C), 152.5 (C), 136.6 (C), 136.2 (C), 129.0 (2 
× CH), 128.9 (2 × CH), 128.4 (2 × CH), 127.7 (CH), 127.6 
(CH), 125.9 (2 × CH), 98.9 (CH), 68.4 (CH), 62.1 (CH2), 
47.2, (CH2) 44.7 (CH2), 35.7 (CH2), 31.5 (CH2), 22.1 (CH2) 
vmax 3386, 3032, 2940, 2878, 1702, 1652, 1496, 1453, 1396, 1216, 
1073, 910, 835, 755, 732, 697 
m/z (CI) 395.2 (100%, [M+H]+), 789.4 (30%, [2M+H]+) 
HRMS (CI) C23H27N2O4 ([M+H]
+) requires 396.1565, found 396.1565 
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Preparation of 1,1'-(1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-
yl)pentane-1,5-diyl)-di-(2,3-bis(tert-butoxycarbonyl))diguanidine (127) 
 
 
 
DIAD (67.1 mg, 0.332 mmol, 1.1 eqv.) was added over 10 min to a cooled (0 
˚C.) and stirred mixture of 126 (119.0 mg 0.302 mmol), PPh3 (95.0 mg, 0.362 mmol, 
1.2 eqv.), and N,N'-di-Boc-guanidine (38.0 mg, 0.362 mmol, 1.2 eqv.) dissolved in dry 
THF (2 mL). After stirring to rt overnight a small drop of water was added and the 
solution evaporated under reduced pressure and purified by flash chromatography on 
silica gel (30-40% EtOAc in petrol) to give impure 127 (201.0 mg, 0.24 mmol) as a 
white solid in 81% yield. 
 
H (CDCl3) 0.08-1.75 (36H, m, 3 × CH2, 10 × CH3), 3.58-80 (2H, m, 
CH2), 4.60-5.30 (7H, 3 × CH, 2 × CH2), 5.60-5.90 (2H, m, 
CH, NH), 7.00-7.60 (10H, m, 10 × CH) and 9.00-9.50 (2H, m, 
2 × NH) 
C (CDCl3) Partial (from COSY): 102.76 (CH) 55.4 (NCH), 44.6 (NCH2) 
m/z (CI) 822.4 (100%, [M+H]+), 844.4 (15% [M+Na]+) 
HRMS (CI)  C42H59N7O10 ([M+H]
+) requires 822.4396, found 822.4390 
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Preparation of 1,3-dibenzyl-6-(4-((tert-butyldimethylsilyl)oxy)-1-hydroxybutyl) 
pyrimidine-2,4(1H,3H)-dione (124) 
 
 
 
Palladium supported on activated carbon (10%, 1.49 g) was added to a solution 
of alkyne 122 (1.49 g, 3.04 mmol, 1.0 eqv.) in EtOAc (5 mL) under an argon blanket 
in a 50 mL RBF. The flask was then purged with hydrogen gas (balloon) and the 
mixture vigorously stirred under the hydrogen atmosphere for 2 h. The mixture was 
then filtered through a Celite© pad which was washed with further portions of EtOAc 
and the filtrate concentrated by evaporated under reduced pressure. The crude product 
was purified by column chromatography on silica gel (20-30% EtOAc/petrol) to give 
124 (1.10 g, 2.22 mmol) as a white solid in 73% yield.  
 
Rf   0.23 (30% EtOAc/petrol) 
Mp   80-82 °C 
H (CDCl3) 0.06 (3H, s, CH3), 0.07 (3H, s, CH3) 0.89 (9H, s, 3 × CH3), 
1.48-1.88 (4H, m, 2 × CH2), 3.55-3.67 (2H, m, CH2), 4.44-
4.49 (1H, m, CH), 4.66 (11H, br s, OH), 5.01 (1H, d, J = 16.4 
Hz, CH), 5.10 (1H, d, J = 13.8 Hz, CH), 5.15 (1H, d, J = 13.8 
Hz, CH), 5.33 (1H, d, J = 16.4 Hz, CH), 6.04 (1H, s, CH), 
7.10-7.12 (2H, m, 2 × CH), 7.20-7.35 (6H, m, 6 × CH) and 
7.43-7.47 (2H, m, 2 × CH) 
C (CDCl3) 162.7 (C), 157.8 (C), 152.4 (C), 136.6 (C), 136.2 (C), 128.8 (2 
× CH), 128.7 (2 × CH), 128.2 (2 × CH), 127.5 (CH), 127.4 
(CH), 125.7 (2 × CH), 98.9 (CH), 68.1 (CH), 62.5 (CH2), 47.0 
(CH2), 44.4 (CH2), 33.6 (CH2), 28.8 (CH2), 25.7 (3 × CH3), 
18.1 (CH), -5.6 (2×CH3) 
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vmax 3405, 3065, 3033, 2954, 2928, 2856, 1702, 1652 1452, 1392, 
1345, 1254, 1215, 1187, 1096, 1030, 834, 776, 696. 
m/z (CI) 495.3 (100%, [M+H]+), 989.5 (20%, [2M+H]+)  
1011.5 (4%, [2M+Na]+) 
HRMS (CI)  C28H39N2O4Si ([M+H]
+) requires 494.2674, found 494.2666 
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Preparation of 4-((tert-butyldimethylsilyl)oxy)-1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)butyl acetate (128) 
 
  
 
Acetic anhydride (0.303 g, 3.82 mmol, 3.7 eqv.) was added drop wise to a 
cooled (0˚C) and stirred mixture of alcohol 124 (0.49 g, 0.99 mmol), pyridine (311.0 
mg, 3.86 mmol, 3.9 eqv.) and DMAP (12.0 mg) in dry CH2Cl2 (3 mL). The mixture 
was warmed to rt and stirred for 1 h, whereupon HCl (aqueous. 2 M, 20 mL) was 
added the mixture stirred for 20 min. The mixture was the extracted with CH2Cl2 (3 x 
50 mL) and the combined extracts washed with 2M HCl (aqueous, 3 × 10 mL) and 
water (20mL). After drying (MgSO4) and evaporated under reduced pressure, column 
chromatography on silica gel gave 128 (0.40 g, 0.745 mmol) as a white solid in 75% 
yield. 
This reaction was repeated three times: i) Ac2O (336.0 mg, 3.30 mmol, 3.7 
eqv.), 124 (440.0 mg, 0.89 mmol), pyridine (274.4 mg, 3.50 mmol, 3.9 eqv.) and 
DMAP (12.0 mg) in CH2Cl2 (2 mL) gave 128 (0.451 g, 0.86 mmol, 94%). ii) Ac2O 
(370.0 mg, 3.46 mmol, 3.7 eqv.), 124 (490.0 mg, 0.99 mmol), pyridine (305.6 mg, 
3.86 mmol, 3.9 eqv.) and DMAP (12.0 mg) in CH2Cl2 (4 mL) gave 128 (0.400 g, 0.75 
mmol, 75%). ii) Ac2O (717.0 mg, 7.00 mmol, 3.7 eqv.), 124 (0.94 g, 1.90 mmol), 
pyridine (586.0 mg, 7.40 mmol, 3.9 eqv.) and DMAP (16 mg) in CH2Cl2 (4 mL) gave 
128 (1.00 g, 1.86 mmol, 98%). 
 
Rf   0.27 (20% EtOAc/petrol), 0.43 (30% EtOAc/petrol) 
H (CDCl3) 0.00 (6H, s, 2 × CH3), 0.86 (9H, s, 3 × CH3), 1.21-1.36 (1H, 
m, CH), 1.41-1.55 (2H, m, CH2), 1.58-1.71 (1H, m, CH), 2.02 
(3H, s, CH3), 3.42 (2H, t, J = 6.0 Hz, CH2), 5.11-5.20 (3H, m, 
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CH, CH2), 5.29 (1H, d, J = 16.3 Hz, CH), 5.49 (1H, dd, J = 
9.5, 2.3 Hz, CH), 5.82 (1H, s, CH), 7.20-7.51 (10H, m, 2 ×Ph) 
C (CDCl3) 170.1 (C), 162.3 (C), 155.2 (C), 152.4 (C), 136.6 (C), 135.9 
(C), 129.1 (2 × CH), 128.9 (2 × CH), 128.4 (2 × CH), 127.9 
(CH), 127.6 (CH), 126.4 (2 × CH), 99.3 (CH), 69.8 (CH), 61.7 
(CH2), 47.8 (CH2), 44.7 (CH2), 31.0 (CH2), 28.5 (CH2), 25.9 
(3 × CH3), 20.6 (CH3), 18.2 (C), -5.4 (2 × CH3)  
vmax 3362, 3089, 3065, 3033, 2955, 2929, 2855, 2856, 1748, 1708, 
1666, 1624, 1607, 1586, 1496, 1452, 1395, 1360, 1248, 1222, 
1156, 1098, 1049, 1030, 977, 938, 834, 777, 760, 728, 697, 
665 
m/z (CI) 537.3 (100%, [M+H]+), 1073.6 (60%, [2M+H]+)  
HRMS (CI) C30H41N2O5Si ([M+H]
+) requires 537.2779, found 537.2769, 
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Preparation of 1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-
hydroxybutyl acetate (129) 
 
 
A solution of TBAF (1 M, 3.02 mL, 3.02 mmol, 1.5 eqv) in THF was added to 
a cooled (0 °C) solution of silane 128 (1.08 g, 2.01 mmol, 1.0 eqv.) in dry THF (2 mL) 
and the mixture stirred for 2h. After warming to rt overnight, the solvent was removed 
under reduced pressure the residue purified by flash chromatography on silica gel 
(gradient elution, 35-40% EtOAc in petrol) to give 129 (0.62 g, 1.47 mmol) as a 
colorless oil in 73% yield. 
 This reaction was repeated twice: i) TBAF (1 M, 1.1 mL, 1.1 mmol, 1.5 eqv) 
and 128 (0.40 g, 0.745 mmol, 1.0 eqv.) in dry THF (7 mL) gave 129 (0.28 g, 0.66 
mmol, 89%); ii) TBAF (1 M, 3.1 mL, 3.1 mmol, 1.5 eqv) and 128 (1.10 g, 2.05 mmol, 
1.0 eqv.) in dry THF (7 mL) gave 129 (0.69 g, 1.63 mmol, 80%). 
 
Rf   0.35 (60% EtOAc in petrol) 
H (CDCl3) 1.50-1.69 (3H, m, CHH, CH2), 1.70-1.83 (1H, m, CHH) 1.98 
(3H, s, CH3), 3.10 (1H, br s, OH), 3.99 (1H, t, J = 6.0 Hz, 
CH2), 4.43-4.50 (1H, m, CH), 4.98 (1H, d, J = 16.8 Hz, CH), 
5.10 (1H, d, J = 13.8 Hz, CH), 5.15 (1H, d, J = 13.8 Hz, CH), 
5.30 (1H, d, J = 16.8 Hz, CH), 6.00 (1H, s, CH), 7.06-7.11 
(2H, m, 2 × CH), 7.23-7.33 (6H, m, 6 × CH), 7.39-7.44 (2H, 
m, 2 × CH) 
C (CDCl3) 171.19 (C), 162.9 (C), 157.9 (C), 152.4 (C), 136.5 (C), 136.1 
(C), 129.0 (2 × CH), 128.8 (2 × CH), 128.4 (2 × CH), 127.8 
(CH), 127.6 (CH), 125.8 (2 × CH), 99.0 (CH), 68.0 (CH), 63.6 
(CH2), 47.1 (CH2), 44.6 (CH2), 32.5 (CH2), 24.8 (CH2), 20.8 
(CH3) 
  
126 
 
vmax 3417, 2962, 1736, 1702, 1652, 1496, 1451, 1392, 1349, 1243, 
1031, 832, 731, 696 
m/z (CI) 423.2 (100%, [M+H]+), 845.4 (28%,[2M+H]+)  
867.4 (18%, [2M+Na]+) 
HRMS (CI)  C24H27N2O5 ([M+H]
+) requires 423.1914, found 423.1917 
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Preparation of 4-(2,3-bis(tert-butoxycarbonyl)guanidino)-1-(1,3-dibenzyl-2,6-
dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)butyl acetate (130) 
 
 
 
DIAD (0.19 g, 0.95 mmol, 2 eqv.) was added drop wise over 10 min to a cooled 
(0 ˚C) and stirred solution of alcohol 129 (0.20 g, 0.47 mmol, 1.0 eqv.), PPh3 (0.248 
g, 0.95 mmol, 2 eqv.), and N,N'-di-Boc-guanidine (0.246 g, 0.95 mmol, 2 eqv.) in dry 
THF (3 mL). After stirring to rt overnight, a drop of water was added and the solution 
was evaporated under reduced pressure. The crude product was then purified by flash 
chromatography on silica gel (30-40% EtOAc/petrol) to give 130 (0.06 g, 0.09 mmol) 
as a white solid in 19% yield. 
This reaction was repeated twice: i) DIAD (0.19 g, 0.95 mmol, 2 eqv.), 129  
(0.20 g, 0.47 mmol, 1.0 eqv), PPh3 (0.25 g, 0.95 mmol, 2 eqv.) and N,N'-di-Boc-
guanidine (0.246 g, 0.95 mmol, 2 eqv.) in dry THF (3 mL) gave 130 (0.06 g, 0.09 
mmol, 19%); DIAD (71.8 mg, 0.355 mmol, 1.5 eqv.) 129 (100.0 mg, 0.237 mmol, 1.0 
eqv.), PPh3 (93.1mg, 0.355 mmol, 1.5 eqv.) and N,N'-di-Boc-guanidine (170.0 mg, 
0.473 mmol, 2 eqv.) in dry THF (3 mL) gave 130 (40.0 mg, 0.06 mmol) as a white 
solid in 26% yield. 
 
Rf   0.24 (30% EtOAc in petrol) 
H (CDCl3) 1.37 (9H, m, 3 × Me), 1.40-1.50 (1H, m, CHH), 1.51 (9H, m, 
3 × Me), 1.59-1.57 (1H, m, CHH), 1.86-2.05 (2H, m, CH2), 
2.03 (3H, s, CH3), 4.02 (2H, t, J = 6.0 Hz CH2), 5.13 (1H, d, J 
= 17.0 Hz, CH), 5.20 (2H, s, CH2), 5.30 (1H, d, J = 17.0 Hz, 
CH), 5.91 (1H, s, CH), 6.52 (1H, t, J = 7.2 Hz, CH), 6.88 (1H, 
d, J = 6.5 Hz, CH), 7.15-7.31 (7H, m, 7 × CH), 7.45-7.49 (2H, 
m, 2 × CH), 8.56 (1H, br s, NH), 8.90 (1H, br s, NH) 
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C (CDCl3) 170.8 (C), 162.9 (C), 162.0 (C), 159.3 (C), 153.6 (C), 153.4 
(C), 152.7 (C), 136.9 (C), 136.0 (C), 128.9 (2 × CH), 128.5 (2 
× CH), 128.4 (2 × CH), 127.6 (CH), 126.9 (CH), 124.7 (2 × 
CH), 103.9 (CH), 86.0 (C), 79.2 (C), 63.6 (CH2), 51.4 (CH), 
48.4 (CH2), 44.4 (CH2), 28.2 (CH2), 28.0 (3 × CH3), 28.0 (3 × 
CH3), 24.6 (CH2), 20.9 (CH3) 
vmax 3391, 2978, 1704, 1663, 1614 1444, 1367, 1308 1243, 1142, 
1106, 1045 
m/z (CI) 686.3 (12%, [M+Na]+), 664.3 (8%, [M+H]+), 464.2 (100% 
[M-2Boc+H]+)  
HRMS (CI)  C35H45N5O8Na ([M+Na]
+) requires 663.3160, found 663.3143 
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Preparation of 1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-
(1,2,3-tris(tert-butoxycarbonyl)guanidino)butyl acetate (131) 
 
 
 
DIAD (0.15 g, 0.762 mmol, 1.5 eqv.) was added drop wise over 20 min to a 
cooled (0 ˚C) and stirred solution of alcohol 129 (0.21g, 0.497 mmol, 1.0 eqv.), PPh3 
(0.20 g, 0.76 mmol, 1.53 eqv.), and N,N′,N′′-tri-Boc-guanidine (0.36 g, 1.00 mmol, 
2.02 eqv.) in dry THF (3 mL). After stirring to rt overnight further PPh3 (0.065 g, 0.248 
mmol, 0.5 eqv.) and DIAD (0.050g, 0.249 mmol, 0.5 eqv.) were added and the reaction 
was stirred for a further 3 h. At this point a drop of water was added and the solution 
was evaporated under reduced pressure. The crude product was then purified by flash 
chromatography on silica gel (20-30% EtOAc/petrol) to give 131 (0.146 g, 0.20 mmol) 
as a white solid in 39% yield.  
This reaction was repeated twice: i) Alcohol 129 (0.30 g, 0.734 mmol), PPh3 
(0.37g, 1.42mmol,  1.93 eqv.), N,N’,N’’-tri-Boc-guanidine (0.51 g, 1.42 mmol, 1.93 
eqv.) and DIAD (0.287 g, 1.42 mmol, 2 eqv.) gave 131 (0.193 g, 0.253 mmol, 34%): 
ii) Alcohol 129 (0.63 g, 1.49 mmol), PPh3 (0.78 g, 2.97, 1.99 eqv.) and N,N’,N’’-tri-
Boc-guanidine (1.06 g, 2.95 mmol, 1.99 eqv.) and DIAD (0.60 g, 2.97 mmol, 1.99 
eqv.) gave 131 (0.43 g, 0.563 mmol, 38%). 
 
Rf   0.20 (20% EtOAc/petrol), 0.50 (30% EtOAc/petrol) 
Mp   42- 45 °C 
H (CDCl3) 1.37 (9H, m, 3 × Me), 1.44 (9H, m, 3 × Me), 1.13-1.40 (2H, 
m, CH2), 1.51 (9H, m, 3 × Me), 1.85-2.01 (1H, m, CHH), 
2.07-2.19 (1H, m, CHH), 1.97 (3H, s, CH3), 3.80 (2H, t, J = 
6.3 Hz CH2), 5.00 (1H, d, J = 17.0 Hz, CH), 5.11 (1H, d, J = 
13.8 Hz, CH), 5.23 (1H, d, J = 13.8 Hz, CH), 5.33 (1H, t, J = 
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7.5 Hz, CH), 5.70 (1H, d, J = 17.0 Hz, CH), 5.99 (1H, s, CH), 
7.21-7.34 (8H, m, 8 × CH), 7.38-7.44 (2H, m, 2 × CH), 10.40 
(1H, s, NH) 
C (CDCl3) 170.8 (C), 161.9 (C), 152.7 (C), 151.9 (C), 151.6 (C), 151.3 
(C), 150.8 (C), 148.7 (C), 137.1 (C), 136.9 (C), 128.9 (2 × 
CH), 128.5 (2 × CH), 128.4 (2 × CH), 127.6 (CH), 127.4 
(CH), 126.5 (2 × CH), 104.2 (CH), 83.9 (C), 83.05 (C), 81.95 
(C), 63.3 (CH2), 55.4 (CH), 47.3 (CH2), 44.6 (CH2), 29.3 
(CH3), 27.9 (3 × CH3), 27.8 (6 × CH3), 24.8 (CH2), 20.8 (CH3) 
vmax 3401, 2947, 2917, 1759, 1739, 1706, 1667, 1621, 1448, 1369, 
1249, 1128 
m/z (CI) 764.4 (75%, [M+H]+), 647.3 (100%)  
HRMS (CI)  C40H54N5O10  ([M+H]
+) requires 764.3865, found 764.3864 
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Preparation of 1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-
(1,2,3-tris(tert-butoxycarbonyl)guanidino)butyl acetate (132) 
 
 
 
Potassium carbonate (36.0 mg, 0.261 mmol, 8.0 eqv.) was added to a solution 
of 131 (25.0 mg, 0.033 mmol) in dry methanol (5 mL) and the mixture stirred at rt for 
1 h. The mixture was evaporated onto silica gel (ca. 1 g) and purified by column 
chromatography on silica gel (gradient elution; 30-50% EtOAc/petrol) to give 132 
(18.0 mg, 0.025 mmol) in 76% yield as a white solid. 
 
Rf   0.20 (20% EtOAc/petrol), 0.50 (30% EtOAc/petrol) 
H (CDCl3) 0.78-0.96 (1H, m, CH), 1.16-1.30 (1H, m, CH), 1.37 (9H, s, 3 
× CH3), 1.43 (9H, s, 3 × CH3), 1.51 (9H, s, 3 × CH3), 1.73-
1.85 (1H, m, CH), 1.94 (1H, br s, OH), 2.16-2.30 (1H, m, 
CH), 3.25-3.40 (2H,  m, CH2),  4.97 (1H, d, J = 16.3 Hz, CH), 
5.11 (1H,d, J = 13.8 Hz, CH), 5.21 (1H, d,  J = 13.8 Hz, CH), 
5.34 (1H, t,  J = 7.4Hz,  CH), 5.71 (1H, d, J = 16.3 Hz, CH), 
5.97 (1H, s, CH), 7.17-7.23 (2H, m, 2 × CH), 7.24-7.34 (6H, 
m, 6 × CH), 7.41-7.44 (2H,  m, 2 × CH), 10.50 (1H, s, NH) 
C (CDCl3) 162.2 (C), 152.9 (C), 152.4 (C), 152.2 (C), 151.6 (C), 137.2 
(C), 137.1 (C), 129.0 (CH), 128.8 (CH), 128.6 (CH), 127.7 
(CH), 127.6 (CH), 126.6 (CH), 103.9 (CH), 84.2 (C), 83.4 (C), 
82.3 (C), 61.0 (CH2), 55.4 (C), 47.5 (CH2), 44.8 (CH2), 29.9 
(C), 28.8 (CH2), 28.4 (CH2), 28.1 (3 × CH3) 28.0 (6 × CH3) 
vmax 3448, 3066, 3034, 2980, 2932, 2251, 1759, 1705 1663, 1619, 
1496, 1451, 1395, 1370, 1251, 1142, 1061, 1030, 911, 839, 
732 
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m/z (CI)  722.4 (100%, [M+H]+), 744.4 (35%, [M+Na]+) 
HRMS (CI)  C38H52N5O9 ([M+H]
+), requires 722.3760, found 722.3757 
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Attempted deprotection of 1-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)-4-(1,2,3-tris(tert-butoxycarbonyl) guanidino)butyl 
acetate (133). 
 
 
A mixture of the dibenzyluracil 132 (170.0 mg, 0.236 mmol), ammonium 
formate solution (40% in methanol, 1 mL) and 10% Pd/C (0.24 g) was refluxed for 24 
h. The mixture was filtered through Celite©, and the solid residue washed with MeOH 
and CHCl3 (ca. 50 mL). After evaporation, a solid (56.0 mg) was obtained which on 
analysis by proton NMR and TLC was shown to be a complex mixture of products.  
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Preparation of 1-(4-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-
hydroxybutyl)guanidine (134) and 1-(4-chloro-4-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)butyl)guanidine (135). 
 
 
 
Guanidine 131 (40.0 mg, 0.052 mmol) and HCl (concentrated, 2 mL) were 
combined in a 5 mL round bottom flask and the mixture was heated (100˚C) for 16 h. 
After cooling to rt the mixture was evaporated and dried under vacuum (P2O5) to give 
a crude mixture of 134 and 135 (12.8 mg) as a solid which were identified solely by 
mass spectrometry. 
 
m/z (CI) 134; 422.2 (70%, [M+H]+); 135; 440.2 (100%, [M+H]+, 35Cl), 
442.2 (35%, [M+H]+, 37Cl)  
HRMS (CI) 134 C23H28N5O3 ([M+H]
+) requires 422.2187, found 422.2162 
135 C23H28
35ClN5O3 ([M+H]
+) requires 440.1848, found 
440.1819; C23H28
37ClN5O3 ([M+H]
+) requires 442.1800, 
found 440.1789 
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Preparation of methyl 2,6-dimethoxypyrimidine-4-carboxylate (102)94    
 
 
 
Orotic acid monohydrate 101 (10.2 g. 58.6 mmol) was suspended in POCl3 (80 
mL) and the solution stirred and heated (120 °C) overnight. After cooling to rt, PCl5 
(25.5 g, 117.0 mmol) was added to the red solution and the mixture refluxed overnight. 
At this point excess solvent was removed by distillation to give crude 2,6-
dichloropyrimidine-4-carbonyl chloride as an oily residue. This oil was cooled (0 °C) 
and dry methanol (50 mL) was added drop-wise over 2h (CAUTION! exothermic 
reaction). After stirring to rt overnight, the mixture was evaporated onto silica gel (100 
g) and the silica placed into a sintered glass filter and flushed with ethyl acetate (3 x 
100 mL). Evaporation of the filtrate gave the crude product which was purified by 
column chromatography on silica gel (25% EtOAc in petrol) to give 102 (2.0 g, 10.1 
mmol) as a white crystalline solid in 17% yield. This reaction was repeated twice on 
an identical scale to give 9% on both occasions. Two repeats were also performed 
where sodium methoxide (0.234 mol; prepared from sodium (5.39 g, 0.234 mol) and 
dry methanol (100 mL) was added to the intermediate crude 2,6-dichloropyrimidine-
4-carbonyl chloride after the addition of methanol and after column chromatography 
yields of 9% and 18% were obtained. 
 
Rf   0.22 (40% EtOAc in petrol) 
Mp   102-104 °C, (Lit.108-109 °C94) 
δH (CDCl3)  3.98 (3H, s, CH3), 4.03 (3H, s, CH3), 4.07 (3H, s, CH3), 7.06 (s, 
1H) 
δC (CDCl3) 172.5 (C), 165.5 (C), 164.2 (C), 156.5 (C), 102.9 (CH), 54.9 
(CH2), 54.1 (CH3), 52.7 (CH3) 
vmax 2925, 1609, 1567, 1458, 1363, 1207, 1109, 1039, 830, 784 
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Preparation of (2,6-dimethoxypyrimidin-4-yl)methanol (103)94  
 
 
 
Ethanol (60 mL) was added to a stirred mixture of solid LiBH4 (0.33 g, 15.15 
mmol, 1.20 eqv) and ester 102 (2.50 g, 12.57 mmol, 1 eqv) in THF (40 mL) and the 
mixture stirred at rt for 2 h where TLC indicated the complete consumption of the 
starting material. A solution of HCl (aqueous 1 M, ca. 8 mL) was then added drop 
wise until the solution became clear and at this point the reaction was evaporated to 
reduce the volume of the mixture to ca 20 mL. Water (50 mL) was added, the mixture 
extracted with EtOAc (3 × 40 mL) and the combined extracts washed with cold water 
(30 mL) and brine (30 mL), dried (MgSO4) and concentrated under reduced pressure. 
The residue was dissolved in ether (30 mL) and the solution passed through a small 
plug of silica (1 cm) and evaporated to give 103 as a white solid (1.80 g, 10.58 mmol) 
in 84% yield. 
 
Rf   0.18 (40% EtOAc in petrol) 
Mp    103-105 °C (Lit.104.9 - 106.1 °C94) 
δH (CDCl3)  3.25 (1H, s, OH), 3.95 (3H, s, Me), 3.97 (3H, s, Me), 4.58 (2H, 
s, CH2), 6.36 (1H, s, CH) 
δC (CDCl3) 172.1 (C), 170.6 (C), 165.0 (C), 97.2 (CH), 63.6 (CH2), 54.7 
(CH3), 53.9 (CH3) 
vmax 3391, 3019, 2952, 1602, 1571, 1463, 1359, 1215, 1055, 1039, 
831, 755, 668 
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Preparation of 2,6-dimethoxypyrimidine-4-carboxaldehyde (11)94 
 
 
 
Dess-Martin periodinane (1.25 g, 2.94 mmol) was added to a solution of 
alcohol 103 (0.5 g, 2.94 mmol) in CH2Cl2 (20 mL) and the mixture stirred at rt for 1 
h. The reaction was then washed with Na2S2O3 (aqueous, 10%, 30 mL) and NaHCO3 
(aqueous, saturated, 30 mL). The combined aqueous washings were back extracted 
with CH2Cl2 (30 mL), and the combined organic layers washed in turn with water (30 
mL), brine (30 mL) then dried (MgSO4) and concentrated under reduced pressure. The 
crude product was purified by silica gel chromatography (gradient elution; 15-20% 
EtOAc in petrol) to give 11 (0.40 g, 2.38 mmol) as a pale yellow solid in 81% yield. 
A repeat of this reaction with 103 (1.0 g, 5.88 mmol) and Dess-Martin 
periodinane (2.50 g, 5.89 mmol) gave 11 (0.95 g, 5.65 mmol) in 96% yield.  
 
Mp   104-107 °C (Lit.105-106.2 °C 94) 
Rf   0.36 (20% EtOAc in petrol) 
δH (CDCl3)  4.04 (3H, s, Me), 4.09 (3H, s, Me), 6.90 (1H, s, CH), 9.89 (1H, 
s, CH) 
δC (CDCl3) 2.1 (CH), 172.8 (C), 166.3 (C), 160.2 (C), 99.5 (CH), 55.2 
(CH3), 54.5 
vmax 3023, 2990, 2949, 2886, 1608, 1582, 1567, 1471, 1361, 1207, 
1110, 1085, 1039, 830, 783 
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Preparation of 1-(2,6-dimethoxypyrimidin-4-yl)-4-((isopropyldimethylsilyl)oxy)-
but-2-yn-1-ol (137) 
 
 
 
A solution of EtMgBr in THF (1M, 2.5 mL, 2.5 mmol, 1.9 eqv.) was added 
over 15 min to a stirred and cooled (0 °C) solution of 119 (405.2 mg, 2.38 mmol, 2 
eqv.) in dry THF (5 mL) and the resulting mixture was stirred for 1 h. This solution 
was then added to a cooled (-78 °C) solution of aldehyde 11 (0.20 g, 1.19 mmol, 1.0 
eqv) in dry THF (5 mL) via cannula and the mixture stirred for 2 h. After warming to 
rt overnight NH4Cl solution (aqueous, saturated, 20 mL), the mixture extracted with 
EtOAc (3 × 25 mL) and the combined organic extracts washed with brine (25 mL) and 
water (25 mL), dried (MgSO4|) and evaporated under reduced pressure. The crude 
residue was purified by flash chromatography on silica gel (EtOAc/petrol 5-30%) to 
give 137 (0.304 g, 0.937 mmol) in 75% yield as a clear liquid which solidifies slowly 
at rt.  
A repeat of this reaction with 119 (1.013 g, 6.0 mmol, 2 eqv), EtMgBr (1 M, 
5.65 mL, 5.65 mmol, 1.9 Eqv) and 11 (500.0 mg, 2.97 mmol, 1.0 eqv.) in dry THF (10 
mL) gave 137 (720.0 mg, 2.13 mmol) as a yellow oil in 71% yield. 
 
Rf   0.32 (25% EtOAc/petrol) 
H (CDCl3) 0.09 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH3), 1.95 (1H, br s, 
OH), 3.97 (3H, s, CH3), 3.99 (3H, s, CH3), 4.35 (2H, d,  J = 
1.1 Hz, CH2), 5.31 (1H, t, J = 1.1 Hz, CH), 6.54 (1H, s, CH). 
C (CDCl3) 172.36 (C), 168.51 (C), 165.04 (C), 98.05 (CH), 84.96 (C), 
82.66 (C), 63.17 (CH), 54.94 (CH3), 54.13 (CH3), 51.68 
(CH2), 25.72 (3 × CH3), 18.21 (C), -5.23 (2 × CH3) 
vmax 3392, 2955, 2930, 2885, 2858, 1597, 1572, 1484, 1463, 1382, 
1358, 1255, 1203, 1129, 1059, 815, 779 
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m/z (CI) 339.2 (100%, [M+H]+), 577.2 (90%, [2M+H]+) 
HRMS (CI)  C16H27N2O4Si ([M+H]
+) requires 338.1735, found 338.1735 
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Preparation of 4-((tert-butyldimethylsilyl)oxy)-1-(2,6-dimethoxypyrimidin-4-
yl)butan-1-ol (141) 
 
 
Palladium on activated carbon (10%, 0.20 g) was added to a solution of alkyne 
137 (0.163 g, 0.476 mmol, 1.0 eqv.) in EtOAc (2 mL) under an argon blanket in a 25 
mL RBF. The flask was purged with hydrogen gas (balloon) mixture and the mixture 
vigorously stirred under the hydrogen atmosphere for 2 h. The mixture was then 
filtered through a Celite© pad which was washed with further portions of EtOAc and 
the filtrate concentrated by evaporated under reduced pressure. The crude product was 
purified by column chromatography on silica gel (10-40% EtOAc/petrol) to give 141 
(130.0 mg, 0.380 mmol) as a colourless oil in 79% yield. 
 
Rf   0.25 (20% EtOAc/petrol) 
H (CDCl3) 0.05 (6H, s, 2 × CH3), 0.89 (9H, s, 3 × CH3), 1.60-1.78 (3H, 
m, CHH, CH2), 1.93-2.03 (1H, m, CHH), 3.65 (2H, t, J = 6.5 
Hz, CH2), 3.95 (3H, s, Me), 3.97 (3H, s, Me), 4.13 (1H, br s, 
OH), 4.56 (1H, m, CH), 6.44 (1H, s, CH) 
C (CDCl3) 174.0 (C), 172.2 (C), 164.9 (C), 97.3 (CH), 72.5 (CH), 63.3 
(CH2), 54.7 (CH3), 53.8 (CH3), 34.6 (CH2), 28.5 (CH2), 25.9 
(3 × CH3), 18.3 (C), -5.4 (2 × CH3) 
vmax 3402, 2955, 2930, 2885, 2857, 1598, 1570, 1481, 1462, 1382, 
1355, 1255, 1203, 1153, 1097, 1006, 836, 776 
m/z (CI) 343.2 (100%, [M+H]+), 365.2 (15%, [M+Na]+), 707.4 (30%, 
[2M+Na]+) 
HRMS (CI)  C16H31N2O4Si ([M+H]
+) requires 343.2048, found 343.2049 
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Preparation of 1-(2,6-dimethoxypyrimidin-4-yl)-4-((tert-
butydimethylsilyl)oxy)butyl acetate (142) 
 
 
 
Acetic anhydride (0.12 g, 0.11 mL, 1.19 mmol, 3.7 eqv) was added drop wise 
to a cooled (0˚C) and stirred mixture of alcohol 141 (0.11 g, 0.32 mmol, 1.0 eqv), 
pyridine (0.10 g, 0.10 mL, 1.25 mmol, 3.9 eqv) and DMAP (4.0 mg, 0.032 mmol, 0.1 
eqv.) in dry CH2Cl2 (3 mL). The mixture was warmed to rt and stirred for 1 h, 
whereupon HCl (aqueous. 2 M, 20 mL) was added the mixture stirred for 30 min. The 
mixture was the extracted with CH2Cl2 (3 x 10 mL) and the combined extracts washed 
with HCl (aqueous, 2M, 3 × 5 mL) and water (20 mL). After drying (MgSO4) and 
evaporated under reduced pressure, column chromatography on silica gel (10-30% 
EtOAc/petrol) gave 142 (84.0 g, 0.218 mmol) as a white solid in 68% yield.  
 
Rf   0.28 (20% EtOAc/petrol) 
H (CDCl3) 0.02 (6H, s, 2 × CH3), 0.87 (9H, s, 3 × CH2), 1.51-1.62 (2H, 
m, CH2), 1.84-1.94 (1H, m, CHH), 1.96-2.04 (1H, m, CHH), 
2.13 (3H, s, CH3), 3.60 (2H, t, J = 6.3 Hz, CH2), 3.94 (3H, s, 
Me), 3.96 (3H, s, Me), 5.61 (1H, dd, J = 4.8, 7.8 Hz, CH), 
6.30 (1H, s, CH) 
C (CDCl3) 172.1 (C), 170.4 (C), 170.2 (C), 165.2 (C), 97.6 (CH), 75.1 
(CH), 62.5 (CH2), 54.7 (CH3), 53.8 (CH3), 30.4 (CH2), 28.2 
(CH2), 25.9 (3 × CH3), 21.0 (CH3), 18.3 (C), -5.4 (2 × CH3) 
vmax 2956, 2930, 2898, 2858, 2253, 1744, 1598, 1572, 1482, 1463, 
1388, 1358, 1242, 1206, 1162, 1104, 1059, 964, 910 and 836 
m/z (CI) 385.2 (100%, [M+H]+), 791.4 (15%, [2M+H]+) 
HRMS (CI)  C18H33N2O5Si ([M+H]
+) requires 385.2153, found 385.2146 
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Preparation of 1-(2,6-dimethoxypyrimidin-4-yl)-4-hydroxybutyl acetate(138) 
 
 
 
A solution of TBAF (0.52 mL, 0.52 mmol, 1.5 eqv) in THF was added to a 
cooled (0˚C) solution of 142 (0.134 g, 0.348 mmol, 1.0 eqv.) in dry THF (3 mL) and 
the resulting mixture stirred for 2 h. At this point the reaction was evaporated under 
reduced pressure and purified by flash chromatography on silica gel (gradient elution; 
30-40% EtOAc/petrol) to give 138 (0.076 g, 0.281 mmol) as colorless oil in 80% yield.  
 
Rf   0.26 (40% EtOAc in petrol) 
H (CDCl3) 1.63-1.89 (4H, m, 2 × CH2), 2.01 (3H, s, CH3), 3.59 (1H, br s, 
OH), 3.94 (3H, s, CH3), 3.97 (3H, s, CH3), 4.02-4.17 (2H, m, 
CH2), 4.55 (1H, dd, J = 2.6, 6.3 Hz, CH), 6.33 (1H, s, CH) 
C (CDCl3) 172.9 (C), 172.1 (C), 171.1 (C), 154.9 (C), 97.2 (CH), 71.8 
(CH), 64.2 (CH2), 54.7 (CH3), 53.9 (CH3), 33.8 (CH2), 24.7 
(CH2), 20.9 (CH3)  
vmax 3440, 3428, 2955, 2927, 1738, 1596, 1569, 1482, 1381, 1351,  
m/z (CI) 271.1 (100%, [M+H]+), 293.1 (40%, [M+Na]+), 563.2 (20%, 
[2M+Na]+) 
HRMS (CI)  C12H19N2O5 ([M+H]
+) requires 271.1288, found 271.1287 
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Preparation of 1-(2,6-dimethoxypyrimidin-4-yl)-4-(1,2,3-
tris(tertbutoxycarbonyl) guanidino)butyl acetate (140) 
 
 
 
DIAD (190.8 mg, 0.94 mmol, 1.5 eqv) was added drop wise to a cooled (0 ˚C) 
and stirred solution of alcohol 138 (0.17 g, 0.629 mmol, 1.0 eqv.), PPh3 (247.5 mg, 
0.960 mmol, 1.53 eqv.) and N,N′,N′′-tri-Boc-guanidine 139 (452.1 mg, 0.314 mmol, 2 
eqv.) in dry THF (5 mL). After stirring to rt overnight, a drop of water was added and 
the solution was evaporated under reduced pressure. The crude product was then 
purified by flash chromatography on silica gel (5-20% EtOAc/petrol) to give 140 (0.19 
g, 0.31 mmol) as a colourless oil in 49% yield. 
 
Rf   0.26 (20% EtOAc/petrol) 
H (CDCl3) 1.32 (9H, s, 3 × CH3), 1.49 (9H, s, 3 × CH3), 1.50 (9H, s, 3 × 
CH3), 1.70-1.91 (2H, m, CH2), 2.04 (3H, s, CH3), 2.15-2.26 
(2H, m, CH2), 3.95 (3H, s, CH3), 3.96 (3H, s, CH3), 4.11 (2H, 
t,  J = 6.4 Hz, CH2), 5.35-5.65 (1H, m, CH), 6.50 (1H, s, CH), 
10.71 (1H, s, NH) 
C (CDCl3) Partial data: 172.2 (C), 171.1 (C), 98.9 (CH, from HSQC), 
83.3 (C), 64.3 (CH2), 61.1 (CH), 54.8 (CH3), 53.9 (CH3), 28.0 
(3 × CH3), 28.0 (3 × CH3), 27.8 (3 × CH3), 25.7 (CH2), 20.9 
(CH3), (5 × C not observed) 
vmax 3644, 3463, 2985, 2936, 2921, 2849, 1742, 1448, 1373, 1242, 
1134, 1098, 1047, 938, 847 
m/z (CI) 612.3 (100%, [M+H]+), 1245.6 (90%, [2M+Na]+), 312 (96%, 
[M-2Boc+H]+) 
HRMS (CI)  C28H46N5O10 ([M+H]
+) requires 612.3239, found 612.3225 
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Preparation of amino((4-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-
hydroxybutyl)-amino)methaniminium chloride (133) and amino((4-chloro-4-
(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)butyl)amino)-methaniminium 
chloride (143) 
 
 
 
Protected uracil 140 (35.0 mg, 0.057 mmol) and concentrated HCl (2 mL) were 
heated at 80 ˚C for 96 h. After cooling to rt, evaporation under reduced pressure and 
drying over P2O5 gave a crude mixture of 133 and 143 (12.0 mg, 0.043 mmol) as a 
solid. 
A similar reaction using 140 (36.0 g, 0.059 mmol) and concentrated HCl (2 
mL) were heated at reflux for 6h. After work, up this reaction gave 143 (13.5 mg, 
0.049 mmol) as a solid. The product was purified by dissolution in methanol (1 mL) 
and precipitation by the addition of diethyl ether to give an approximate 1:1 mixture 
of 133/143 (5.4 mg). 
 
H (CD3OD) 1.52-2.20 (4H, m, 2 × CH2), 3.55-3.69 (2H, m, CH2), 4.27-
4.43 (1H, m, CH) and 5.56 (1H, br m, CH)   
C (CD3OD) Partial data: 29.4/30.0 (CH2), 31.8/32.5 (CH2), 44.8/61.8 
(CH2), 53.8/53.9 (CH) and 97.9/98.1 (CH)  
m/z (CI) 133; 242.1 (25%, [M+H]+); 143; 260.1 (86%, [M+H]+, 35Cl), 
262.1 (28%, [M+H]+, 37Cl), 235 (100%) 
HRMS (CI)  133 C9H16N5O3 ([M+H]
+) requires 242.1248, found 242.1248 
143 C9H15
35ClN5O2 ([M+H]
+) requires, 260.0909, found 
260.0911; C9H15
37ClN5O2 requires 262.0880, found 262.0880. 
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Preparation of 5-chloro-2,4-dinitro-benzoic acid (170)155 
 
 
 
3-Chlorobenzoic acid 169 (25.0 g, 160.0 mmol) was dissolved in concentrated 
sulfuric acid (300 mL) and the mixture was stirred and warmed to 40 °C. Potassium 
nitrate (16.0 g, 158.0 mmol) was added in portions over 35 min and the reaction 
mixture was then warmed to 100 °C and an additional (28.0 g, 277.0 mmol) of 
potassium nitrate was added in portions over 25 min. The reaction was heated at 145 °C 
for 15 min then slowly cooled to rt and poured into ice (2 kg) which was agitated for 
30 min. to precipitate 170 as a yellow solid. This precipitate was filtered under a 
vacuum and washed with water then added to water (1 L) stirred for 1 h at rt. The solid 
formed was removed by filtration and dried under vacuum to give 170 (27.0 g, 68 %) 
of product as a pale yellow solid 
. 
δH (acetone-d6): 8.75 (1H, s, CH), 8.25 (1H, s, CH) 
δC (acetone-d6): 122.7 (CH), 131.8 (CH), 132.3 (C), 134.1 (C), 147.2 (C), 149.4 
(CH), 163.7 (CH) 
Mp 179 °C (lit 180-183 °C155)  
vmax 3500-2500 (br), 3024, 1716, 1586, 1542, 1422, 1346, 1286, 
1136, 909 
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Preparation of 5-chloro-2,4-dinitrobenzamide (171)155 
 
 
 
5-Chloro-2,4-dinitro-benzoic acid 170 (5.0 g, 20.3 mmol) was suspended in  
thionyl chloride (30 mL) and then DMF (3 drops) was added and the mixture was 
stirred under reflux for 4 h. After cooling to rt the solvent was evaporated to give a 
yellow liquid which was diluted with acetone (21 mL) and added to cooled (0 °C) conc. 
ammonium hydroxide solution (15 mL) over 20 min. The reaction mixture was cooled 
(0 °C) and stirred for 30 min then poured into ice (ca. 150 g) and stirred until the ice 
melted. The yellow precipitate formed was removed by filtration, washed with cold 
water and dried under high vacuum to give 171 (4.3 g, 17.5 mmol, 87% yield) as a 
pale yellow solid.  
 
δH (acetone-d6): 8.74 (1H, s, CH), 8.07 (1H, s, CH), 7.8 (1H, br s, NH), 7.4 
(1H, br s, NH). 
δC (acetone-d6): 123.0 (CH), 132.0 (C), 133.2 (CH), 137.7 (C), 146.4 (C),  
148.5 (C), 165.3 (C) 
Mp 200 °C (lit 201-203 °C155) 
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Preparation of 5-(bis(2-hydroxyethyl)amino)-2,4-dinitrobenzamide (172)154,156 
 
 
A mixture of 5-chloro-2,4-dinitrobenzamide 171 (3.3 g, 13.4 mmol) and 
diethanolamine (3.5 g, 33.3 mmol) was stirred and heated (100 °C) for 4 h. The 
reaction mixture was then cooled to rt and poured onto a prewashed (EtOAc) silica gel 
pad which was eluted with 2-8% MeOH in EtOAc. Combination of the fractions 
containing the product gave the diol 172 (2.30 g, 10.74 mmol, 80%) as an orange 
yellow solid.  
 
δH (acetone-d6): 8.44 (1H, s, CH), 7.55 (1H, br s, NH), 7.50 (1H, s, CH), 
7.04 (1H, br s, NH), 3.79 (4H, t, J = 5.4 Hz, 2 × CH2), 
3.61 (4H, t, J = 5.4 Hz, 2 × CH2), 4.13 (2H, br s, 2 × 
OH) 
δC (acetone-d6): 55.1 (CH2), 59.3 (CH2), 120.8 (CH), 124.8 (CH), 135.3 
(C), 137.8 (C), 148.6 (C), 167.6 (C) 
m/z (CI) 629.2 (10%, [2M + H]+), 391.3, (12%), 315.1 (100%, 
[M + H]+), 199.2 (7%). 
HRMS (CI) C11H15O7N4 ([M+H]
+) requires 315.0935, found 
315.0939 
Mp    180 °C (lit. 176-178 °C154,156) 
vmax 3425, 3356, 2928, 1675, 1604, 1580, 1516, 1437, 
1333, 1172, 970, 915 
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Preparation of 5-(bis(2-(mesityloxy)ethyl)amino)-2,4-dinitrobenzamide 
(173)156,154 
 
 
 
5-(bis(2-Hydroxyethyl)amino)-2,4-dinitrobenzamide 172 (1.00 g, 3.2 mmol) 
was dissolved in dry pyridine (15 mL) and cooled (0 °C) and MsCl (0.81 g, 7.1 mmol) 
was added. The mixture was then stirred to rt over 90 min and the solvent removed 
under reduced pressure below 40 °C. The residue was partitioned between EtOAc (100 
mL) and water (100 mL) and the organic layer washed with deionised water (3 ×300 
mL), dried (MgSO4), evaporated and purified by column chromatography (EtOAc) to 
give 173 (1.00 g, 2.13 mmol, 67%) as a yellow solid. 
 
δH (acetone-d6): 8.54 (1H, s, CH), 7.65 (1H, s, CH), 7.48 (1H, br s, NH), 7.15 
(1H,br s, NH), 4.49 (4H, t, J = 5.3Hz, 2 × CH2), 3.89 (4H, t, J 
= 5.35, Hz, 2 × CH2), 3.09 (6H, s, 2 × CH3) 
δC (acetone-d6): 167.1 (C), 148.5 (C), 140.3 (CH), 138.5 (CH), 138.3 (C), 
124.9 (CH), 122.9 (CH), 67.6 (CH2), 51.9 (CH2), 37.1 (CH3) 
m/z (CI) 958.1 (35%, [2M + NH4]
+), 488.1 (100%, [M + H]+), 454.0 
(65%), 391.3 (8%) 
HRMS (CI)  C13H19O11N4S2 ([M+H]
 +) requires 471.0486, found 471.0482 
Mp   138-143 °C (lit. 140-144 °C154,156) 
vmax 3410, 3292, 3020, 2938, 1671, 1579, 1509, 1346, 1328, 1174, 
1214, 1174, 1002, 936, 904, 754 
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Preparation of 5-(bis(2-chloroethyl)amino)-2,4-dinitrobenzamide (174)156 
 
 
 
Lithium chloride (0.21 g, 5.0 mmol) was added to a solution of 173 (0.25 g, 
0.53 mmol) in dry DMF (15 mL) and the mixture stirred and warmed to 120 °C for 20 
min. After cooling the mixture was concentrated to dryness under high vacuum and 
dissolved in a mixture of EtOAc (50 mL) and water (50 mL). After separation the 
organic layer was washed with saturated ammonium chloride solution (aqueous, 3 x 
50 mL), dried (MgSO4) and evaporated. Column chromatography of the residue on of 
silica gel (20% EtOAc in diethyl ether) gave 174 (0.14 g, 0.40 mmol, 75%) as a yellow 
solid.  
δH (acetone-d6): 8.53 (1H, s, CH), 7.62 (1H, br s, NH), 7.58 (1H, s, CH), 7.17 
(1H, br s, NH), 3.89-3,80 (8H, m, 4 × CH2) 
δC (acetone-d6): 167.2 (C), 148.2 (C), 139.9 (C), 138.6 (C), 138.0 (C), 124.9 
(CH), 122.1 (CH), 54.1 (CH2), 42.0 (CH2) 
m/z (CI) 351.0 (100%, [M+H]+, 2 × 35Cl), 353 (68%, [M+H]+, 35Cl, 
37Cl), 355 (10%, [M+H]+, 2 × 37Cl). 
HRMS (CI) C11H13
35Cl2N4O5 ([M+H]
+) requires 351.0258, found 
351.0262; C11H13
35Cl37ClN4O5 ([M+H]
+), requires 353.0228, 
found 353.0232; C11H13
37Cl2N4O5 ([M+H]
+), requires 
355.0199, found 355.0201 
Mp   107-112 °C (lit. 109-111 °C156) 
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Preparation of 5-(bis(2-bromoethyl)amino)-2,4-dinitrobenzamide (175)156 
 
 
 
Sodium bromide (2.50 g, 24.7 mmol) was added to a solution of 173 (0.25 g, 
0.53 mmol) in dry DMF (12.5 mL) and the mixture stirred and warmed to 125 °C for 
20 min. After cooling the mixture was concentrated to dryness under high vacuum and 
dissolved in a mixture of EtOAc (50 mL) and water (50 mL). After separation the 
organic layer was washed with saturated ammonium chloride solution (aqueous, 3 x 
50 mL), dried (MgSO4) and evaporated. Column chromatography of the residue on of 
silica gel (50% EtOAc in diethyl ether) gave 175 (0.23 g, 0.52 mmol, 98%) as a yellow 
solid. 
 
δH (acetone-d6): 8.53 (1H, s, CH), 7.61 (1H, br s, NH), 7.58 (1H, s, CH), 7.12 
(1H,br s, NH), 3.89 (4H, t, J = 6.5 Hz, 2 × CH2), 3.74 (4H, t, J  
= 6.5 Hz, 2 × CH2) 
δC (acetone-d6): 167.2 (C), 148.0 (C), 140.2 (C), 138.9 (C), 138.5 (C), 125.1 
(CH), 122.4 (CH), 54.2 (CH2), 30.0 (CH2) 
m/z (CI) 438.9 (51%, [M+H]+, 2 × 79Br), 440.9 (100%,  [M+H]+, 81Br, 
79Br), 442.9 (49%, [M+H]+, 2 × 81Br), 897.9 (20 %, 
[2M+NH4]
+, 2 × 79Br, 100%), 
HRMS (CI) C11H13
79Br2N4O5 ([M+H]
+) requires 438.9247, found 
438.9247; C11H13
81Br79BrN4O5 ([M+H]
+) requires 440.9227, 
found 440.9225, C11H13
81Br2N4O5 ([M+H]
+) requires 
442.9209, found 442.9204  
Mp   124-130 °C (lit 126-128 °C156) 
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Preparation of 5-(bis(2-iodoethyl)amino)-2,4-dinitrobenzamide (176)156 
 
 
 
Sodium iodide (3.60 g, 24.0 mmol) was added to a solution of 173 (0.25 g, 
0.53 mmol) in dry DMF (12.5 mL) and the mixture stirred and warmed to 125 °C for 
20 min. After cooling to rt, the mixture was concentrated to dryness under high 
vacuum and dissolved in a mixture of EtOAc (50 mL) and water (50 mL). After 
separation the organic layer was washed with saturated ammonium chloride solution 
(aqueous, 3 x 50 mL), dried (MgSO4) and evaporated. Column chromatography of the 
residue on of silica gel (30% EtOAc in diethyl ether) gave 176 (0.23 g, 0.43 mmol, 
81%) as a yellow solid. 
 
δH (acetone-d6): 8.52 (1H, s, CH), 7.63 (1H, br s, NH), 7.55 (1H, s, CH), 
7.19 (1H, br s, NH), 3.83 (4H, t, J = 7.2 Hz, 2 × CH2), 
3.49 (4H, t, J = 7.2 Hz, 2 × CH2) 
δC (acetone-d6): 167.1 (C), 147.0 (C), 139.7 (C), 138.4 (C), 137.9 (C), 
124.8 (CH), 122.0 (CH), 54.6 (CH2), 1.6 (CH2) 
m/z (CI) 1085.8 (15%, [2M+NH4]
+), (534.9 (100%, [M + H]+), 
391.3 (33%), 361.3 (23%), 313.1 (7%), 199.2 (8%) 
HRMS (CI) C11H13I2N4O5 ([M+H]
+) requires 534.8970, found 
534.8964 
Mp    173-175 °C (lit 170-172 °C156) 
vmax 3401, 3299, 3169, 3020, 1656, 1605, 1578, 1511, 
1438, 1329, 1273, 1215, 758, 669    
max    377 nm ( = 11 400 L mol-1 cm-1) 
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Assay method 
All E. coli (DH5α), as used for genetic manipulation and cloning, was obtained 
from the Promega Corporation (Madison, WI, USA). All E. coli strain Rosetta pLysS 
(DE3λ), as used for protein expression, was obtained from Novagen (EMD 
Biosciences, Inc., affiliate of Merck KGaA, Darmstadt, Germany). 
E. coli strains harbouring pET-28 plasmids were grown in Luria-Bertani (LB) 
liquid and solid media containing 50 μg/ mL kanamycin; all the powders were 
obtained from Lab M Limited (Heywood, Lancashire, UK). Plasmid and DNA 
purification kits were obtained from Qiagen Ltd (Manchester, UK); these were used 
according to manufacturer’s instructions. PCR reagents were obtained from 
Finnzymes (Fermo Fisher Scientific Inc., Waltham, MA USA). The restriction 
enzymes T₄ DNA ligase and buffers were obtained from the Promega Corporation. 
The plasmid vector pET-28a(+), as used as cloning and expression vector, was 
obtained from Novagen. 
Enzyme kinetics 
 
Concentration, temperature, and pH profiles of purified enzymes were assessed 
spectrophotometrically as NADPH oxidation (µmol min-1) by reading the absorbance 
at 340 nm (absorption wavelength of reduced NADPH). The candidate prodrug was 
the substrate, phosphate buffer 0.05 M (pH 7.2) and NADPH was the electron donor. 
For each assay, in order to prevent the effects of background NADPH oxidation, both 
blank and assay cuvettes contained NADPH and enzyme solution. The purified 
proteins were stored at -20 °C. All reactions were performed between 1 and 2 weeks 
of the initial purification; this was to prevent loss of enzyme activity. 
Enzyme concentration versus reaction rate 
Concentration profiles were performed in 1000 µl in cuvettes; these contained 
0.05 M phosphate buffer (pH 7.2), 10 µM prodrug substrate, 30 µM NADPH, and 
varyious enzyme concentrations (2.5, 5, 10, 15, and 30 µg/ mL). The enzyme, PB, and 
NADPH were incubated at 37 °C for 5 min. The measurements were repeated three 
times for each enzyme concentration; the average (mean) value was then calculated. 
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The concentration profile of the cys-tagged enzyme was conducted using the 
three substrates 174-176 and CB 1954; this procedure utilised the same protocol as 
before, using 1000 µl curvettes and varying the enzyme concentrations. 
Substrate concentration versus reaction rate 
The parameters Km and Vmax were determined spectrophotometrically at 420 
nm (based on equal absorption of the 2- and 4-hydroxylamine reduction products of 
CB 1954 at this a wavelength of 1200 M-1 cm-1); this was achieved using constant 
enzyme and NADPH concentrations under a range of different substrate 
concentrations. Reactions were performed in 1000 µL cuvettes; these contained 0.05 
M phosphate buffer (pH 7.2), 4 mM NADPH, 10 µg/ mL enzyme, DMSO 
(concentration of DMSO in sample cuvettes: X µL prodrug + X µl DMSO= 50 µL; 
concentration of DMSO in reference = 50 µl), and increasing CB 1954 concentrations 
(from 0.05 to 5 mM). The enzyme, phosphate buffer and NADPH were incubated at 
37 °C for 3 min. All measurements were repeated three times for each prodrug 
concentration; the average (mean) value was then calculated. Non-linear regression 
and Michaelis-Menten curve fitting were performed using Sigma Plot 10 (Systat 
Software Inc., Richmond, CA, USA). For kinetic assay, the eluted fractions containing 
the most pure proteins were supplemented with a 5-fold excess molar ratio of a 
concentrated 5.6 mM FMN solution (this was to ensure that all enzymes had bound 
FMN—some may have been lost during the imidazole purification and sonication 
step). The enzyme and FMN solution were incubated on ice for 1 h before buffer-
exchange into 0.05 M PB (pH 7.2), using a PD-10 desalting column (GE Healthcare, 
Scientific Laboratory Supplies Ltd, Nottingham, UK).  
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